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ABSTRACT
The popular recreational drug MDMA or ‘Ecstasy’ is a selective serotonin neurotoxin in 
non-human primates, and has been demonstrated to specifically affect the hippocampus 
and neocortex, brain regions involved in memory and general cognitive functioning. 
The enduring nature of this neurotoxicity has been demonstrated in studies of non­
human primates 7 years after administration of MDMA. Neuroimaging, 
neuroendocrine and CSF serotonin metabolite studies have demonstrated that similar 
patterns of neurotoxicity may occur in recreational users of MDMA. Memory 
dysfunction has been identified as a functional consequence of MDMA-induced 
neurotoxicity in recreational users of the drug. The study of memory dysfunction in 
recreational MDMA-users to date has failed to present a revealing clinical picture of the 
nature of memory impairment. Furthermore, these studies have failed to adequately 
control for the potentially confounding influence of other factors known to affect 
memory and cognitive functioning, such as anxiety and depression. Therefore, the first 
of the two studies conducted sought to determine whether memory impairment occurred 
as a result of encoding, storage or retrieval dysfunction, while controlling for the effects 
of potential confounding variables. Thirty-one current recreational MDMA-users were 
compared to 30 controls in terms of their memory performance on the Wechsler 
Memory Scale-Third Edition (WMS-III). MDMA-users demonstrated significant 
impairment in immediate and delayed memory when compared to controls and the 
nature of memory impairment was consistent with dysfunction in encoding processes. 
The second study sought to determine if this pattern of memory impairment was 
enduring. Thirty two-year abstinent MDMA-users were compared with 30 controls for 
memory performance on the WMS-III. Abstinent users demonstrated significant
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impairment in immediate, delayed and working memory and manifested impairment 
that was also consistent with encoding dysfunction. A more pervasive pattem of 
memory impairment was evident in abstinent MDMA-users when compared to controls, 
than was evident in the cohort of current MDMA-users. In comparison to the current 
MDMA-users, the abstinent cohort reported a very high frequency of use and the more 
pervasive impairment evident in this group may be due to this factor. The results 
suggest that recreational MDMA-users are at risk for incurring enduring memory 
impairment and encoding dysfunction. The cognitive implications of frequent regimens 
of MDMA use and the replication of encoding dysfunction in other cohorts of 
recreational users are highlighted as important areas for future research.
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CHAPTER 1
MDMA-Induced Memory Impairment:
The functional implications of the selective serotonergic
neurotoxicity of MDMA
1.1 THE PHARMACOLOGY AND RECREATIONAL USE OF MDMA
1.1.1 The Chemical Composition of MDMA
MDMA is the accepted abbreviation for the ring-substituted amphetamine 3,4- 
methylendioxymethamphetamine, a commonly used recreational drug of abuse. 
Chemically, MDMA can be designated as N-methyl-l(3,4-methylenedioxyphenyl)-2- 
aminopropane and structurally, it is related to the psychomotor stimulant amphetamine 
and the hallucinogen mescaline (Steele, McCann & Ricaurte, 1994). It is a member of a 
group of drugs (amphetamines and derivatives) which include amphetamine (‘speed’), 
methamphetamine, (‘speed’ or ‘ICE’), para-methoxyamphetamine (PMA), and 
methylenedioxyamphetamine (MDA). The reactions of humans to this class of drugs 
range from stimulant effects with little or no hallucinogenic properties to LSD-like 
hallucinogenic effects (White, Irvine & Bochner, 1996). It has been proposed that the 
psychoactive effects of MDMA are unique and distinct from other hallucinogenic 
amphetamine analogues, leading some researchers to suggest that it represents a new 
class of drugs, for which the name ‘entactogens’ has been conceived (Nichols &
Oberlender, 1990).
1.1.2 Acute Changes in Monoamine Concentrations Following MDMA Use
In vitro studies indicate that MDMA evokes the release of brain monoamines and 
inhibits their re-uptake inactivation. MDMA influences dopamine and noradrenaline, 
however, its serotonergic effects appear to be the more prominent (Steele et al., 1994). 
MDMA induces an acute release of serotonin and dopamine. This acute release then 
leads to depletion of intraneural serotonin stores (Sprague, Everman & Nichols, 1998). 
The change in serotonin concentrations following administration of MDMA is thought 
to be due to alterations in the synthesis, uptake and release of serotonin (Schmidt & 
Taylor, 1990). Although it is difficult to identify the specific behavioural consequences 
of these alterations in monoamine concentrations, it has been proposed that a sudden 
increase in dopamine may be related to feelings of euphoria and increased sociability, 
energy and activity. Serotonin is thought to be involved in the inhibition of both 
behaviour and emotions (Zuckerman, 1984).
1.1.3 Duration of Acute and Residual Effects of MDMLA
A pharmacokinetic study of MDMA in humans found that the half-life of the drug was 
7.6 hours with peak plasma concentration (mean = 105.6ng/ml) occurring after 2 hours 
(White et al., 1996). In Solowij, Hall & Lee’s (1992) survey of ‘Ecstasy’ users in 
Sydney, Australia, the effects of one dose or tablet of MDMA were reported to last 
anywhere between 1 and 12 hours. The acute effects of the drug were more commonly 
reported to endure for 3 to 6 hours, depending on the individual and the dose taken, with 
the effects first noted within half an hour following administration. In an additional half 
hour to an hour, a plateau of effects was reported to occur and symptoms of intoxication 
largely dissipated in an additional two hours except for mild residual stimulation (White 
et al., 1996; Shulgin, 1990).
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1.1.4 Modes of Administration in the Recreational Use of MDMA
The Solowij et al. (1992) study of recreational users in Sydney found that MDMA was 
most frequently taken in tablet form, however, it is also reportedly available in capsule 
and powdered forms. In Australia it is generally accepted that a tablet of ‘Ecstasy’ 
contains between 60-150mg of MDMA (White et al., 1996; Solowij et al., 1992; Boot, 
McGregor & Hall, 2000). Solowij et al. (1992) found that, among their sample, 
‘Ecstasy’ was ingested orally 98 percent of the time, however, snorting, injecting and 
suppositories were also reported as modes of administration by a small proportion of 
users. In a more recent study of ‘Ecstasy’ users sampled from three major Australian 
capital cities, 99 percent of the sample had swallowed ‘Ecstasy’, 30 percent had snorted 
the drug, 16 percent of the sample had injected the drug and 12 percent had smoked the 
drug mixed with cannabis (Topp, Hando, Dillon, Roche & Solowij, 1999).
Different modes of administration have been reported to result in different experiences 
with the drug (Topp et al., 1999). Injecting is described as having the quickest onset 
and producing a more intense but shorter lasting experience. Snorting is identified as 
acting more quickly than an oral dose, but lasting for a shorter period of time, while a 
suppository produces a slow onset but a more intense and prolonged experience 
(Solowij et al., 1992).
1.1.5 Patterns of Recreational Use of MDMA
Although MDMA was initially patented as an appetite suppressant, it was used 
therapeutically in the United States as an adjunct to psychotherapy in the late 1970’s 
(Steele et al., 1994). The emotional effects of MDMA, including an increased sense of 
intimacy and heightened communication skills, contribute to its role as a facilitator for
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interpersonal relationships, making it an attractive adjunct to psychotherapy. Despite 
interest in its therapeutic potential, MDMA was placed on schedule 1 of controlled 
substances in the United States in 1985 as a result of increasing recreational usage and 
animal studies demonstrating toxic effects of the drug and its potential for abuse (Steele 
et al., 1994).
Studies of recreational use of ‘Ecstasy’ throughout Europe, America and Australia have 
established that MDMA is commonly used within dance party or ‘rave’ settings in 
addition to amphetamine and LSD (Lenton, Boys & Norcross, 1997; Forsyth, 1996; 
Gerra, Zaimovic, Giucastro, Maestri et al., 1998; Steele et al., 1994). The rave scene 
reportedly began in the United Kingdom in the late eighties and has evolved from 
underground dance parties held in secret venues to more mainstream dance events held 
in licensed clubs (Lenton et al., 1997). Accordingly, it has been noted that ‘Ecstasy’ use 
in some groups in Australia has become increasingly mainstream (Lenton et al., 1997). 
In a survey of ‘Ecstasy’ users living in the metropolitan regions of three Australian 
capital cities, Topp et al. (1999) found that users were typically young adults who were 
relatively well educated and who were generally employed or students. In a survey 
exploring the patterns of MDMA use in Sydney in the early 1990’s, ‘Ecstasy’ users 
reported that dance parties were the most popular venues for taking MDMA, followed 
by private parties and nightclubs (Solowij et al., 1992). Similar patterns of use have 
been noted in Perth (Boys, Lenton & Norcross, 1997) and Glasgow in the mid 1990’s 
(Forsyth, 1996). In accordance with this pattern of use, the most popular time for taking 
‘Ecstasy’ was found to be on weekends, usually in the late evenings, and preferably 
when the user was not working the following day (Solowij et al., 1992).
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The frequency of ‘Ecstasy’ use is highly variable. However, a survey of Australian 
users in the late 1990’s found that ‘Ecstasy’ was used on average every 10 days in the 
preceding 6 months (Topp et al., 1999). Over a third of the sample had taken ‘Ecstasy’ 
between 1 and 6 days in the preceding 6 months, a further third had used between 7 and 
12 days, 19 percent had used between 13 and 24 days, and 12 percent had used 
‘Ecstasy’ on more than 24 days in the preceding 6 months. An earlier survey of Sydney 
users found that one third of the sample used MDMA somewhere between once a month 
to once every 3 months (Solowij et al., 1992). Approximately one quarter of the sample 
used ‘Ecstasy’ more frequently and roughly 18% used only on special occasions. The 
authors reported that patterns of use appear to be affected by the drug’s availability, 
personal preferences and the social climate. Similar patterns of use have been 
documented by researchers from Europe and America, where it has been reported that 
individuals generally use MDMA once or twice a month, although more frequent use of 
the drug is sometimes reported (Steele et al., 1994).
A distinctive feature of drug use amongst both the dance and rave scene is polydrug use. 
A survey of rave goers in Western Australia reported that a significant proportion of 
respondents used more than one ‘dance drug’ concurrently (Boys et al., 1997). Similar 
patterns of use among MDMA-users have been documented in other Australian capital 
cities (Topp et al., 1999; Solowij et al., 1992) and in Europe (Forsyth, 1996; Boys et al., 
1997; Williamson, Gossop, Powis, Griffiths et al., 1997). In these studies, the term 
‘dance drug’ is used to describe ‘Ecstasy’, LSD and amphetamines, however, 
concurrent use of nitrous oxide, amyl nitrate, cocaine and methylenedioxyamphetamine 
(MDA) has also been documented. Topp et al. (1999) identified that polydrug use was 
the norm among their sample of Australian MDMA-users with 93 percent using other 
drugs in combination with ‘Ecstasy’ at least two-thirds of the time. The drugs typically
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used in conjunction with ‘Ecstasy’ include tobacco, cannabis, amphetamine, alcohol, 
amyl nitrate and nitrous oxide. Mixing MDMA with other ‘dance drugs’ such as 
amphetamine was reported to increase stamina for dancing. Drinking alcohol, smoking 
cannabis and taking benzodiazepines after MDMA is also commonly reported in the 
‘coming down’ phase to help induce relaxation and sleep (Topp et al., 1999; Boys et al., 
1997). On the basis of these patterns of polydrug use, Topp et al. (1999) concluded that 
‘Ecstasy’ users are adept at obtaining drugs to self medicate the adverse physical and 
psychological effects of MDMA and other drug use.
The use of multiple doses of ‘Ecstasy’ or ‘binges’ are also commonly reported among 
MDMA-users. Over half of the ‘Ecstasy’ users sampled in Sydney ingested more than 
one dose of MDMA on the one occasion (Solowij et al., 1992) and the use of ‘booster’ 
doses to prolong the effects of the drug are commonly reported in other studies (White 
et al., 1996; Beck & Rosenbaum, 1994). Topp et al. (1999) reported that more than 
one-third of their sample had ‘binged’ on ‘Ecstasy’ in the preceding 6 months, which 
was defined as using the drug on a continuous basis without sleep for 48 hours or more. 
Subjective reports indicate that larger doses of MDMA change the nature and intensity 
of its effects, in that the stimulant properties and negative side effects appear to be 
highlighted (Green, Cross & Goodwin, 1995).
Of particular interest to Australian patterns of MDMA use is an observation made by 
Topp et al. (1999) who noted differences in the features of MDMA use in their sample 
collected from three Australian capital cities in the late 1990’s when compared to the 
Solowij et al. (1992) study, conducted in Sydney in 1990. While acknowledging that 
comparing two cross-sectional surveys is problematic, Topp et al. (1999) ascertained 
that their more recent sample reported increased quantity and frequency of MDMA use,
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greater levels of concurrent polydrug use and a wider range of contexts of use. If this is 
the case, it is evident that the use of MDMA is spreading beyond the rave scene and that 
Australian MDMA-users are progressively placing themselves at a greater risk for harm 
associated with high dose regimens and the unknown effects of concomitant polydrug 
use.
1.2 SHORT-TERM SEQUELAE OF RECREATIONAL MDMA USE
The short-term physical, emotional, and cognitive sequelae of recreational MDMA-use 
have been studied from varying professional perspectives and are reviewed in the 
following section. The survey of recreational MDMA-users in Australia and overseas 
has examined the subjective experience of MDMA use. The acute and residual, 
psychological and physical effects of MDMA, commonly reported by recreational users, 
are discussed in the following review of the literature. Objective examinations of the 
cognitive and emotional effects of MDMA have also been conducted, and these are 
examined subsequently. Finally, the clinical investigation of cases of adverse physical 
reactions to MDMA and psychopathological sequelae associated with its use are 
reviewed. The long-term consequences of MDMA-use are discussed in later sections.
1.2.1 Self-Reported Short-Term Effects of Recreational MDMA Use
The unique psychoactive effects of MDMA have been described as an elevated mood 
state encompassing feelings of euphoria, intimacy and closeness to other people, which 
are experienced in conjunction with additional stimulant and hallucinogenic effects 
(White et al., 1996). The acute stimulant effects of MDMA include increased alertness 
and energy, talkativeness, increased heart rate, increased blood pressure, dry mouth, 
decreased appetite, and jaw clenching (Steele et al., 1994; Peroutka, 1990). Although 
some hallucinogenic properties of MDMA are reported, unlike LSD, they are described 
as mild changes in perception without significant distortions of consciousness or
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disorientation. Sensory disruption and loss of contact with reality have not been 
commonly reported with MDMA (Peroutka, 1990). The acute effects of MDMA 
reported in surveys are listed in Table 1.1.
Table 1.1: Reported Acute Effects of MDMA
Positive Acute Effects Reported Negative Acute Effects Reported
Elevated mood Loss of appetite
Euphoria Jaw clenching / tension and grinding of 
teeth
Increased physical and emotional energy Nausea
Heightened sensual awareness Ataxia or transient gait disturbance
Increased self-esteem and confidence Tremors and motor restlessness
Increased sense of intimacy Dry mouth
Heightened sensuality Tachycardia
Enhanced communication skills Insomnia
Facilitator for interpersonal relations Hot and cold flushes
Increased sensual properties of sex Increased sweating and sweaty palms
Lowered inhibitions Poor concentration 
Nystagmus 
Blurred vision 
Panic and Paranoia 
Dehydration
Increased skin sensitivity / touch
sensitivity
Reduced urine flow
The residual effects of MDMA persist for up to 24 hours after acute intoxication wears 
off and include drowsiness, a continuing sense of ‘closeness’ to others, tight jaw 
muscles, depression, difficulty concentrating, muscle aches, and fatigue (Steele et al., 
1994; Gerra et al., 1998; Curran & Travill, 1997; Topp et al., 1998). The residual 
effects reported in surveys of recreational MDMA-users are listed in Table 1.2. Some 
residual psychological effects have been reported to last up to 5 days including mood
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disturbance and deficits in concentration and attention (Curran & Travill, 1997) and
these will be discussed in greater detail in the following section.
Table 1.2: Reported Residual Effects of MDMA
Psychological Residual Effects Physical Residual Effects
Irritability Energy loss / lethargy
Insomnia Muscular aches
Confusion Hot / cold flushes
Anxiety Blurred vision
Paranoia Numbness / tingling
Depression Profuse sweating
Hallucinations Dizziness
Panic attacks Tremors
Poor Concentration Headaches
Increased aggressive behaviour Stomach pain
Dental problems from jaw grinding
1.2.2 Psychometric Assessment of the Acute and Residual Sequelae of Recreational 
MDMA Use
The short-term psychological consequences of recreational MDMA use have been 
investigated by studies examining cognitive and emotional sequelae in the week 
following self-administration of MDMA. In their study of the acute and residual effects 
of MDMA on both mood and cognition, Curran and Travill (1997) compared MDMA- 
users with alcohol using controls over three days on measures of working memory, 
depression, and immediate and short-term memory. The first day of testing was carried 
out in a dance club setting whilst each of the participants was under the influence of 
either alcohol or MDMA. Subjects were then assessed the following day (Day 2) and 
mid-week (Day 5). The authors assessed subjects’ mood with both the Beck Depression 
Inventory (BDI) and a mood rating scale. Working memory was assessed via a serial 
sevens task and both immediate and short-term memory were assessed using an
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immediate and delayed prose recall task. The researchers reported that participants had 
refrained from using any illicit substances between Days 1 and 5. Comparison of the 
MDMA and alcohol groups revealed deficits in working memory in MDMA-users 
compared to controls over the three days. MDMA-users made fewer subtractions in the 
serial sevens task on all three test days, however this difference was more marked on 
Day 2. The authors noted that there was no significant difference between the two 
groups in the number of errors made. Although the authors did not interpret their data 
in this fashion, a plausible clinical interpretation of these results suggests that MDMA- 
users had slower processing speed than alcohol users, however the accuracy of their 
responses was not affected. There were no significant differences between the two 
groups’ immediate and short-term memory performance on the prose recall tasks.
In their assessment of depression (BDI), Curran and Travill (1997) found that MDMA- 
users rated lower depression on Day 1, whilst under the influence of MDMA, when 
compared to controls who were under the influence of alcohol, but showed similar 
ratings of depression on the ‘hangover’ Day 2. While Alcohol users returned to Day 1 
baseline levels on Day 5, MDMA-users rated even higher depression, which in some 
cases reached clinical levels. The higher rating of depression on Day 5 was interpreted 
as indicative of an MDMA-induced ‘mid-week low’, which is consistent with self- 
reported lowered mood in surveys of ‘Ecstasy’ users (Topp et al., 1999). For the 
remaining mood measures, the authors described a similar pattern of results, which 
emerged over the three assessment days, for the two groups. While alcohol users 
showed a ‘U’ shape curve over the three days, with participants rating a slightly lower 
mood on Day 2 compared to 1 and 5, MDMA-users rated progressively lower mood 
from Days 1 to 5. These findings suggest that the residual effects of MDMA use 
include elevated depression mid-week, which in some cases reaches clinical levels. The
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authors postulate that the lowered mood experienced mid-week after using MDMA on 
the weekend may be a functional consequence of depleted serotonin levels, following 
acute elevation of serotonin after administration of MDMA, a pattem observed in the 
study of the pharmacological effects of MDMA in animals.
Evidence for MDMA’s neurotoxic potential, which will be discussed at length in a later 
section, has been obtained from both animal studies and examinations of serotonin 
metabolites in cerebrospinal fluid (CSF) and brain imagery studies in humans. 
Although consequences of long-term neurotoxicity were not examined in the Curran 
and Travill study, it has been demonstrated that MDMA use results in persistent 
cognitive and mood disturbance (Steele et al., 1994; Morgan, 1999). The fact that over 
half of the alcohol using controls in the Curran and Travill study were also recreational 
MDMA-users is a significant confound, because the presence of enduring cognitive and 
mood disturbance was a possible feature of both groups. Consequently, the comparison 
between alcohol users and MDMA-users may not accurately reflect the residual effects 
of MDMA use. This may have contributed to the researchers’ failure to find significant 
group differences on the prose recall tasks and may have underestimated the residual 
effects of MDMA on mood and cognition.
Comparative studies with controls without a history of MDMA use are needed to 
accurately determine the extent of mood and cognitive disturbance in the week 
following MDMA use. A further criticism of the Curran and Travill (1997) study was 
the researchers’ failure to establish a drug free baseline to control for pre-existing group 
differences. Parrott and Lasky (1998) addressed these problems in their subsequent 
study of the residual effects of MDMA on mood and cognition. The performance of 
regular MDMA-users (over 10 occasions of use) was compared to novice MDMA-users
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(less than 10 occasions of use) and controls who had never taken MDMA, on measures 
of verbal memory, visual scanning and mood. The assessment of mood and cognition 
was carried out on four separate occasions and a drug free baseline was established to 
which the acute and residual effects of the drug were compared. The cognitive 
assessment included a measure of verbal memory involving an auditory word recall task 
and a visual search task involving the scanning and discrimination of stimuli. Sixteen 
mood states were also assessed using visual analogue scales rating from 1 to 100, 
including depression, clear headedness, calmness, energy levels and sadness. At Time 1 
the baseline measurement was obtained when participants were drug free and had not 
used MDMA for a week or other illicit drugs for more than 24 hours. The assessment at 
Time 2 was carried out at a London nightclub, between 2 and 16 hours after self­
administration of MDMA, while participants were under the influence of MDMA and 
other recreational drugs. The controls, who were also assessed whilst intoxicated, 
reported being under the influence of alcohol, cannabis and cocaine. Mood and 
cognitive assessments were then carried out two and seven days after attendance at the 
nightclub.
Statistical analyses revealed that both novice and regular recreational MDMA-users 
displayed significantly worse memory scores than controls whilst under the influence of 
MDMA and at two and seven days after administration of MDMA. At the baseline 
measurement, regular MDMA-users’ performance on the word recall task was worse 
than both novice users and controls, indicating comparative deficits in verbal memory 
for regular users whilst drug free, and when free of the residual effects of MDMA. This 
group difference may reflect the enduring cognitive consequences of long-term 
MDMA-induced neurotoxicity mentioned earlier. Novice MDMA-users had 
comparable memory performances to controls at baseline. Whilst intoxicated, both
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novice and regular MDMA-users displayed deficits in verbal memory when compared 
to controls, and two days after self-administration of MDMA, regular users exhibited 
deficits in verbal memory when compared to both novice users and controls. These 
deficits continued to be apparent 7 days after self-administration of MDMA for both 
novice and regular users. The verbal memory deficits evident in MDMA-users, when 
compared to controls, contradict Curran and Travill’s (1997) earlier findings, however, 
this anomaly may be attributed to the use of MDMA-naive controls. Indeed the 
difference between the two groups at baseline measurement of verbal memory in the 
Parrott and Laskv study indicates memory deficits were apparent independent of the 
acute or residual effects of MDMA. An examination of comparative deficits in memory 
performance within each group over the four assessment times would have determined 
whether the group differences evident in the seven days following self-administration of 
MDMA reflected residual effects of the drug or simply emulated the baseline variance, 
however the researchers failed to examine this factor. It is apparent, however, that the 
memory deficits evident during the acute effects of MDMA, for both novice and regular 
users, were greater than those manifested at baseline and two and seven days after 
MDMA use, indicating the presence of significant cognitive difficulties whilst under the 
acute influence of MDMA. The researchers claim that memory deficits were more 
pronounced in regular users, suggesting that there might be a dose-response relationship 
between MDMA use and memory disturbance. However, the researchers failed to take 
an extensive history of MDMA use from participants and instead arbitrarily classified 
them as novice or regular users on the basis of whether the self-reported number of 
‘Ecstasy’ tablets taken exceeded ten. It is therefore impossible to conclude that a true 
dose-response relationship exists from the available data.
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Parrott and Lasky (1998) found that participants’ performance on the visual search task 
was similar for all three groups at baseline, however, visual scanning skills of regular 
MDMA-users were impaired when compared to novice users and controls when under 
the acute influence of MDMA. Unlike verbal memory, the visual performance of 
MDMA-users was unimpaired in the seven days following self-administration of 
MDMA. The assessment of mood over the seven days revealed similar mood for all 
three groups at baseline and on the Saturday night whilst participants were intoxicated. 
Group differences became apparent two days after self-administration of MDMA when 
users of the drug reported significant elevations in a range of negative mood states, 
including depression, sadness, unsociability, unpleasantness and abnormality. It was 
noted that while mood fluctuated markedly over the week in MDMA-users, it remained 
fairly stable over time for the controls.
In summary, through their examination of the acute and residual effects of MDMA upon 
mood and cognition, Parrott and Lasky (1998) demonstrated that MDMA-users 
manifested verbal memory impairment when compared to controls, both before and 
after MDMA administration. Furthermore, visual scanning and verbal memory 
dysfunction was apparent whilst under the acute influence of MDMA. However, 
despite the researchers’ claim to have examined the acute effects of MDMA on mood 
and cognition, the wide variation among subjects in the amount of time lapsed between 
self-administration of MDMA and the assessment, prevents reliable conclusions from 
being drawn from these data. Indeed, it can be argued that in some cases the delay of up 
to 16 hours after MDMA administration prevented the researchers from examining 
acute effects in these participants. Finally, fluctuating mood in the week following self­
administration of MDMA was also apparent in MDMA-users when compared to 
controls.
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1.2.3 Systemic Toxic Effects of MDMA Use Associated with Fatality
As the popularity of MDMA has grown, the reported number of adverse medical 
sequelae associated with MDMA use, such as acute toxicity and even death, have 
increased. Adverse medical sequelae following administration of MDMA have 
included: cardiac abnormalities including arhythmias and cardiovascular collapse; 
rhabdomyolysis; disseminated intravascular coagulation; hypertension; convulsions; 
liver necrosis; metabolic disturbance; hyperthermia; acute renal failure; and 
hepatotoxicity (White et al., 1996). A review of the case reports of fatalities in the 
literature indicates that the pattem of events associated with severe morbidity and 
fatality after ingestion of MDMA is consistent with malfunction of normal temperature 
control and water balance (White et al., 1996). However, the illicit source of ‘Ecstasy’ 
in these cases has made it difficult to determine whether contaminants play a role in 
severe morbidity or death (Steele et al., 1994).
1.2.4 Short-Term Psychopathological Sequelae of Recreational MDMA Use
While we are presently unable to fully understand the contribution of MDMA use to the 
onset of psychiatric disturbances, MDMA has been associated with lasting 
psychopathological sequelae (Schifano, DiFuria, Forza, Minicuci et al., 1998; McCann 
& Ricaurte, 1991). In a survey of MDMA using patients presenting at an addiction 
treatment unit in Italy, over half of the sample was affected by one or more 
psychopathological problem (Schifano et al., 1998). The most frequently reported 
problem were depression, psychotic disorders, cognitive disturbances, bulimic episodes, 
impulse control disorders, panic disorders and social phobia. Although no implication 
of causality between MDMA use and psychopathology can be made from the survey, 
the researchers found that psychopathological disturbance was associated with longer-
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term and larger dose MDMA users. Similarly, reports of psychological disturbance 
have been found in non-clinical populations. In a study of 15 MDMA users who had 
ceased taking the drug 3 weeks prior to the psychological assessment, the researchers 
found evidence for dysphoria and mood changes in over half the sample (Gerra et al., 
1998). It is apparent that psychiatric morbidity developed in the context of MDMA use 
is identical to psychopathology unrelated to the use of MDMA. One study compared 
cases of psychosis which had developed in the context of MDMA abuse with cases 
unrelated to substance abuse and found no difference between the two presentations 
(McGuire, Cope & Fahy, 1994).
Although several studies have described various forms of psychiatric morbidity in 
MDMA users, the majority of these have been examinations of a small number of cases 
from clinical populations. In a recent study of light MDMA users ( 1 - 2 0  occasions) 
and heavy MDMA users (30 -  1000 occasions) from a non-clinical sample, the 
researchers found that heavy users reported significantly higher scores than controls on 
measures of paranoid ideation, psychoticism, somatisation, obsessionality, anxiety, 
hostility, phobic anxiety, impulsiveness, alteration in appetite and restlessness during 
sleep (Parrott, Sisk & Turner, 2000). Light users reported significantly higher scores 
than controls on a measure of psychoticism and significantly lower scores than heavy 
users on measures of anxiety, paranoid-ideation, and alterations in appetite. It is 
apparent from these studies that MDMA has been associated with a variety of 
psychiatric morbidity, however, the nature of MDMA’s role in the development of this 
psychopathogy is unclear. It has, however, been proposed that the lasting effects of 
MDMA on the serotonergic system may contribute to the development of 
psychopathology. Serotonin has been implicated in the pathophysiology of several 
psychiatric syndromes, including depression, anxiety, panic, eating disorders and
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psychosis. McGuire et al. (1994) claim that an association between MDMA use and the 
development of psychopathology might therefore be expected on theoretical grounds. 
However, the observation that only some individuals develop psychiatric morbidity 
after MDMA use suggests that certain predisposing factors make some individuals more 
susceptible than others (Steele et al., 1994). Alternatively, it has been suggested that 
individuals with serotonin depletion related psychopathology are attracted to MDMA as 
a result of its serotonin releasing properties and that MDMA has no causal relationship 
with the development of psychopathology.
1.3 MDMA-INDUCED SEROTONERGIC NEUROTOXICTY
The neurotoxic effects of MDMA have been widely demonstrated and explored in 
various animal species and there is a considerable body of literature documenting the 
pharmacological effects of MDMA among experimental animals. Of particular 
significance to the recreational use of MDMA in humans is the examination of this 
process in non-human primates. Evidence of MDMA’s neurotoxic potential derived 
from animal studies has lead researchers to investigate whether similar patterns of 
toxicity are found in human recreational users of MDMA. The following review of the 
literature will firstly examine the characteristics of MDMA-induced neurotoxicity in 
experimental animals and non-human primates, and discuss a proposal for the 
mechanism of neurotoxicity. The evidence supporting the presence of MDMA-induced 
neurotoxicity in human recreational users will then be discussed.
1.3.1 Evidence for MDMA-Induced Neurotoxicity from Animal Studies
MDMA has been demonstrated both histologically and biochemically to be a selective 
neurotoxin for serotonin pathways in many species of experimental animals, including 
the mouse, rat, guinea pig and dog, (reviewed in Green et al., 1995). Animals given
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MDMA show long-term reductions in concentrations of biochemical markers for 
serotonergic functioning, including direct measures of brain serotonin levels, the 
number of serotonin uptake sites (reflecting destruction of brain serotonin terminals), 
and the level of serotonergic metabolites in cerebrospinal fluid (CSF). Anatomical 
studies indicate that MDMA produces these neurochemical deficits by damaging 
serotonergic nerve fibres (Ricaurte, DeLanney, Wiener, Irwin et al., 1988a).
Animal studies have revealed that MDMA-induced neurodegeneration is related to both 
the dose and frequency of administration (O’Shea, Granados, Esteban, Colado et al., 
1998; Commins, Vosmer, Virus, Woolverton et al., 1987). Long-term neurotoxic effects 
have been found to occur after either a single large dose or when several lower doses 
were administered subcutaneously over a short period of time (Green et al., 1995). 
Early animal studies of the toxic effects of MDMA in the rat brain demonstrated that 
one large dose or repetitive low doses of MDMA administered twice daily over four 
days, produced lasting decreases in biochemical markers for serotonergic functioning 
(Sprague et al., 1998). Studies in this area found that the administration of MDMA to 
rats resulted in a decrease in serotonin levels for up to 8 weeks after a single dose 
(Commins et al., 1987) and for 6 to 12 months after multiple doses administered twice 
daily for four days (Sprague et al., 1998). The most severe reductions in serotonin 
levels were found in the neocortex, striatum, and hippocampus, while much smaller 
decreases were found in the brainstem and the hypothalamus (Sprague et al., 1998). 
Animal studies have also revealed that MDMA causes a reduction in the density of 
serotonin uptake sites (Commins et al., 1987). Notably, the density of uptake sites for 
dopamine and noradrenaline are not affected to the same extent by MDMA and require 
much higher doses before evidence of neurotoxicity is apparent (Steele et al., 1994;
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Sprague et aL, 1998). These findings suggest that MDMA is a selective serotonin 
neurotoxin.
The neurochemical changes and the depletion of biochemical markers of serotonergic 
functioning evidenced after MDMA administration have been attributed to serotonergic 
axonal damage. It has been demonstrated that MDMA produces a profound loss of fine 
serotonergic axons in the rat brain. Studies using the Fink-Heimer staining method to 
detect degenerating axon terminals and cell bodies have identified axonal damage in 
several brain regions after administration of MDMA (Commins et al., 1987). Those 
regions of the brain rich in serotonin terminals, such as the cerebral cortex and 
hippocampus, show more damage than those areas containing cell bodies or fibres of 
passage such as the brainstem or hypothalamus (Steele et al., 1994). It is apparent that 
MDMA selectively destroys the fine serotonergic axons, which generally innervate the 
cortex, while the cell bodies and thick beaded axonal fibres remain intact (Sprague et 
al., 1998). Serotonergic toxicity has been further demonstrated by 
immunocytochemical studies in the rat brain. These studies have shown that 
neurodegenerative changes occur after administration of MDMA, including increased 
serotonin axon calibre, huge swollen varicosities, fragmentation and dilated axon 
stumps, and the loss of forebrain serotonin terminals (Green et al., 1995). The findings 
in rat brains that the cell bodies appear resistant to MDMA induced damage suggests 
that there may be potential for regeneration of the damaged serotonergic axons in the rat 
brain (Sprague et al., 1998).
While the pattern of MDMA-induced serotonergic neurodegeneration in experimental 
animals is replicated in non-human primates, there is evidence to indicate that the 
neurotoxicity of MDMA is prolonged and possibly permanent in non-human primates
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and that they may be more sensitive than rodents to the neurotoxic effects of MDMA. 
Insel, Battaglia, Johannessen, Marra et al., (1989) administered high doses of MDMA 
(10 mg/kg) to rhesus monkeys twice daily for 4 days. This produced selective and 
significant neurochemical decreases in both CSF concentrations of serotonergic 
metabolites and brain concentrations of serotonin. A selective decrease in serotonin 
uptake sites was also observed. In a second study, the monkeys were monitored for 14 
weeks after administration of MDMA (10 mg/kg twice daily for 4 days). Throughout 
this period the MDMA-treated animals had decreased levels of serotonergic metabolites 
in CSF when compared to controls. Post-mortem analyses revealed significant 
decreases in the concentration of serotonin, serotonergic metabolites and uptake sites in 
the cerebral cortex and striatum, indicating prolonged damage. An indication of long 
term neurotoxic effects was also revealed by a study which found that seven years after 
administration of MDMA to squirrel monkeys, abnormal brain serotonergic innervation 
patterns were still evident in the neocortex, hippocampus, and striatum (Hatzidimitriou, 
McCann & Ricaurte, 1999). However, deficits in some areas, including the 
hypothalamus and thalamus, were less severe than those observed two weeks after 
administration and there was evidence for complete recovery in some regions of the 
hypothalamus and thalamus.
Numerous other studies have documented the effect of MDMA on different sites of the 
non-human primate brain. Studies of squirrel and Macaque monkeys treated with 
repeated doses of MDMA have demonstrated degeneration of fine serotonergic 
terminals and decreased serotonin levels in many brain regions and similar patterns have 
been demonstrated using PET studies of the baboon brain (see Sprague et al., 1998 for 
review).
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One issue regarding the mode of administration of MDMA in animal studies warrants 
clarification. In the majority of animal studies MDMA is injected subcutaneously, 
which is 2-3 times more neurotoxic than oral administration of the drug as a result of 
higher peak blood concentrations (Boot et al., 2000). Although a small minority of 
recreational users inject MDMA, the preferred route of administration is oral. 
Therefore, the applicability of animal studies, employing subcutaneous methods of 
administration, to humans has been questioned. The neurotoxic effects of orally 
administered MDMA were demonstrated when low oral doses of MDMA (2.5mg/kg), 
given twice daily, were found to lower the levels of serotonin and its metabolites in the 
hippocampus of rhesus monkeys (Sprague et al., 1998). This study indicates that orally 
administered MDMA results in serotonergic degeneration in non-human primates.
The studies demonstrating serotonergic degeneration in non-human primates have 
important ramifications for humans. Significantly, these primate studies have used 
weight-adjusted doses and dose regimens that are similar to those typically used by 
humans at raves and dance parties (Sprague et al., 1998). The lowest effective dose of 
MDMA capable of producing long-term depletion of serotonin in primates is roughly 
equivalent to a dosage of about one or two tablets in humans (Schifano et al., 1998). 
Also of concern is the finding that when administered orally MDMA results in damage 
to central serotonergic neurons in non-human primates. A study by Ricaurte, 
DeLanney, Irwin and Langston (1988b) indicates that when MDMA is given to 
monkeys in a manner similar to that employed by humans it continues to affect central 
serotonergic neurons. Animal studies have also confirmed that levels of metabolites of 
serotonin in CSF can be employed to detect MDMA-induced central nervous system 
(CNS) serotonergic damage. Monkeys found to have decreased concentrations of 
serotonergic CSF metabolites after administration of MDMA also displayed reductions
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in CNS serotonin in post-mortem analyses (Ricaurte et al., 1988a). The findings from 
studies in non-human primates have important implications for both the incidence and 
detection of serotonergic neurodegeneration in humans. Firstly, both the dose and mode 
of administration of MDMA typically employed by humans has been found to result in 
serotonergic neurotoxicity in non-human primates. Secondly, levels of serotonergic 
metabolites in CSF may be used as a marker for brain serotonin levels to determine the 
existence of CNS serotonergic damage in human recreational users of MDMA.
1.3.2 A Proposed Mechanism of Neurotoxicity
Evidence for long-term neurotoxicity of serotonin neurons and receptors after 
administration of MDMA has been demonstrated by the depletion of markers such as 
brain serotonin, its metabolite 5-hydroxyindoleacetic acid (5-HIAA), and the number of 
serotonin uptake sites (Sprague et al., 1998; Green et al., 1995). The mechanism 
involved in MDMA-induced neurotoxicity of serotonergic neurons is thought to be 
highly complex and many of the explanations proposed are speculative. Studies on the 
rat brain have shown that the loss of serotonin after administration of MDMA occurs in 
two phases. After an initial release of serotonin, a massive and rapid depletion in 
serotonin content of the brain occurs within 4 hours of MDMA injection, with reports of 
an 80% loss in the content of brain serotonin and its metabolites (Green et al., 1995). 
Serotonin levels start to return to normal within 24 hours, however, after approximately 
24 hours, brain serotonin content (particularly in the cortex, hippocampus and striatum) 
starts to fall again. This decrease becomes unequivocal by 2-3 days and concentrations 
continue to decrease for up to a year indicating long-term neurotoxicity. 
Immunocytochemistry studies have demonstrated that while the fine serotonergic axons 
throughout the rat forebrain are degenerated after MDMA administration, the cell 
bodies remain intact, indicating the potential for regeneration of serotonergic
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projections. Indeed, regeneration has been shown to occur both in rats and non-human 
primates, however, the pattern of reinnervation is abnormal with some regions showing 
hyperinnervation and others deinnervation, (Sprague et al., 1998).
Although currently there is no one theory that can account for all of the data available, 
Sprague et al. (1998) have proposed an integrated hypothesis for the mechanisms 
involved in serotonergic neurodegeneration after MDMA administration. The authors 
state that MDMA induces an acute release of serotonin and dopamine. This acute 
release then leads to depletion of intraneural serotonin stores. The initially released 
serotonin also activates post-synaptic serotonin receptors located on gamma- 
aminobutyric acid (GABA) intemeurons. The role of the GABAergic system in the 
neurotoxic process appears to be predominately as a modulator of dopamine activity. 
Activation of post-synaptic serotonin receptors on GABA intemeurons results in a 
decrease in inhibitory GABAergic transmission, and this leads to an increase in the 
production and release of dopamine. Dopamine has been shown to play a clear role in 
MDMA-induced neurotoxicity. A linear correlation has been demonstrated between the 
release of dopamine and the extent of long-term damage to serotonin terminals (Sprague 
et al., 1998). Moreover, when the synthesis of dopamine is inhibited prior to the 
administration of MDMA, serotonin terminals are protected against degeneration and 
complete elimination of MDMA-induced neurotoxicity occurs when dopamine 
terminals are destroyed. Conversely, when dopamine levels are elevated MDMA- 
induced neurotoxicity increases (Steele et al., 1994; Sprague et al., 1998; Stone, 
Johnson, Hanson & Gibb, 1988). The serotonin released by MDMA is therefore 
thought to be largely responsible for the activation of post-synaptic serotonin receptors, 
which in turn enhance the release and synthesis of dopamine, resulting in markedly 
amplified concentrations of dopamine in the CNS.
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In light of the observation of excessive dopamine production and release following 
MDMA treatment and the known relationship between dopamine and MDMA-induced 
neurotoxicity the role of dopamine in the destruction of serotonin terminals has been the 
subject of speculation. It has been proposed that the excessive dopamine released is 
transported into the depleted serotonin terminal. Consistent with this hypothesis is the 
observation that the serotonin uptake carrier will also transport dopamine. The 
dopamine is then deaminated by monoamine oxidase B (MAO-B) located within the 
serotonin terminal. One of the products of this deamination process is hydrogen 
peroxide, which may lead to selective destruction of the serotonin terminal (Sprague et 
al., 1998).
The potential role for dopamine in the destruction of serotonin terminals raises an 
important issue, which has not been addressed by animal studies of MDMA-induced 
serotonergic neurotoxicity to date. The effect of polydrug regimens on the mechanism 
of neurotoxicity has not been examined despite its relevance to human MDMA use. 
Human patterns of MDMA use typically involve the intake of other drugs either 
voluntarily or inadvertently such as when other drugs are compounded within the 
‘Ecstasy’ tablet (Topp et al., 1999). It can be hypothesised that other drugs, commonly 
used in conjunction with MDMA, that potentiate monoamine transmission, such as 
amphetamine and cocaine, may increase susceptibility to neurotoxicity.
1.3.3 Evidence for MDMA-Induced Neurotoxicity in Humans from the Biological 
Assessment of Central Nervous System (CNS) Functioning
Findings from animal studies have lead researchers to hypothesize that similar patterns 
of MDMA-induced neurotoxicity may be found in recreational users of ‘Ecstasy’. As
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noted in the previous section, the neurotoxic dose of MDMA in non-human primates is 
similar to the dose range of MDMA typically taken by recreational users and oral 
administration of MDMA, the mode preferred by recreational users, is neurotoxic in 
non-human primates (Ricaurte et ah, 1988b). Moreover, there is evidence to suggest 
that non-human primates are more susceptible than other species to MDMA-induced 
serotonergic degeneration and that MDMA-induced neurotoxicity is prolonged and 
possibly permanent (Insel et al., 1989; Hatzidimitriou et al., 1999). These findings have 
led to a growing concern that human MDMA-users might also incur serotonergic 
degeneration.
Studies in this area have attempted to establish whether patterns of neurotoxicity found 
in non-human primates generalize to humans, however, there are currently no available 
methods for directly evaluating the integrity of serotonin neurones in the living human 
brain. Therefore studies of MDMA’s neurotoxic potential in humans have employed 
indirect methods to assess the integrity of serotonergic functioning in the central 
nervous system (CNS), including the measurement of metabolites of serotonin, such as 
5-hydroxyindoleacetic acid (5-HIAA), in cerebrospinal fluid (CSF) and the assessment 
of neuroendocrine functioning. As noted in the discussion of the literature above, 
studies in non-human primates indicate that concentrations of serotonergic metabolites 
in CSF, such as 5-HIAA, can be used to reliably detect damage to the CNS serotonergic 
system. Through post-mortem analyses Ricaurte et al. (1988a) established that the 
measurement of concentrations of 5-HIAA in CSF effectively detected brain 
serotonergic damage in squirrel monkeys. Moreover the concentrations of CSF 5-HIAA 
underestimated the extent of serotonergic damage in the brain. The authors generalised 
from these findings to suggest that concentrations of serotonergic metabolites in CSF
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may be useful for detecting MDMA-induced neuronal damage in humans (Ricaurte et 
al., 1988a).
Human CSF studies examining concentrations of serotonergic metabolites after 
exposure to MDMA have found evidence in support of serotonergic degeneration. 
McCann, Ridenour, Shaham and Ricaurte (1994) compared abstinent MDMA-users to 
matched controls, in a controlled inpatient setting, on several biological measures of 
central serotonergic functioning, including concentrations of CSF 5-HIAA. As 
expected, MDMA-users were found to have lower concentrations of 5-HIAA in CSF 
than controls. The authors concluded that this pattern of results was consistent with the 
hypothesis that recreational MDMA use is associated with an alteration in central 
serotonergic metabolism (McCann et al., 1994). The authors caution that the nature of 
these alterations is difficult to establish on the basis of CSF data alone. However, the 
fact that similar decrements have been observed in MDMA-treated monkeys, with 
known serotonergic CNS deficits, supports the conclusion that CSF 5-HIAA reductions 
in recreational MDMA-users reflect MDMA-induced neurotoxicity (McCann et al., 
1994). This hypothesis has received further support through replications of these 
findings in similar studies (Bolla, McCann & Ricaurte, 1998; McCann, Mertl, 
Eligulashvili & Ricaurte, 1999).
An alternative biological index of central serotonergic functioning can be obtained 
through analyses of neuroendocrine functioning.. Gerra et al. (1998) found evidence for 
neuroendocrine functional deficits in MDMA-users, suggesting impairment in the 
serotonergic system. The researchers found that when compared to controls, MDMA- 
users had blunted prolactin and cortisol responses to D-fenfluramine, a serotonin 
agonist, which suggests serotonin receptor downregulation or dysfunction. However,
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McCann et al. (1994) failed to find a difference between MDMA-users and controls on 
a similar measure of neuroendocrine functioning. The researchers found the prolactin 
response to L-tryptophan, which is thought to provide a measure of CNS serotonergic 
functioning, to be similar in MDMA-users and controls. The authors postulated that 
their failure to find differences in neuroendocrine functioning may be attributable to the 
long period of abstinence in their sample of MDMA-users and the possibility of axonal 
recovery. However, prolonged effects of MDMA on serotonergic functioning have 
been observed after long periods of abstinence (Gerra, Zaimovic, Ferri, & Zambelli, 
2000). Gerra et al. (2000) found that reductions in prolactin response to D-fenfluramine 
observed in three week abstinent MDMA-users were unchanged after twelve months of 
abstinence. In contrast, reductions in cortisol response to D-fenfluramine in the same 
three-week abstinent cohort were restored after twelve months of abstinence. The 
authors concluded that the restored cortisol response indicated that MDMA-induced 
neuroendocrine impairment may be partially reversible. Finally, the observation of 
cortisol recovery after twelve months of abstinence from MDMA, in conjunction with 
the correlation between time of exposure to MDMA and neuroendocrine changes, lend 
further support to the hypothesis regarding the neurotoxic potential of MDMA on the 
human brain.
1.3.4 Evidence for MDMA-Induced Neurotoxicity in Humans from Neuroimaging 
Techniques
Alternative methods used to assess serotonergic functioning in the living human brain 
include neuroimaging techniques such as positron emission tomography (PET) and 
electroencephalography (EEG). Dafters, Duffy, O’Donnell and Bouquet (1999) used 
quantitative EEG measures in an attempt to identify abnormal brain states in MDMA- 
users. Although some abnormalities consistent with brain damage were found there was
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no control group and the observed abnormalities were not correlated with the extent of 
MDMA exposure.
Neuroimaging techniques such as PET have also been used to assess the status of 
serotonin neurons in living humans. McCann, Szabo, Scheffel, Dannals et al. (1998) 
found that heavy MDMA-users (over 200 occasions of MDMA use) had a lower density 
of brain serotonin transporter sites, which is indicative of serotonergic neural injury, 
when compared to controls. Moreover decreases in serotonin transporter sites were 
positively correlated with the extent of MDMA use. Participants had abstained from all 
psychoactive drug use for three weeks prior to the study to ensure that the decreases 
observed were not due to the acute or residual pharmacological effects of MDMA 
(McCann et al., 1998). In another PET study measuring general metabolic activity 
through the examination of glucose metabolic uptake, the researchers found significant 
differences between MDMA-users and controls in several brain regions, including the 
amygdala, the hippocampus and Brodman’s area 11 (Obrocki, Buchert, Vaterlein, 
Thomasius et al., 1999). Importantly the affected brain regions identified in this human 
study are consistent with post-mortem animal studies examining the effects of MDMA- 
induced neurotoxicity, which lends further support to the occurrence of MDMA- 
induced neurotoxicity in humans (Obrocki et al., 1999).
Recent developments in neuroimaging techniques have enabled researchers to assess the 
density of post-synaptic serotonin receptors in the living human brain. Reneman, Booij, 
Schmand, van den Brink et al. (2000) used single photon emission computed 
tomography (SPECT) in conjunction with a radioligand with a high affinity and 
selectivity for postsynaptic serotonin receptors, to assess the density of serotonin 
receptors in five abstinent MDMA-users. The researchers found evidence for
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significant serotonergic depletion in the occipital cortex of MDMA-users. High 
densities of postsynaptic receptors are an indirect measure of serotonergic depletion and 
the researchers found significantly higher densities in the occipital cortex of MDMA- 
users when compared to controls. Alternatively, SPECT and Magnetic Resonance 
Imaging (MRI) have been combined to study the effects of MDMA on regional cerebral 
blood flow (rCBF), a function believed to be regulated by serotonergic mechanisms 
(Chang, Grob, Ernst, Itti, et al., 2000). Two week abstinent MDMA-users showed mild 
but non-significant reductions in blood flow when compared to control subjects, 
indicating that either recreational MDMA use does not substantially alter serotonergic 
regulation of rCBF or a process of adaptation to serotonergic abnormalities occurs after 
long-term exposure to MDMA. Decreases in rCBF were, however, observed in 
individuals after the administration of MDMA in a controlled clinical setting. 
Decreases in rCBF were evident in most brain regions, including the caudate, superior 
parietal cortices and the frontal cortex, and these alterations were dose related (Chang et 
al., 2000). Thus, through the use of neuroimaging techniques, several studies have 
identified suggestions of MDMA-induced neurotoxicity and it is apparent that MDMA 
use has lasting implications for the integrity of serotonergic receptors in humans.
It is evident from the discussion of the literature in the previous sections that the 
neurotoxic effects of MDMA have been demonstrated in a variety of species using 
several neurobiological measures of serotonergic functioning. MDMA has been found 
to be a selective neurotoxin for serotonin axons and neurochemical studies have 
documented resulting decrements in concentrations of CNS serotonin metabolites. 
Moreover MDMA-induced axonal damage is prolonged with long-term reductions in 
the density of serotonin axons evident in non-human primates. The most severe deficits 
in serotonergic functioning have been observed in the neocortex, striatum and
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hippocampus, and neurotoxicity is related to both dose and frequency of administration. 
Importantly, when administered at doses and in the mode commonly employed by 
recreational users, MDMA is neurotoxic in animals. In accordance with concerns raised 
by animal data, biological assessments of serotonergic functioning in humans, including 
examination of concentrations of serotonergic metabolites in CSF and neuroendocrine 
challenges, have indicated that similar patterns, consistent with MDMA-induced 
serotonergic neurotoxicity, are found in recreational users of ‘Ecstasy’. Neuroimaging 
techniques have confirmed the presence of MDMA-induced serotonergic neural injury 
and reduced density of serotonin uptake sites in humans. Each of these research fields 
converges to support the hypothesis that recreational use of MDMA produces prolonged 
damage to CNS serotonergic functioning in humans. The functional consequences of 
the resulting neurochemical and anatomical alterations will be examined in the 
following section.
1.4 MEMORY AND COGNITIVE IMPAIRMENT AS A FUNCTIONAL 
CONSEQUENCE OF MDMA-INDUCED SEROTONERGIC NEUROTOXICITY
Animal studies of MDMA-induced neurotoxicity have demonstrated that the long-term 
effects of MDMA are most evident in those areas of the brain rich in serotonin terminals 
such as the cerebral cortex, hippocampus and striatum (Steele et al., 1994; Boot et al., 
2000). Notably, the hippocampus is densely innervated by serotonergic axons and 
terminals and it has been postulated that this region is particularly vulnerable to 
MDMA’s neurotoxic effects (Boot et al., 2000). Of the little that is known of the 
structural basis of cognitive functioning, the hippocampus and cerebral cortex have been 
strongly implicated in memory functioning and general cognition, respectively 
(Martinez & Kesner, 1986). Therefore, when considering the functional consequences 
of serotonergic neurotoxicity it can be inferred that MDMA-induced damage has
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potential implications for memory and cognition. Additional justification for an 
examination of memory in MDMA-users can be gleaned from neuropharmacological 
studies of the biochemical basis of memory and learning, which have implicated a role 
for serotonin in mnemonic functioning (Cooper, Bloom & Roth, 1978). Serotonin’s 
involvement in memory has been consolidated further through the study of 
neurodegenerative illnesses such as dementia, which feature memory dysfunction 
(Cross, 1990). In support of these hypotheses, deficits in memory functioning have 
been identified as one of the more pervasive and enduring consequences of MDMA use. 
In addition to studies of immediate and short-term memory, investigations of attention 
and concentration, executive functioning and processing speed have demonstrated that 
the implications of recreational MDMA use also include more pervasive impairment in 
cognitive functioning. Observations of impairment in general cognition suggest that the 
neurotoxic effects of MDMA are widespread, implicating neuronal damage in other 
brain regions. The following review of the literature will examine these findings and 
discuss the case for a causal relationship between MDMA use and memory and 
cognitive impairment.
1.4.1 Memory Functioning in MDMA-users
The term memory has been defined in numerous different ways but customarily refers 
to the storage and retrieval of information. Human memory is conceptualised in terms 
of both the structure of the memory system and the processes operating within that 
system. While structure refers to the way in which the memory system is organised, 
processes refer to the activities occurring within the system (Eysenck & Keane, 1990). 
The structure of memory is commonly described in terms of stages, including short­
term and long-term memory. The first stage of short-term memory is referred to as 
immediate memory. It serves as a limited capacity store from which information is
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transferred to a more permanent store and typically lasts from 30 seconds to several 
minutes. The restricted capacity of immediate memory imposes limitations on the 
amount of information able to be processed and remembered. The second stage of 
short-term memory, labeled delayed memory in some assessment batteries, has duration 
of up to one hour (Lezak, 1995), but is more typically measured 25 to 35 minutes after 
the presentation of stimuli (Wechsler, 1997). Finally, long-term memory is a store of 
essentially unlimited capacity, which can hold information over extremely long periods 
of time (Eysenck & Keane, 1990).
Important distinctions can also be drawn between the different stages of memory 
processing. The process whereby information is transformed into a memory is referred 
to as encoding. Encoding occurs during the presentation of information and determines 
which stimuli are stored within memory (Eysenck & Keane, 1990). Encoding processes 
are essential for transferring information from the temporary memory store, which lasts 
only seconds and which is believed to be governed by the working memory system, to 
more durable memory stores. The “depth of processing effect” has been studied to 
differentiate between superficial encoding, where information is only fleetingly stored, 
and deep encoding, which results in more enduring memories. Superficial encoding 
occurs when information, such as a phone number, is rapidly repeated for several 
seconds in what is known as the phonological loop. Information recycled in this 
manner is encoded only superficially and therefore is readily forgotten after a few 
seconds. To establish a more durable memory, Schacter (1996) postulates that 
incoming information must be encoded more thoroughly, or deeply, by associating it 
meaningfully with knowledge that already exists in memory. Information encoded 
deeply is recalled more accurately and remembered for longer periods of time than 
information encoded superficially. These two levels of encoding processes are thought
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to depend on different networks of brain structures (Schacter, 1996). The process of 
recalling stored information is referred to as retrieval (Eysenck & Keane, 1990). It is 
thought that the brain engages in an act of construction during the retrieval process, 
whereby a complex combination of past encodings and pre-existing knowledge are 
triggered (Schacter, 1996).
Finally, those memory functions that mediate information in the verbal modality are 
differentiated from those that deal with information that cannot be communicated in 
words or symbols such as complex visual patterns. These memory modalities differ 
from one another in their neuroanatomical organisation (Lezak, 1995). The following 
sections will review the literature examining immediate and delayed memory 
functioning in MDMA-users for both the verbal and non-verbal modalities.
Verbal Memory
Verbal memory dysfunction has consistently been observed in recreational MDMA- 
users, however, the pattern of impairment evident in this population has varied across 
studies. The use of different assessment batteries and study designs, in addition to 
variations across cohorts of MDMA-users, have contributed to these discrepancies. 
Immediate verbal memory dysfunction in MDMA-users has been observed in several of 
the studies reviewed below, and the case for a causal relationship between MDMA use 
and immediate memory impairment is supported by observations of a dose-response 
relationship between different features of MDMA exposure and immediate memory 
performance. Delayed verbal memory dysfunction has also been observed in MDMA 
users, however, a dose-response relationship has been found with less consistency. A 
possible explanation for the inconsistency evident across the studies reviewed below in 
their observation of a dose-response relationship is discussed in a later section.
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In an early study of cognitive functioning in MDMA-users, Krystal, Price, Opsahl, 
Ricaurte et al. (1992) examined the clinical significance of verbal memory dysfunction 
by administering a comprehensive standardised neuropsychological battery to 9 three 
week abstinent MDMA-users. Although the researchers did not compare MDMA- 
users’ performances with controls they evaluated the clinical significance of the 
subjects’ neuropsychological profiles in relation to normative data on measures of 
frontal executive functioning, memory, verbal and non-verbal cognitive functioning, 
and intelligence. The authors found no clinical impairment in cognitive functioning 
amongst MDMA-users after conducting preliminary mental status examinations. More 
extensive neuropsychological assessment revealed group patterns of impairment on the 
Wechsler Memory' Scale (WMS). The examination of memory functioning identified 
mild impairment in performances on the WMS initial and delayed paragraphs, which 
assess immediate and short-term verbal memory, in 5 of the 9 subjects. Profiles were 
labeled as mildly impaired if they fell one standard deviation below age-matched 
normative values. The researchers concluded that their results indicated that individuals 
with histories of extensive MDMA use exhibited sub-clinical impairment in verbal 
memory, while other cognitive functioning remained intact. However these subtle 
memory impairments were not of sufficient magnitude to be evident upon examination 
of general mental status.
In a controlled study of memory in MDMA-users, Bolla et al. (1998) compared the 
memory performances of two week abstinent MDMA-users with controls matched for 
age, gender and verbal intelligence. The researchers used a composite measure of 
immediate and delayed verbal memory which was comprised of raw scores from the
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logical memory and verbal paired associates subtests of the Wechsler Memory Scale 
(WMS), the digit span subtest of the Wechsler Adult Intelligence Scale Revised (WAIS- 
R) and the Rey Auditory Verbal Learning Test (RAVLT). The logical memory subtest 
of the WMS assesses subjects’ memory for contextual material presented in story 
format while the verbal paired associates subtest of the WMS requires subjects to 
remember a list of eight unrelated word pairs over four presentations. The RAVLT is a 
test of verbal learning requiring subjects to recall a list of 15 unrelated words over 5 
successive presentations. Recall after the first presentation of the word list provides a 
measure of immediate memory span, while consecutive presentations provide a measure 
of learning. Subjects are then presented with an interference list of 15 different words, 
followed by free recall of the original list, to assess any decrement in performance after 
interference. Delayed memory is assessed with free recall of the original list after a 
thirty minute delay and the recognition component requires subjects to identify words 
from the original list from either a story or word list.
The immediate verbal memory factor was computed from test scores on the RAVLT, 
the digit span subtest of the WAIS-R, and the verbal paired associates subtest of the 
WMS. Although the researchers claim that this factor was a measure of immediate 
verbal memory, the inclusion of the digit span subtest, which requires subjects to recall 
number spans both forwards and backwards, suggests that this factor also comprised 
measures of attention and working memory. The delayed verbal memory factor was 
computed from raw scores on both the recall and recognition component of the RAVLT 
and the 30 minute delay of the logical memory and verbal paired associate subtests of 
the WMS.
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Statistical analyses revealed that MDMA-users manifested impaired visual and verbal 
memory performance when compared to controls. Regression analyses examining the 
association between MDMA use and memory performance revealed that the estimated 
monthly dose of MDMA was associated with impaired immediate verbal memory. No 
association between estimated monthly dose of MDMA and delayed verbal memory 
was found. However, the combination of free recall and recognition performances in 
the delayed verbal factor may have masked the nature of memory impairment and 
prevented the relationship from becoming apparent. A composite measure of delayed 
free recall scores alone may have revealed an association. Thus, Bolla et al. (1998) 
found that more extensive MDMA use was associated with greater impairment in 
immediate verbal memory in a dose-response fashion. Although Bolla et al. (1998) 
matched participants for age, intelligence and sex, the researchers did not control for the 
effects of polydrug use, depression or anxiety, factors also known to influence memory 
functioning (Lezak, 1995). Although the observed relationship must be interpreted with 
caution, the evidence for a dose-response relationship between MDMA-exposure and 
immediate memory dysfunction is consistent with the hypothesis that MDMA-use 
causes memory impairment.
In an attempt to demonstrate a dose-response effect for MDMA consumption and 
cognitive impairment, Parrott, Lees, Garnham, Jones et al. (1998) examined the 
consequences of different levels of MDMA consumption on memory. Parrott et al. 
(1998) compared the verbal memory performances of novice MDMA-users (less than 
10 occasions of use) with regular MDMA-users (more than 10 occasions of use) and 
non-drug using controls to determine if regular MDMA use resulted in greater 
impairment. The three groups were not matched for age, intelligence, sex depression, 
anxiety or other drug use, and the researchers did not statistically control for these
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variables. The researchers used measures taken from the Cognitive Drug Research 
computerised test battery to assess memory. The verbal memory assessment consisted 
of a word recall task, where subjects were visually presented with 15 words at a rate of 
one every two seconds and were then required to write down recalled words. The 
delayed recall task was conducted at the end of the assessment battery when subjects 
were instructed to write down words recalled from the original list.
Both novice and regular MDMA-users performed significantly worse than controls for 
immediate and delayed recall, indicating a comparative deficit in memory functioning. 
However, the observed differences in memory performance between both MDMA 
groups and controls must be interpreted with caution because the researchers’ did not 
control for the confounding effects of age, sex, depression, anxiety, polydrug use, and 
intelligence. Despite previous findings of a dose-response relationship between MDMA 
use and memory deficits, there was no difference between the performance of regular 
and novice users on the verbal memory task. However, a detailed assessment of the 
amount of MDMA consumed by participants was not conducted, and subjects were 
classified into novice and regular users on the basis of an arbitrary cut-off point of 
MDMA consumption. Thus the researchers did not determine in a precise fashion the 
level of MDMA consumption in participants. It is therefore possible that the two user 
groups did not differ sufficiently in their consumption of MDMA to manifest 
differences in memory impairment. Furthermore, the researchers did not control for 
residual effects of recent MDMA use on memory performance, which potentially may 
have masked any differences between novice and regular MDMA-users. Despite these 
methodological limitations, Parrott et al. (1998) demonstrated both immediate and 
delayed memory dysfunction when compared to controls.
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A valid methodological criticism of earlier studies of memory impairment in MDMA- 
users was made by Morgan (1998) who claimed that because these studies did not 
compare MDMA-users with other polydrug users who had never taken MDMA, it was 
possible that the memory deficits observed in MDMA-users were in fact associated with 
a history of other illicit drug use. To address this problem Morgan (1999) assessed 
cognitive functioning in MDMA-users in comparison to polydrug users who had never 
taken MDMA and non-drug using controls. The polydrug using controls and MDMA- 
users were matched for consumption of amphetamine, LSD, hallucinogenic mushrooms, 
inhalants, and cocaine in the previous year. The three groups were not matched for pre- 
morbid intelligence, however, correlational analyses revealed that intelligence did not 
correlate with either immediate or delayed recall performance. Immediate and delayed 
verbal memory was assessed using the story recall test from the Rivermead Behavioural 
Memory Test. Participants were played an audiotaped news story and were required to 
recall the story both immediately and after a 40 minute delay. The MDMA-users were 
found to have significantly poorer performances on both the immediate and delayed 
recall than polydrug using and non-drug using controls, which is consistent with the 
findings of the Parrott et al. (1998) study reported above. These results suggest that 
MDMA use is uniquely associated with immediate and delayed memory impairment 
rather than polydrug use per se, which lends further support to the hypothesis that 
MDMA causes memory impairment. Immediate and delayed recall performances were 
not correlated with estimated total lifetime consumption of MDMA, however a 
combined measure of frequency of use and estimated dose per session was correlated 
with immediate recall in a dose-response fashion. There was no association between 
this indicator of MDMA consumption and delayed recall, which is consistent with the 
Bolla et al. (1998) study reported above. These results provide further evidence for a
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causal relationship between consumption of MDMA and the severity of impairment of 
immediate recall performance.
In accordance with observations of neuronal recovery in animals with MDMA-induced 
neurotoxicity, Morgan (1999) attempted to determine whether MDMA-users regained 
memory functioning after a period of abstinence. The relationship between the period 
of time since MDMA was last used and memory impairment was examined by dividing 
the MDMA cohort into three groups, representing those who had taken MDMA within 
the last month, those who had last used between 1 to 6 months prior to testing and those 
who had not used for over 6 months. Analyses revealed that recall performance of 
individuals who had not taken MDMA within the past six months was better than those 
who had used MDMA. Morgan claims that these results provide tentative evidence for 
the recovery of memory after a period of abstinence from MDMA. However, there 
were only three individuals in the six-month abstinence group thus this landing must be 
regarded with caution. The study of neuronal recovery in animals suggests that this 
period of abstinence is not sufficient to examine the implications of potential neuronal 
recovery for memory performance in humans (Hatzidimitriou et al., 1999). These 
issues are addressed in the study of the long-term effects of MDMA reported in Chapter 
three.
Evidence for delayed verbal memory dysfunction was replicated in a more recent study. 
Reneman et al. (2000) found significant deficits in delayed verbal memory, as measured 
by the delayed free recall task from the RAVLT, in five abstinent MDMA-users 
compared to controls. The small sample size of this study and the researchers’ failure to 
control for the effects of intelligence, sex, anxiety, depression and other drug use,
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prevents definitive conclusions from being drawn, however, this result is consistent with 
other reported findings.
In another recent highly controlled study, Gouzoulis-Mayffank, Daumann, 
Tuchtenhagen, Pelz et al. (2000) compared the memory performance of MDMA-users 
who had no regular use of other psychotropic drugs, with the exception of cannabis, to 
matched controls with a history of cannabis use and drug-naive controls. The three 
groups were similar in terms of age, sex and education level and the investigators 
statistically controlled for intelligence. Memory was assessed using a German 
equivalent of the RAVLT, the standardised measure of verbal memory and learning 
described earlier.
The authors found that MDMA-users recalled fewer words after the first presentation of 
the word list than dmg-nai've controls, indicating a comparative deficit in immediate 
verbal memory in MDMA-users when compared to non-drug users. MDMA-users’ 
performance on this task did not differ significantly from cannabis using controls 
indicating comparative performances in immediate verbal memory, while the cannabis 
users’ performance on this task did not differ significantly from (hug-naive controls. 
MDMA-users required a greater number of repetitions to leam the word list than both 
control groups and forgot more words after interference than drug-naive controls. 
Moreover, verbal memory performance was associated with several different 
characteristics of MDMA use. Specifically, poorer immediate recall performance was 
associated with estimated cumulative dose of MDMA, a greater decrement in 
performance after interference was associated with frequency of use and greater number 
of repetitions required for learning was associated with average dose. Despite the 
variability in the observations of a dose-response relationship, collectively the findings
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of the Gouzoulis-Mayfrank et al. study lend further support to the existence of a dose- 
response relationship and are consistent with both the Bolla et al. (1998) and Morgan 
(1999) studies. Finally, there was no difference between the three groups’ performance 
on the recognition task. Although the authors did not examine this aspect of their data, 
a clinical interpretation of these results suggests that MDMA-users have comparative 
learning deficits and require greater exposure to information than non-users and 
cannabis users to effectively commit information to memory, which may be indicative 
of encoding difficulties. Furthermore, these individuals have greater difficulty 
consolidating information in memory, and interference stimuli result in a greater 
decrement in performance than non-MDMA-users.
Despite the customary pattern of polydrug use reported in surveys of MDMA-users 
(Topp et al., 1999), the non-polydrug using sample of MDMA-users in the Gouzoulis- 
Mayfrank et al. study rules out the cumulative effects of poly drug use in conjunction 
with MDMA as a likely alternative explanation for memory impairment in MDMA- 
users. These findings, in addition to Morgan’s (1999) observation of memory 
impairment in polydrug-using MDMA-users when compared to polydrug-using 
controls, further strengthens the argument for a specific causal relationship between 
MDMA-use and verbal memory impairment.
Non-Verbal Memory
The body of literature documenting evidence supporting the presence of non-verbal 
memory deficits in MDMA-users is less comprehensive than for verbal deficits. Of the 
few studies that have examined non-verbal memory some indications of impairments in 
MDMA-users when compared to non-users have emerged, however, many of these 
findings are limited by the methodological problems discussed earlier. In their
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previously described study of three week abstinent MDMA-users and controls matched 
for age, sex, and intelligence, Bolla et al. (1998) computed a visual memory factor from 
raw scores on the Rey Complex Figure and the visual reproduction, figural memory and 
visual paired associates subtests of the WMS. The Rey Complex Figure is a test of 
visual memory requiring subjects to copy a geometric figure, then reproduce it after 
either a 3 or 30 minute delay. The figural memory subtest of the WMS assesses 
immediate visual recognition where the subject is presented with three abstract 
rectangular target designs and is then required to identify them from an array of similar 
designs. On the visual paired associates subtest the subject is presented with nonsense 
line drawings paired with a coloured square. The subject is subsequently presented with 
the shapes in a different order and is required to recognise the colour that previously 
accompanied them. This is repeated after a thirty-minute delay. Finally, on the visual 
memory subtest, geometric shapes are exposed to subjects for 5 seconds, which they 
then reproduce. Subjects are then required to freely recall these shapes after a delay of 
thirty minutes. Regression analyses revealed that higher average monthly doses of 
MDMA were associated with greater decrements in delayed visual memory function. 
However, the inclusion of both free recall and recognition tasks in the researchers’ 
visual memory factor makes it difficult to determine the exact nature of any visual 
memory impairment observed.
In a more recent study of non-verbal memory, McCann et al. (1999) compared the 
performance of 3 week abstinent MDMA-users and controls on an incidental learning 
task taken from the computerised Walter Reed Army Institute of Research Performance 
Battery over three test days. Subjects were matched for age, however the study failed to 
control for sex, intelligence, depression, anxiety and other drug use. Subjects were 
initially presented with a key of letter-digit pairings and were simultaneously required to
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indicate which digit corresponded to a series of displayed letters. This exercise results 
in incidental learning of the letter-digit pairings. The code key is then removed and 
subjects are required to continue to match the pairs from memory to receive full points 
for each task. Subjects are able to view the code key if necessary, and thus continue to 
learn the stimuli pairings. After a delay of approximately 20 minutes, subjects are then 
required to complete one block of the task without the code key or feedback. The 
researchers reported that when memory performance was averaged over the three days 
MDMA-users performed significantly worse than controls. Although MDMA-users 
performed significantly worse than controls on the delayed recall task on the first day of 
testing, this discrepancy between the groups was not evident on the second and third 
days of testing. McCann et al. did not consider the clinical implications of these data, 
however, this pattern of results may suggest encoding difficulties in MDMA-users 
similar to those evidenced on verbal memory tasks. An evaluation of subjects’ speed 
and accuracy on this task revealed that the MDMA-users were less accurate than 
controls but there was no difference in the two groups’ speed of performance. 
Regression analyses revealed a dose-response relationship between extent of exposure 
to MDMA and memory performance indicating that greater exposure to MDMA was 
associated with poorer non-verbal memory functioning.
In their German study outlined earlier, Gouzoulis-Mayfrank et al. (2000) examined both 
memory and learning in the non-verbal modality in MDMA-users. The researchers 
compared MDMA-users with cannabis using controls and non-drug using controls on a 
standardised measure of non-verbal memory which assessed immediate memory span 
and learning for visuo-spatial material. Subjects were presented with complex visual 
arrangements consisting of geometric figures in the same format outlined for the 
RAVLT. The researchers found that MDMA-users recalled fewer figures after the first 
presentation than both non-users and cannabis users, indicating a relative deficit in
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immediate recall and single-trial learning, however, there were no differences between 
the three groups on the number of repetitions required for learning. Although 
Gouzoulis-Mayfrank et al. did not consider the clinical implications of these data, the 
pattern of results is suggestive of encoding problems for non-verbal stimuli, but an 
intact learning curve.
In summary, although the evidence for comparative deficits in non-verbal memory in 
MDMA-users is less comprehensive than that for verbal memory, it is apparent that a 
similar pattern of disturbance is evident in both modalities. While acknowledging the 
methodological shortcomings in the literature, it can be cautiously inferred that MDMA- 
users have poorer immediate memory for both verbal and non-verbal material than non­
users. The pattem of memory performance evidenced in several of the studies 
demonstrates MDMA-users have problems with single trial learning and require greater 
exposure to material before it is committed to memory and this may be indicative of 
encoding problems. Furthermore, interference results in a greater decrement in verbal 
memory performance in MDMA-users suggesting they have greater difficulty 
consolidating information in memory. Additionally, MDMA-users display poorer 
performance on delayed memory tasks indicating deficits in either storage or retrieval of 
information from memory. Finally, MDMA exposure is related to poorer memory 
performance in a dose-response fashion indicating that heavier MDMA-use is 
associated with greater impairment in memory functioning. This dose-response 
relationship supports the inference of a causal relationship between MDMA-use and 
memory impairment. The argument for a causal relationship is further strengthened by 
the observation that non-polydmg-using MDMA-users also manifest memory 
impairment and polydrug-using MDMA-users display impairment when compared to 
polydrug-using controls. These two lines of evidence suggest that the cumulative
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effects of the polydrug use, commonly reported among this population, do not account 
for the memory impairment observed in MDMA-users. Importantly, although 
comparative memory deficits are evident in MDMA-users it is unclear whether these 
impairments are of sufficient magnitude to be clinically significant, however, there is 
some indication that MDMA-users manifest sub-clinical memory impairment.
1.4.2 Information Processing in MDMA-users
Attention
The concept of attention can refer to several different capacities or processes. Lezak 
(1995) proposes that the different processes involved in attention relate to aspects of 
how the individual is receptive to stimuli in the environment and how they initially 
process incoming information. Lezak (1995) differentiates between four aspects of 
attention. Selective attention refers to the ability to highlight important stimuli in the 
environment while suppressing awareness of competing distractions. Sustained 
attention involves the capacity to maintain attention over a period of time. Divided 
attention is described as the capacity to attend to multiple elements within a task with 
competing demands and alternating attention involves a shift in focus between tasks.
Attentional deficits can impede an individual in almost every area of cognitive 
functioning, including the ability to learn and remember. Several researchers have 
examined attention and concentration in MDMA-users and have found evidence of 
impairment when compared to individuals who have not used MDMA. McCann et al. 
(1999) administered a computerised psychological battery to assess attention and 
concentration in 3-week abstinent MDMA-users over three days of testing. The 
researchers found deficits in MDMA-users when compared to unmatched controls on a 
mental arithmetic task involving sustained attention on the second and third days of
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testing. The poorer performance by the MDMA-users on this task may be indicative of 
relative deficits in higher order attention and concentration skills. Interestingly, there 
was no difference between the two groups at the baseline measurement on the first day 
of testing. However, while both groups’ performance improved over the three days of 
testing, controls’ performance improved more dramatically and the disparity between 
the two groups increased over progressive days. Moreover, MDMA-users exhibited 
slower reaction times for this task on the second and third days of testing, but did not 
differ from controls at the baseline measurement. The clinical interpretation of this 
pattem of results suggests that MDMA-users did not benefit from repeated exposure to 
the same degree as non-users and this may reflect some limitations in learning.
In the German study described earlier, Gouzoulis-Mayfrank et al. (2000) compared 
MDMA-users with non-drug using and cannabis using controls on measures of selective 
visual attention requiring response inhibition, divided attention and an attentional task 
requiring intermodal integration of both visual and auditory information. Each of these 
attention tasks measured subjects’ reaction time in response to relatively complex 
stimuli or stimuli involving competing cognitive demands. The authors found that 
MDMA-users exhibited slower reaction times than non-drug users and cannabis users 
on the selective visual attention task and MDMA-users had longer reaction times than 
cannabis users on the tests of divided attention and intermodal integration. Moreover, 
longer reaction times on the divided attention task were associated with regular MDMA 
use over a long period, but not with estimated total dose or frequency of use. 
Significantly, however, there were no differences between MDMA-users and controls 
on the less complex reaction time tasks, which measured responses to simple visual 
stimuli. The clinical interpretation of the results of this study suggests that MDMA- 
users exhibit problems with more complex tasks requiring sophisticated attention and
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concentration skills when compared to controls, however, they have similar 
performances to non-users on measures of basic attention and concentration.
In their attempt to establish a dose-response relationship between MDMA exposure and 
attention deficits, Parrott et al. (1998) compared the performance of regular and novice 
MDMA-users with unmatched controls on three measures of basic attention. Subjects 
were administered a forced choice reaction time task, where individuals were required 
to press a button when a target stimulus randomly appeared; a number vigilance task, 
where subjects were required to respond when the presented number matched a target 
number; and a number recognition task, where subjects indicated if a number string was 
identical to a previously presented string of digits. No difference in performance 
between the three groups was found. These results, in conjunction with the Gouzoulis- 
Mayfrank et al. (2000) study, lend further support to the hypothesis that MDMA-users 
only begin to display comparative deficits in attention when the task is of sufficient 
complexity to require higher order or more sophisticated attention and concentration 
skills.
Working Memory
Lezak (1995) refers to working memory as a process by which information is held in the 
mind, internalised, then used to guide behaviour in the absence of reliable external cues. 
In more practical terms, the concept of working memory refers to situations in which 
the individual must hold, manipulate, and transform cognitive material before 
generating a response (Squire & Butters, 1984). In their study outlined in the previous 
sections, Gouzoulis-Mayfrank et al. (2000) assessed verbal working memory in 
MDMA-users using the digits backward sub-scale from the Wechsler Adult Intelligence 
Scale-Revised. This task requires subjects to recall number spans in the reverse of the 
presented order. The authors found that MDMA-users performed significantly worse
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than non-MDMA-users, indicating a comparative deficit in working memory. 
Moreover, poorer performance on this working memory task was associated with 
heavier MDMA use. There was no difference between the two groups on the less 
complex digits forward task, which does not require the same degree of mental 
manipulation. These results are consistent with the clinical interpretation of the findings 
described previously, which propose that MDMA-users have difficulties when more 
sophisticated attention and concentration skills are required to process more complex 
information. This pattem was replicated for information presented in the non-verbal 
modality. The visuo-spatial assessment of basic attention also yielded no differences 
between MDMA-users and controls. The block-tapping task used by the authors to 
assess visuo-spatial attention skills does not place competing cognitive demands on the 
individual and thus requires less sophisticated concentration skills to complete 
successfully.
In their study described in earlier sections, McCann et al. (1999) compared the 
performance of 3 week abstinent MDMA-users with unmatched controls on a visual 
discrimination task, which the authors claim to be a measure of working memory. The 
task required subjects to memorize standard visual stimuli, which consisted of matrices 
of random coloured cells. Subjects were then presented with two comparison stimuli, 
one of which was identical to the first matrix. Subjects were then required to identify 
the matching stimuli. The researchers found that MDMA-users performed significantly 
worse than controls and concluded that MDMA-users exhibited deficits in working 
memory. Although the researchers claim that this task assesses working memory, it can 
be argued that the task involves visual recognition memory. Therefore the researchers’ 
conclusions regarding working memory functioning in MDMA-users are problematic.
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These results do, however, suggest MDMA-users have impairment in non-verbal 
memory, when compared to non-users.
Speed o f Information Processing
Slowed mental processing impacts on an individual’s ability to grasp complex 
information involving competing cognitive demands or to process larger quantities of 
material (Lezak, 1995). Deficits in this area, therefore, are likely to impact on attention 
and learning, and consequently, memory functioning.
Wareing, Fisk and Murphy (2000) compared current and 6 month abstinent MDMA- 
users with non-MDMA using controls, matched for age and sex, on a measure of 
processing speed. Subjects were required to complete a time-limited letter 
discrimination task with three levels of complexity. The researchers found that controls 
and MDMA-users completed a similar number of sets within the time frame, however, 
the controls were more accurate than the two MDMA groups at the highest level of 
complexity. This indicates that both current and 6 month abstinent MDMA-users 
process complex information less accurately than non-MDMA-users within a limited 
time frame. The authors propose that these results are indicative of MDMA-users being 
unable to cope with high levels of cognitive demands.
In summary, research has demonstrated that MDMA-users exhibit comparative deficits 
in attention when required to invoke higher order attentional capacities, such as when 
responding to competing cognitive demands in the case of divided attention, and when 
manipulating and transforming information in the case of working memory. Moreover, 
in support of a causal relationship between MDMA-use and impairment in information 
processing, deficits in both divided attention and working memory were associated with 
heavier MDMA-use in a dose-response fashion. The clinical examination of the 
literature in terms of the nature of attentional impairment indicates that MDMA-users
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have intact basic attentional capacities and only begin to display deficits when 
challenged sufficiently. Consistent with this pattern of results is the observation that 
divided attention is a sensitive indicator for any condition that reduces attentional 
capacity (Lezak, 1995). Finally, comparative deficits in speed of mental processing for 
complex information provides further evidence for MDMA-users’ difficulties in coping 
with high levels of cognitive demands.
1.4.3 Executive Functioning in MDMA-users
Executive functioning refers to the higher-level cognitive processes involved in 
planning and executing action, as well as adapting behaviour as required. They consist 
of those capacities that enable individuals to engage in independent, purposive, self- 
serving behaviours. Impaired executive functioning may affect cognitive processing by 
compromising an individual’s ability to devise strategies in planning, initiating and 
completing cognitive tasks. Executive functioning has its neuroanatomical basis in the 
frontal lobes of the brain (Lezak, 1995). Therefore, it is plausible that MDMA-induced 
neurotoxicity has implications for executive functioning as a consequence of the 
serotonergic projections that innervate the frontal lobes (Kandel, Schwartz & Jessell, 
1991). Executive functioning in MDMA-users has been investigated by researchers 
with varying results.
Wareing et al. (2000) assessed executive functioning in both current and 6 month 
abstinent MDMA-users compared to controls matched for age and sex, using a random 
letter generating task where subjects were asked to speak aloud consonants (no vowels) 
in a random sequence, whilst avoiding redundant responses and adhering to several 
rules. The level of difficulty of the task was increased as the speed at which the 
subjects’ responded was increased. Successful performance on this task is thought to be
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indicative of efficient central executive performance. The researchers found that 
MDMA-users generated fewer letters and exhibited a greater degree of redundancy and 
broke more rules than controls at the highest level of difficulty. These results suggest 
that MDMA-users exhibit comparative deficits in central executive functioning when 
compared to non-MDMA-users when faced with a task of sufficient complexity to place 
demand on cognitive resources.
Further evidence for executive impairment was reported by McCann et al. (1999) who 
assessed logical reasoning skills in MDMA-users via a self-paced task of semantic 
recognition and transformational grammar in which the subject was required to indicate 
true or false to statements regarding letter pairings. When the researchers averaged 
subjects’ responses over three days of testing they found MDMA-users performed 
significantly worse than controls. However, in their more adequately controlled study, 
Gouzoulis-Mayfrank et al. (2000) assessed executive functioning in MDMA-users with 
a word fluency task and found no evidence of executive impairment. Subjects were 
required to generate as many words as possible within a minute whilst adhering to 
specific mles. This task is designed to assess frontal lobe functioning, which is 
involved in the generation of ideas. The researchers found no difference between the 
two MDMA-using groups and controls. It can therefore be concluded that of the few 
studies examining executive functioning in MDMA-users, inconsistent results prevent 
definitive conclusions from being drawn regarding the existence or nature of any 
deficits, however, some indications of relative impairment are evident.
In summary, it is apparent from the review of the literature in the previous sections, that 
recreational MDMA use is associated with comparative deficits in verbal and non­
verbal memory, higher order attentional capacity and working memory. Indications of
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deficits in mental processing speed and executive functioning have also been identified, 
though inconclusively. It can therefore be proposed that recreational MDMA use 
results in cognitive disturbance. A summary of the studies reviewed in the previous 
sections is represented in Table 1.3.
Table 1.3: Summary of the Studies of Cognitive Disturbance in MDMA-Users.
Dose-
Study Verbal Non- W ork Atten- Proc. Exec. Response
M em . verbal M em. tiou Speed Funct. relation-
M em. ship
Parrott et al. (1998) X -
B o lla e ta l. (1998) X
M cC ann et al. 
(1999)
X X X X
M organ (1999) X X X
Gouzoulis- 
M ayfrank et al. 
(2000)
X X X X - X
Renem an et al. 
(2000)
X
Wareing et al. 
(2000)
- X X X
Note: x Significant results; - non-significant results.
1.4.4 Methodological Considerations Regarding the Validity of Studies of 
Cognitive Impairment Among MDMA-Users
Several methodological issues must be considered when evaluating the validity of the 
studies examining cognitive dysfunction in MDMA-users, described in the previous 
review of the literature. Clearly, it is unethical to randomise participants and expose 
individuals to a potential toxin, thus a retrospective cohort design is commonly 
employed when studying the effects of MDMA on memory (Hennekens & Buring, 
1987). Within this design individuals who have previously been exposed to MDMA are 
matched with controls and their memory performances are compared. For a valid study, 
the groups being compared should be matched with respect to all other factors that may
52
be related to memory functioning. As this is often difficult, potential confounding 
factors, which may contribute to differences in memory performance, can be measured 
and statistically controlled for. Intelligence, sex, age, depression, anxiety and drug use 
are either known or are potentially related to memory functioning (Lezak, 1995). Thus 
an appropriate method of studying the effects of MDMA on memory would involve 
matching the MDMA-exposed group and controls on these factors, or controlling for the 
confounding effects of these factors statistically. Of the eight published studies 
reviewed in the previous sections, only two have adequately controlled for the influence 
of the potential confounders age, sex, intelligence, and other drug use. None of the 
studies reviewed have controlled for depression or anxiety, despite the impact of both of 
these conditions on memory and attentional functioning (Lezak, 1995). Table 1.4 
presents the methodological limitations of these studies by indicating whether they have 
adequately controlled for the potentially confounding effects of age, intelligence (IQ), 
sex and other drug use on memory and cognitive performance.
Table 1.4: Potential Confounders Adequately Controlled for in Present Studies of 
Cognitive Functioning in MDMA-Users.
Confounders
Study Design Age IQ Sex Other
drugs
Krystal et al. (1992) N o control group
Parrott et al. (1998) Retrospective cohort
Bolla et al. (1998) Retrospective cohort X X X
McCann et al. (1999) Retrospective cohort X
Morgan (1999) Retrospective cohort 
(matched for age, sex and
IQ)
X X X X
Gouzoulis-Mayfrank et al. 
(2000) Retrospective cohort
X X X X
Reneman et al. (2000) Retrospective cohort 
(matched for age and 
education)
X
Wareing et al. (2000) Retrospective cohort 
(matched for sex)
X X
Note: x indicates where confounders were adequately controlled for in the study.
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Although some investigators screened for potential confounds during the preliminary 
stages of the study, it is apparent from Table 1.4 that in the majority of cases neither 
matching nor statistical adjustment was employed to control for the effects of age, sex, 
intelligence and other drug use on memory performance. Furthermore, as mentioned 
above, none of the studies reviewed have controlled for the confounding effects of 
depression and anxiety. Consequently, the validity of many of the studies 
demonstrating a relationship between MDMA use and memory disturbance is 
questionable. However, the comparative cognitive impairment evident in MDMA-users 
in the two well controlled studies lends more weight to the view that MDMA-use is 
associated with memory dysfunction and general cognitive impairment.
1.4.5 Studies Examining the Relationship Between Memory Impairment and 
Serotonin Concentrations through Examination of Metabolites
There is one other literature relevant to the consideration of the role of MDMA in 
memory impairment, namely the metabolic examination of the relationship between 
memory impairment and serotonin concentrations. The functional consequences of 
MDMA-induced serotonergic neurotoxicity have been researched from a metabolic 
perspective in an attempt to establish a relationship between reduced central 
serotonergic functioning and impaired cognition. Studies examining memory and 
metabolic concentrations of serotonin in MDMA-users have provided tentative evidence 
to support an association between serotonin levels and memory performance, however, 
to date this evidence is inconclusive. Bolla et al. (1998) found that lower levels of 
serotonergic metabolites in CSF were associated with poorer memory performance in 
MDMA-users. Conversely, however, a similar study of attention and memory in 
MDMA-users failed to reveal any correlation between CSF serotonergic metabolites 
and cognitive performance (McCann et al., 1999).
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Through the study of receptor density in MDMA-users, Reneman et al. (2000) have 
attempted to consolidate the relationship between serotonergic functioning and memory 
impairment. The researchers compared memory functioning and brain cortical 
postsynaptic serotonergic receptor density in five abstinent MDMA-users, to controls. 
It is known that severe serotonin depletion causes upregulation of postsynaptic 
serotonergic receptors. The researchers found a correlation between memory 
performance and density of postsynaptic serotonergic receptors in the MDMA-users, 
however the small sample size of this study prevents any definitive conclusions from 
being drawn. Despite the inconclusive nature of these results, the fact that cognitive 
studies have consistently found evidence of impairment in MDMA-users suggests 
MDMA-use is associated with memory dysfunction.
1.4.6 Is There a Causal Relationship Between MDMA-Use and Memory 
Dysfunction?
Despite the methodological limitations of the memory and cognitive literature reviewed 
above, the collective body of evidence as a whole suggests that MDMA-use is 
associated with memory impairment and general cognitive dysfunction. The question 
of whether MDMA-use causes cognitive dysfunction and memory impairment is 
addressed in the following discussion.
As it is ethically impossible to examine the causal relationship between MDMA-use and 
memory and cognitive impairment through experimental means, this hypothesis will 
instead be assessed by drawing on the converging lines of evidence from the literature. 
The hypothesis that recreational MDMA-use causes memory and cognitive dysfunction 
will be evaluated in terms of the set of criteria developed by Hill (1965) as a guideline 
for making inferences about disease aetiology from observational data. These criteria
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were used by Hall, Ward and Mattick (1998) to evaluate the evidence pertaining to the 
question of whether methadone maintenance treatment causes reductions in heroin use 
and crime among opioid dependent individuals. These criteria have been adapted to 
evaluate the legitimacy of making causal inferences regarding MDMA-use and memory 
and cognitive dysfunction from the quasi-experimental and observational studies 
reviewed above. The extent to which the literature satisfies the following criteria will 
determine whether the hypothesis that MDMA-use causes cognitive dysfunction can be 
substantiated.
Consistency: A relationship is deemed consistent if it is replicated in studies conducted 
by different investigators, using different assessment measures. A consistently observed 
relationship is less likely to be due to sampling errors or bias. The review of the 
literature in the previous sections has demonstrated that the relationship between 
MDMA-use and cognitive dysfunction has been observed by several different 
investigators using a variety of cognitive and biological measures. Although some 
studies have not reported significant relationships, the majority of studies indicate that 
this relationship has been consistently observed.
Specificity: Specificity exists when the relationship between exposure to the drug and
outcome is such that if the drug is given, the outcome occurs. This criterion suggests a 
strong relationship between the two, which increases confidence in causality. The 
animal literature reviewed in previous sections demonstrates specificity, where 
neurotoxicity occurs after administration of MDMA. Neurotoxicity has additionally 
been demonstrated in human recreational MDMA-users through metabolic and 
neuroimaging techniques. However, the specificity of the relationship between 
MDMA-use and cognitive dysfunction is variable as a function of the numerous factors
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mediating cognitive functioning, such as intelligence, and the individual effects of 
different dose regimens in recreational users. It has, however, been established that the 
memory impairment evident in MDMA-users is specific to MDMA use and not 
cannabis or polydrug use.
A dose-response relationship: A dose-response relationship between exposure to a 
substance and an outcome increases confidence in the assumption that the substance is 
responsible for the outcome. A dose-response relationship between exposure to MDMA 
and memory dysfunction has been demonstrated in several of the studies reviewed in 
earlier sections, suggesting that more extensive use of MDMA is associated with greater 
impairment, however this relationship has not been consistently observed. Evidence for 
a dose-response relationship is variable within the literature as a result of the complexity 
of the concept of ‘dose’ in the case of MDMA. Animal studies have established that 
frequency of administration, total exposure and highest blood concentration each 
mediate the neurotoxic process. Thus it is difficult to construct a simplistic linear dose- 
response equation. Furthermore, measurement of these exposure factors is unreliable 
due to the problematic nature of self-report of drug use, the unknown composition of the 
drug sold as ‘Ecstasy’, the highly variable dose regimens of users, and the unknown 
interactive effects of polydrug use on the neurotoxic process. Finally, the possibility of 
a threshold effect for neurotoxicity, in addition to individual differences in premorbid 
cognitive functioning, complicate the relationship further. It is therefore not surprising 
that evidence for a dose-response relationship between MDMA-use and cognitive 
dysfunction is not always consistent, however, this relationship has been observed in 
some form in the majority of studies.
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Plausibility: A relationship is plausible if it is consistent with other relevant
knowledge. The causal relationship between memory dysfunction and MDMA-use is 
plausible because it is consistent with our knowledge of the mechanism of MDMA- 
induced serotonergic neurotoxicity and the role of serotonin in memory and cognition.
Coherence: A relationship is coherent if it makes sense of other information about the 
condition. The observed serotonergic neurotoxic effects of MDMA and resulting 
cognitive impairment are consistent with our knowledge regarding the high density of 
serotonergic receptors in the hippocampal region and our understanding of the role of 
the hippocampus in memory functioning (Steele et al., 1994; Martinez & Kesner, 1986). 
The study of neurodegenerative disorders featuring memory dysfunction, which have 
been found to be associated with the degeneration of the serotonergic system, offers 
further support to the coherence argument (Cross, 1990).
Experiment: It is not possible to experimentally establish whether MDMA use results in 
memory dysfunction in humans, however, it is possible to demonstrate MDMA’s 
neurotoxicity in animals. Experimental evidence of MDMA-induced neurotoxicity has 
been demonstrated in those species most closely related to humans (primates), using 
oral administration and similar dose regimens to those employed in recreational users.
In summary, the examination of the nature of the relationship between MDMA-use and 
memory and cognitive dysfunction in response to these criteria, suggests that when the 
literature is taken as a whole, there is a strong case for the recreational use of MDMA 
causing memory impairment and cognitive dysfunction.
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CHAPTER 2
Encoding Deficits in Recreational MDMA-Users:
A clinical examination of the nature of MDMA-induced
memory dysfunction
The previous chapter has reviewed the literature examining the neurotoxicity of MDMA 
and the functional implications of MDMA-induced serotonergic damage. Several lines 
of evidence have converged to support a causal relationship between recreational 
MDMA use and memory impairment. First, the review of the animal literature 
established that MDMA is selectively toxic to serotonergic neurons in non-human 
primates when administered orally, the manner typically employed by human 
recreational users, and when given in doses comparable to human use. Second, human 
studies of CSF serotonin metabolite concentrations and neuroimaging techniques have 
confirmed the presence of degeneration in the serotonergic system in the brains of 
recreational MDMA-users. Third, studies in non-human primates have found that the 
hippocampus, an area strongly implicated in memory functioning, is particularly 
vulnerable to MDMA’s neurotoxic effects, as a function of the area’s dense innervation 
by serotonin terminals (Steele et al, 1994; Boot et al, 2000; Martinez & Kesner, 1986). 
Finally, examinations of the biochemical basis of memory and neurodegenerative 
illnesses featuring memory impairment have suggested an integral role for serotonin in 
mnemonic functioning (Cooper, Bloom & Roth, 1978; Cross, 1990). Collectively these 
research findings support the hypothesis that recreational MDMA-use causes memory 
dysfunction. Indeed, while acknowledging the methodological shortcomings outlined in 
the previous chapter, the collective body of literature to date indicates that MDMA- 
users manifest impairment in both verbal and non-verbal immediate and short-term
memory when compared to non-users. Additionally, evidence for a dose-response 
relationship between MDMA exposure and memory performance has been 
demonstrated, lending further support to there being a causal relationship between 
MDMA-use and memory deficits.
Despite the evidence supporting the existence of memory dysfunction in MDMA-users, 
of the eight memory studies reviewed in the previous chapter, only two adequately 
controlled for the influence of possible covariates. Furthermore, neither of these studies 
controlled for the influence of depression and anxiety, two factors known to interfere 
with cognitive functioning (Lezak, 1995). It has been hypothesised that individuals 
with serotonin depletion, who are likely to be suffering from depression and / or 
anxiety, are attracted to recreational use of MDMA, as a result of its mood enhancing 
and serotonin releasing properties. Thus, these factors may be significant confounders 
in the study of cognition in recreational MDMA-users. It is therefore the intention of 
the study reported in this chapter to investigate whether MDMA-users exhibit 
comparative memory deficits after controlling for the influence of age, sex, intelligence, 
the use of other drugs and anxiety and depression. All of these variables are either 
known to be or may plausibly be associated with cognitive impairment (Lezak, 1995).
While the current literature indicates the presence of memory dysfunction in MDMA- 
users, research to date has failed to present a revealing clinical picture of the pattern of 
impairment evident, beyond simplistic modality and storage distinctions. The 
haphazard use of assessment batteries, as opposed to a hypothesis testing approach to 
the assessment of memory, has impeded any attempts to extricate a meaningful 
representation of memory dysfunction in MDMA-users. This failure to examine the 
nature of any memory dysfunction has prevented researchers from determining whether
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encoding, storage or retrieval problems are responsible for the impairment evident in 
MDMA-users. In contrast, the present study was designed to discover a meaningful 
clinical picture of memory dysfunction in MDMA-users through the neuropsychological 
examination of the different memory modalities and mechanisms involved in memory 
functioning.
In summary, this study has two aims:
1. To determine whether there are differences in memory performance between 
MDMA-users and controls after adjusting for the effects of age, sex, intelligence, 
depression, anxiety and other drug use.
2. If differences in memory performance are found, to ascertain the nature of the 
dysfunction. Therefore to determine whether memory dysfunction in MDMA-users 
is due to encoding, storage or retrieval difficulties.
2.1 METHOD
2.1.1 Participants
A total of sixty-two individuals, thirty-one MDMA-users and thirty-one controls, 
participated in the study. The MDMA group comprised thirty-one recreational MDMA- 
users who had used ‘Ecstasy’ within the previous six months and at least ten times in 
their lives. All MDMA-users abstained from use for at least 7 days before the 
assessment to control for residual effects of the drug. MDMA is an illicit drug and 
MDMA-users are consequently a hidden population of unknown size and composition. 
It is therefore impossible to systematically sample this population. Thus subjects were 
recruited via peer networks using the snowball technique, in which participants
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introduced the researcher to MDMA-using friends. Initial contacts were generated by 
MDMA-users already known to the experimenter. Thirty-one control subjects were 
recruited from university students and graduates. MDMA-users were paid $20 for 
participation in the study. Controls completed the study to obtain credit points as a 
component of their undergraduate degree in psychology. There was no mean difference 
between the two groups in intelligence, age, sex, depression and anxiety. Exclusionary 
criteria for the study included: past or present psychotic illness, previous incidence of 
serious head injury, and English as a second language. Neither depression nor anxiety 
was accepted as grounds for exclusion because both conditions were measured and 
controlled statistically. One control subject was excluded as an outlier after presenting 
an amnestic memory profile, leaving thirty valid control subjects.
2.1.2 Study Design
A retrospective cohort study design was employed to examine the effects of MDMA use 
on memory functioning. Within this design, individuals who have previously been 
exposed to MDMA are compared with controls and statistical adjustment is used to 
control for the influence of potentially confounding variables on memory functioning. 
This is an accepted method for studying the effects of a potential toxin on cognitive 
functioning, while controlling for potential confounders (Hennekens & Buring, 1987).
2.1.3 Procedure
Participants were screened through a telephone interview to assess their suitability for 
inclusion in the study. Assessment schedules were arranged to ensure at least 7 days of 
abstinence from MDMA at the time of testing. Written consent was obtained from 
subjects before commencing the assessment. A consent form outlining the nature of the 
study informed participants of their right to withdraw from the study at any time and
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included an assurance of anonymity and confidentiality (a copy of the consent form can 
be found in Appendix I). In order to protect the anonymity and confidentiality of 
participants, no identifying information was recorded, completed assessment profiles 
were catalogued under subject numbers and signed consent forms were stored 
separately from profiles. The study was granted approval by the Australian National 
University Human Research Ethics Committee.
Participants were assessed individually by the candidate. Demographic information 
such as age, sex, and education level was obtained, in addition to information regarding 
MDMA use, including age of first use, highest frequency of use over one month, and 
highest ever dose administered at the one time, using a questionnaire designed for this 
purpose (a copy of the questionnaire can be found in Appendix II). A detailed history 
of MDMA use was attained through the use of the time line method to ensure as 
accurate an estimation as possible of the total number of ‘Ecstasy’ pills consumed. This 
method involves a detailed examination of each year of drug taking, using landmarks 
and events to map the changing frequency and pattern of MDMA use over time. This 
method was adapted from the procedure described by Anglin, Hser and Chou (1993) 
which has reasonable reliability and validity. A detailed history of concurrent drug use 
was taken, including the frequency of amphetamine, cocaine, LSD, heroin, inhalant, 
cannabis, benzodiazepine and alcohol use whilst under the influence of MDMA. An 
assessment of general drug use was then conducted, examining previous and current 
consumption of amphetamine, cocaine, LSD, heroin, benzodiazepines, inhalants, 
cannabis and alcohol.
Participants were administered a battery of standardised assessment measures to obtain 
an estimate of intellectual functioning, memory functioning, depression, and anxiety.
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Each of these measures is described in detail in the following section. On average, the 
entire assessment was completed in an hour.
2.1.4 Measures
Intelligence
An estimate of intellectual functioning was obtained by administering the National 
Adult Reading Test (NART; Nelson, 1982). The NART comprises of a list of 50 
phonetically irregular words, which examinees are required to read aloud. Correct 
pronunciation of the words is credited. General word knowledge, which is required for 
correct pronunciation of the irregular words, was used to estimate pre-morbid 
intellectual functioning because it correlates highly with overall ability and tends to be 
more resilient to the effects of toxins or dementing processes than other intellectual 
capacities (Lezak, 1995). The NART has been identified as one of the most reliable 
methods for estimating pre-morbid intelligence because it has greater resistance to the 
effects of a number of psychiatric and neurological conditions than other vocabulary 
measures (Lynch & McCaffrey, 1997).
Depression
Depression was assessed using the Beck Depression Inventory Second Edition (BDI-II; 
Beck, Steer & Brown, 1996). The BDI-II is a 21 item self-report inventory designed to 
measure the severity of depression that has well established reliability and validity. It 
assesses typical depressive symptoms including mood, pessimism, guilt, self­
punishment, irritability, social withdrawal, sleep disturbance, appetite disturbance, loss 
of libido, agitation, worthlessness, concentration difficulty, and loss of energy. Each 
item is rated on a 4 point scale ranging from 0 to 3. The BDI-II requires between 5 and 
10 minutes to complete.
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Anxiety
Anxiety was assessed using the Beck Anxiety Inventory (BAI; Beck & Steer, 1993). 
The BAI is a self-report instrument designed to measure the severity of anxiety. It has 
well established reliability and validity. It consists of 21 descriptive statements of 
anxiety symptoms, which are listed on a 4-point scale. Both cognitive and somatic 
symptoms of anxiety are represented and the scale was constructed to measure 
symptoms that are minimally shared with depression. The BAI requires between 5 - 1 0  
minutes to complete.
Memory
Memory was assessed using the Wechsler Memory Scale Third Edition (WMS-III) 
(Wechsler, 1997). The WMS-III is an individually administered neuropsychological 
battery, which assesses clinically relevant aspects of learning and memory in both the 
verbal and non-verbal modalities, in addition to evaluating working memory. The 
WMS-III is a standardised battery with normative data derived from a stratified 
nationally represented US sample of over 12 000 healthy adults aged from 16 to 89 
years. It has well established reliability and validity and is a widely used psychometric 
tool (Wechsler, 1997).
The WMS-III consists of 6 primary subtests and 5 optional subtests, however, only the 
primary subtests and the optional digit span subtest were administered in the present 
study. The following description of each of the subtests outlines the nature of each task.
65
Auditory (Verbal) Sub tests
Auditory subtests are presented orally. Memory performance both immediately 
after presentation, or following a 25 -35 minute delay, is believed to be 
indicative of immediate and delayed verbal memory functioning respectively.
Logical Memory I: Two short stories, Story A and B, are orally presented 
to examinees. The second story is presented twice and examinees are 
required to retell the stories via free recall immediately after each 
presentation. A total of 25 chunks of information are present in each 
story.
Logical Memory II: Examinees are required to freely recall both stories 
from Logical Memory I after the delay.
Logical Memory Recognition: Examinees are required to answer a series 
of questions about the two Logical Memory stories requiring a yes / no 
response.
Verbal Paired Associates I: This task requires examinees to learn novel 
word associations. Eight pairs of illogically associated words are 
presented orally. The first word in each pair is then provided and 
examinees are required to recall the word with which it was paired. Four 
repeat presentations of the set of word pairs, in 4 differing orders, are 
administered with examinees receiving feedback over successive trials.
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Verbal Paired Associates II: The examinee is provided with the first 
word in each pair after the delay and required to recall the word with 
which it was paired. No feedback is given.
Verbal Paired Associates Recognition: Examinees are read a list of 24 
word pairs and asked to identify the original word pairs.
Visual Subtests
These subtests are presented in the visual modality and performance is believed 
to be indicative of nonverbal memory functioning. As in the case of the auditory 
subtests, memory is examined immediately after presentation of stimuli and 
following a delay of 25 - 35 minutes.
Faces I: Examinees are shown a series of 24 faces for 3 seconds each. A 
set of 48 photographs, including the 24 previously exposed faces, is 
presented immediately afterwards and the examinee is required to 
identify the 24 original faces. The Faces subtest is a recognition task 
involving cued recall.
Faces II: The examinee is presented with a set of 48 photographs after 
the delay, including 24 different distraction faces, and is asked to identify 
the original set of 24 faces.
Family Pictures I: A family portrait is initially presented to familiarise 
examinees with the family members. Examinees are then shown four 
successive scenes depicting members of the family engaging in everyday 
activities in four different environments for ten seconds each. After all
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four scenes are shown the examinee is required to recall which members 
were present in each scene, where they were situated and what activities 
they were engaged in.
Family Pictures II\ After the delay, the examinee is asked to recall the 
details described above in Family Pictures I about each scene.
Attention and Working Memory Subtests
Letter - Number Sequence: A string of alternating letters and numbers are 
presented orally to the examinee, who is required to repeat the string, 
recalling the numbers in ascending order, followed by the letters in 
alphabetical order. The length of the string is increased by one after 
every two trials and the task is discontinued after two consecutive errors 
are made on the same string length. The letter-number sequence subtest 
is a measure of working memory as it requires the examinee to 
manipulate information in immediate memory.
Spatial Span - Forwards and Backwards: There are two components to 
this task: a forward component, which is believed to provide a measure 
of basic attention and concentration, and a backward component, which 
is believed to be a measure of working memory. In both, a series of 
spatial patterns are visually presented on a three dimensional board. The 
examiner taps a pattern on a set of blocks at a rate of one per second and 
the examinee is required to copy either the exact pattern in the forwards 
component, or the pattern in reverse order for the backwards component. 
The length of the pattern is increased by one block after every two trials.
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The task is discontinued after two consecutive errors on a pattern of the 
same length.
Digit Span - Forwards and Backwards: The forwards component to Digit 
span is believed to be a measure of basic attention and concentration, 
while the backwards component is believed to provide a measure of 
working memory. The examinee is read a series of digits at a rate of one 
every second and is required to repeat the numbers immediately after the 
presentation in either the same order or in the reverse order to that 
presented by the examiner. The span is increased by one every two trials 
and the examinee is discontinued after two consecutive errors on a span 
of the same length.
Raw scores from the 6 primary subtests of the WMS-III yield 8 primary indexes: the 
Immediate Memory Index, a composite measure of verbal and visual immediate 
memory; the General Memory Index, a composite measure of delayed and recognition 
verbal and visual memory; the Auditory and Visual Immediate Indexes, providing a 
measure of immediate memory in the two modalities; the Auditory and Visual Delayed 
Index providing a measure of the ability to retain information over time in the two 
modalities; the Auditory Recognition Index providing a measure of the ability to 
remember information via cued recall after a delay; and the Working Memory Index.
2.1.5 Data Analysis
The data were analysed using the software package SPSS for Windows Version 9.0. 
The procedures recommended by Tabachnick and Fidell (1989) were used to screen the 
data prior to conducting statistical analyses.
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For discrete variables, comparisons between groups were performed using Pearson’s 
chi-square test and Fisher’s exact test, where expected cell frequencies in two by two 
tables were less than five. For continuous variables with approximate normal 
distributions, comparisons between groups were made using Student’s t-test for 
independent samples. All statistical tests employed a two-tailed alpha criterion of 0.05.
Comparisons between the two groups’ performances, while adjusting for possible 
confounding variables, were made by developing multiple linear regression models. The 
assumptions of linearity and normality of the error distribution were assessed by 
graphical analysis of the residuals, while outliers were also assessed graphically. In 
order to maximise power and precision, each of the regression models was reduced 
using the backward elimination method recommended by Kleinbaum, Küpper and 
Muller, (1988). This method involves the elimination of variables when they are not 
statistically significant in the model, providing that they do not substantially alter the 
estimates of the remaining variables. This method results in the most parsimonious 
model that is able to explain the data. The results of these statistical analyses are 
presented in the following section.
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2.2 RESULTS
The results of the statistical analyses are reported in the following sections. Firstly, 
demographic information describing general characteristics of the sample is presented, 
along with the results of assessments of current intellectual and psychological 
functioning. Secondly, patterns of recreational drug use are reported for both MDMA- 
users and controls, followed by an examination of the characteristics of MDMA use 
amongst the MDMA-using cohort. The results of comparisons between MDMA-users 
and controls for memory performance are then presented, followed by analyses of dose- 
response relationships between MDMA-exposure and memory performance.
2.2.1 Demographic Information
The demographic characteristics of the sample are presented in Tables 2.1 to 2.3. As 
discussed in previous sections, age, sex, intellectual functioning, depression and anxiety 
may have an influence on memory functioning (Lezak, 1995). Thus possible 
differences between the MDMA-using cohort and controls on these variables have been 
examined.
Table 2.1: Means and Standard Deviations for Age, Education 
and Estimated Intelligence (IQ).
Age Education IQ
(years) (years) (NART)
Controls 23.33 (6.59) 14.67(1.94) 106.97 (7.17)
MDMA 24.00 (4.66) 13.77 (2.22) 103.39 (7.64)
It can be seen from Table 2.1 that the cohort of MDMA-users was well matched with 
controls. Independent sample t-tests revealed no significant difference between the two 
groups for age, t(59) = -.046, p>.05, years of education, t(59) = 1.67, p>.05 and 
estimated pre-morbid intelligence, as measured by the NART, t(59) = 1.89, p>.05.
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Table 2.2: Sex Distribution for Controls and MDMA-Users
Female (%)
Sex
Male (%) Total
Control 20 (66.7) 10(33.3) 30
MDMA 19(61.3) 12 (38.7) 31
Total 39 (63.9) 22 (36.1)
The two groups were also well matched in terms of sex. There was no significant 
difference in the distribution of males and females in each of the groups, x (1,N = 61) = 
.191, p>.05 (see Table 2.2).
Table 2.3: Means and Standard Deviations for 
Depression and Anxiety
Depression Anxiety
(BDI) (BAI)
Controls 8.07 (8.72) 8.03 (8.30)
MDMA 10.53 (10.37) 10.10(8.88)
Finally, as can be seen from Table 2.3, there were no significant differences between 
controls and MDMA-users on measures of depression, t(58) = -.10, p>.05 or anxiety, 
t(58) = -.93, p>.05. An examination of the clinically relevant categories of severity for 
the BDI and BAI indicated that the means for both groups were within the ‘Minimal’ 
range for depression and the ‘Mild’ range for anxiety. The distributions of depression 
and anxiety scores in terms of these clinically relevant categories of severity were also 
analysed in order to rule out the possibility that the mean scores for depression and 
anxiety underestimated group differences by masking variances in the distribution of 
severity on these measures (see Tables 2.4 and 2.5).
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Table 2.4: Distribution of Depression Scores for Categories of Severity on BDI
Depression -  BDI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Control 27 (90.0) 3(10.0) 30
MDMA 25 (80.6) 6(19.4) 31
Total 52 (85.2) 9(14.8)
Table 2.5: Distribution of Anxiety Scores for Categories of Severity on BAI
Anxiety - BAI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Control 25 (83.3) 5 (16.7) 30
MDMA 22 (71.0) 9 (29.0) 31
Total 47 (77.0) 14 (23.0)
The two groups were also well matched in terms of depression and anxiety’ (see Table 
2.5). There were no significant differences between the two groups in the distribution 
of either depression, Fisher’s exact test, p>.05, or anxiety scores, x2 (1, N = 61) = 1.32, 
p>.05.
2.2.2 Patterns of Other Recreational Drug Use
Alcohol consumption and illicit drug use may also impact on general cognitive 
functioning (Lezak, 1995). To address this, estimates of recreational drug use other 
than MDMA were obtained and differences between the two groups were statistically 
controlled for in later comparative analyses. The analyses of lifetime use and current 
use of recreational drugs other than MDMA are presented in Table 2.6. For the 
purposes of the present study, lifetime use was defined as reporting ever taking the drug,
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and current use was defined as reporting present use of the drug once a month or more 
frequently.
Table 2.6: Patterns of Other Recreational Drug Use
Lifetime Use 
(i.e. ever used) 
(%)
Current Use 
(i.e. once a month or 
more) (%)
A lc o h o l
Control 25 (83.3) 24 (80.0)
MDMA 31(100)* 27 (87.1)
C a n n a b is
Control 17(56.7) 6 (20.0)
MDMA 21 (67.7) 19(61.3)**
B e n z o d ia z e p in e
Control 1 (3.3) 0 (0)
MDMA 9 (29.0)* 2 (6.5)
A m p h e ta m in e
Control 2 (6.7) 2 (6.7)
MDMA 26 (83.9)** 14(45.2)**
H ero in
Control 0 (0) 0 (0)
MDMA 2 (6.5) 1 (3.2)
C o c a in e
Control 1 (3.3) 0 (0)
MDMA 18(58.1)** 6(19.4)*
L S D
Control 2 (6.7) 2 (6.7)
MDMA 19(61.3)** 6 (19.4)
I n h a la n ts
Control 2 (6.7) 0(0)
MDMA 8 (25.8) 0(0)
*p< .05, **p<.01.
As might be expected, there were a number of differences between the MDMA-users 
and controls in both the lifetime and current use of recreational drugs. As shown in 
Table 2.6, MDMA-users had significantly greater lifetime use of alcohol, Fisher’s exact 
test, p<.05, benzodiazepines, Fisher’s exact test, p<.05, amphetamine, x2(l> N = 61) = 
36.60, 2<.01, cocaine, x2(l, N = 61) = 21.30, 2<.05, and LSD, x2(l, N = 61) = 20.15, 
p<.05. Additionally, a greater number of MDMA-users currently used cannabis, x (1» 
N = 61) = 10.75, p<.05, amphetamine, x2(U N = 61) = 11.68, p<.01, and cocaine, 
Fisher’s exact test, p<.05. These differences in drug use were controlled for statistically 
in the comparative analyses.
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2.2.3 Patterns of Recreational MDMA-Use Within MDMA-Using Cohort
A comprehensive analysis of recreational MDMA use was conducted for the MDMA- 
using cohort to obtain a thorough representation of their pattern of use. The estimated 
total lifetime dose of MDMA, the highest frequency of MDMA use in one month and 
the highest number of pills swallowed at the same time, as reported by subjects, were 
examined. These characteristics were measured as a result of the animal literature, 
which has shown that total exposure, frequency of exposure and absolute concentrations 
of MDMA in the bloodstream each mediate the neurotoxic process (Steele et al., 1994). 
These three characteristics of MDMA use were then combined to create a composite 
measure of MDMA exposure. This representation of MDMA exposure was 
subsequently used to examine the dose-response relationship between MDMA use and 
cognitive dysfunction. Similar MDMA exposure variables have been computed in other 
studies of MDMA-use and cognitive dysfunction to examine a dose-response 
relationship (Bolla et al., 1998).
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Table 2.7: Pattem of MDMA Use in MDMA-Users (n=31)
Minimum Maximum Mean
(SD)
Estimated Total
Dose (no. of 
MDMA pills)
11 680 166
(171)
Highest Frequency
of Use3 0.5 16 5
(4 )
Highest Doseb 
Time since last
0.5 5 2
(1)
MDMA use (days) 
Duration of use
7 168 37
(33)
(months) 5 156 50
(36)
Age of first use 14 30 20
(4 )
Polydrug Usec 0 184 44
(60)
^Highest number of occasions o f MDMA use in one month.
bHighest number of MDMA pills swallowed at one time.
dum ber of occasions cocaine and/or amphetamine were taken concurrently.
Table 2.7 summarises the pattem of recreational use in MDMA-users. There was a 
wide range in exposure to MDMA in the sample, ranging from 11 to 680 pills consumed 
in a lifetime, (M = 166). The frequency of use was highly variable, ranging from less 
than one occasion of use per month to sixteen occasions in one month. The mean for 
the highest frequency of use was 5 occasions per month, which is greater than every 
weekend in the month. The number of pills swallowed at the one time ranged from a 
half to 5 pills (M = 2). The time since last use within the cohort was also highly 
variable, ranging from 7 days to 5 months, with a mean period of abstinence of 37 days. 
The duration of MDMA use ranged from 5 months to 13 years, with a mean duration of 
approximately 4 years of use. Finally, the mean age of first use, being 19 years (range 
14 to 30), in this cohort is not dissimilar to other Australian cohorts (Topp et al., 1999).
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The polydrug measure of concurrent amphetamine and / or cocaine use was collected to 
examine whether a relationship existed between MDMA-use, concurrent amphetamine 
and / or cocaine use, and memory dysfunction. Knowledge of the neurochemical 
actions involved in the MDMA-induced neurotoxic process suggests that the dopamine 
releasing properties of amphetamine and cocaine may potentially increase the 
neurotoxicity of MDMA (Sprague et al., 1998). However, correlational analyses 
revealed no significant relationship between these variables.
2.2.4 Memory Functioning in MDMA-Users and Controls
The results of analyses comparing memory performance in MDMA-users and controls 
are presented in the following sections. Firstly, comparisons between MDMA-users 
and controls on the WMS-III memory indexes are presented. As outlined in greater 
detail in the method section, the memory indexes are composite measures of memory 
functioning. The summary indexes, representing immediate, delayed and working 
memory functioning, are examined, followed by the indexes representing immediate 
and delayed memory functioning for both the auditory (verbal) and visual modalities. 
Secondly, comparisons between MDMA-users and controls are made for performance 
on each of the verbal memory subtests, followed by comparisons for performance on 
each of the visual memory subtests. Finally, MDMA-users and controls are compared 
in terms of their performance on the subtests assessing attention and working memory.
Memory Indexes
Both adjusted and unadjusted comparisons between MDMA-users and controls were 
conducted for each of the WMS-III memory indexes. The unadjusted differences were 
calculated using independent samples t-tests, while multiple linear regression models
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were constructed to examine the differences between the two groups while adjusting for 
the potentially confounding effects of sex, age, intelligence, depression, anxiety, and 
other drug use. These regression models were reduced using the backward elimination 
method described in the method section and the adjusted means and t-values were 
derived from the final reduced models. The results of these analyses are summarised in 
Tables 2.8 to 2.13. (The final regression models, for significant comparisons, can be 
found in Appendix III).
Table 2.8: WMS-III Memory Index Means and Comparisons for MDMA-Users (n = 31) 
and Controls (n = 30).
W M S-III 
M em ory Index
M ean U nadjusted
M ean
Difference
A djusted
M ean
D ifference
U nadjusted t A djusted t
Im m ediate
M em ory
Control 112.83 11.87 10.30 4 09*** -3.57**
MDMA 100.97
G eneral M em ory
(delayed)
Control 110.23 8.62 6.60 3.12** -2.45**
MDMA 101.61
W orking M em ory
Control 111.47 5.66 4.19 1.67 -1.30
MDMA 105.81
**p<.01, ***p<.001
Table 2.8 shows the results for the unadjusted and adjusted comparisons involving the 
memory indexes. It is evident that MDMA-users displayed significantly poorer 
immediate and general (delayed) memory functioning, as measured by the WMS-III 
composite memory indexes. The differences between the two groups in memory 
function remained after adjusting for the effects of potential confounders. Estimated 
intelligence was a significant covariate for the immediate memory index, while 
intelligence and sex were significant in the case of the general memory index. There 
was no significant difference between MDMA-users and controls on the WMS-III 
composite measure of working memory functioning.
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Given a significant difference was found in the immediate memory index, it is pertinent 
to examine the measures contributing to this in greater detail. Table 2.9 shows the 
results of analyses for the visual and auditory memory indexes, which constitute the 
immediate memory index.
Table: 2.9 WMS-III Immediate Memory Index Means and Comparisons for MDMA- 
Users (n = 31) and Controls (n = 30).
W M S-III
M em ory
Index
M ean U nadjusted
M ean
Difference
A djusted
M ean
D ifference
U nadjusted t A djusted t
A uditory
(verbal)
Im m ediate 118.87 11.90 9.73 4.27*** -3.60**
Controls
MDMA
106.97
V isual
Im m ediate
Controls 102.07 7.87 7.87 2.51* -2.51*
MDMA 94.19
*p<.05, **p<.01, ***p<.001
As can be seen in Table 2.9, the unadjusted comparisons between MDMA-users and 
controls for the immediate memory indexes indicated that MDMA-users displayed 
significantly poorer verbal and visual immediate memory functioning than controls. 
These group differences in immediate memory functioning remained apparent after 
adjusting for the effects of potential confounders. Both intelligence and sex were 
significant covariates within the final regression model. In the case of the visual 
immediate memory index, the unadjusted model was retained because none of the 
potential confounding variables were significant within the final model or significantly 
altered the estimate of the difference when removed.
The measures contributing to the significant difference in the delayed memory index 
were also examined in greater detail. Table 2.10 shows the results of comparisons
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between the two groups for auditory and visual delayed memory, and the auditory 
recognition performance, which constitute the delayed memory index.
Table 2.10: WMS-III Delayed Memory Index Means and Comparisons for MDMA- 
Users (n = 31) and Controls (n = 30).
W M S-III
M em ory
Index
M ean U nadjusted
M ean
D ifference
A djusted
M ean
D ifference
U nadjusted t A djusted t
A uditory
(verbal)
D elayed
Controls 111.70 5.09 3.57 1.92 -1.36
MDMA 106.61
V isual
D elayed
Controls 101.63 8.41 6.94 2.57* -2.11*
MDMA 93.23
A uditory
R ecognition
Controls 113.83 8.03 7.67 2.76** -2.73**
MDMA 105.81
*p<.05, **p<.01
It is evident from Table 2.10 that MDMA-users were significantly worse than controls 
on the WMS-III composite measures of visual delayed memory. Both the unadjusted 
and adjusted comparisons were statistically significant and intelligence was a significant 
covariate. No significant differences between the two groups’ memory functioning in 
the verbal modality, as measured by the WMS-III auditory delayed index, was evident 
from either the unadjusted or adjusted comparisons. Finally, it is also apparent from 
Table 2.10 that MDMA-users’ cued recall performance, as measured by the WMS-III 
verbal recognition index, was significantly poorer than controls and this group 
difference endured after controlling for the effects of potential confounders. Sex was a 
significant covariate for this measure.
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Verbal Memory Subtests
In the following section, both the adjusted and unadjusted analyses comparing 
performances of MDMA-users and controls on the verbal memory subtests are 
presented. Tables 2.11 and 2.12 summarise performance on each of the verbal memory 
subtests, both before and after controlling for the potential confounding effects of sex, 
age, intelligence, depression, anxiety and other drug use. (Final regression models for 
significant analyses and analyses where group differences were no longer significant 
after controlling for possible confounders can be found in Appendix III).
The total Logical Memory subtest performance for the immediate (I) and delayed (II) 
conditions were compared for MDMA-users and controls, in addition to an examination 
of group performance on each of the individual stories (A and B), including the two 
trials of B in the immediate condition (Bi and Bii). Finally, performance on the 
recognition trial of Logical Memory, a measure of cued recall, was compared. The 
results of these analyses are presented in Table 2.11.
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Table 2.11: WMS-III Logical Memory Subtest Means and Comparisons for MDMA- 
Users (n = 31) and Controls (n = 30).
Subtest Mean Unadjusted
Mean
Adjusted
Mean
Unadjusted t Adjusted t
Difference Difference
Logical 
Memory I 
Total
Control 49.80 8.19 6.98 4.05*** -3.55**
MDMA 41.61
Logical 
Memory I 
Story A 
Control 16.97 3.48 3.88 4.10*** -3.91***
MDMA 13.48
Logical 
Memory I 
Story B i
Control 13.87 2.54 2.14 3.16** -2.65*
MDMA 11.32
Logical 
Memory I 
Story B ii
Control 18.97 2.16 1.71 2.61* -2.08*
MDMA 16.81
Logical 
Memory II 
Total
Control 31.40 5.14 3.93 3.11** -2.45*
MDMA 26.26
Logical 
Memory II 
Story A 
Control 14.07 3.00 2.48 3.00** -2.57*
MDMA 11.07
Logical 
Memory II 
Story B 
Control 17.27 2.07 1.58 2.24* -1.72
MDMA 15.19
Logical
Memory
Recognition
Control 27.80 1.09 .865 2.20* -1.78
MDMA 26.71
*p<.05, **p<.01, ***p<.001
Table 2.11 shows that MDMA-users recalled significantly less information than 
controls on the total Logical Memory I subtest, a measure of immediate contextual
82
verbal memory. Both the unadjusted and adjusted analyses were significant and 
intelligence, depression and anxiety were significant covariates for this measure. The 
unadjusted and adjusted analyses, represented in Table 2.11, indicate that MDMA-users 
recalled significantly less information than controls from Story A and after both the first 
presentation and second presentation of Story B. Intelligence and depression, were 
significant covariates in the case of Story A, and intelligence was a significant covariate 
in the case of the first and second presentations of Story B.
It is also apparent from Table 2.11 that after a delay of 25 to 35 minutes, MDMA-users 
recalled significantly less information than controls on the total Logical Memory II 
subtest, as evidenced by the adjusted and unadjusted comparisons (sex, depression and 
anxiety were significant covariates). An examination of the amount of information 
recalled from the two stories after the delay revealed that MDMA-users recalled 
significantly less from both Story A and B. In the case of Story A, this group difference 
in verbal memory performance remained after controlling for potential confounders 
(sex, intelligence, depression, and anxiety were significant covariates). Group 
differences in delayed verbal memory performance on Story B were no longer 
significant after controlling for the effects of intelligence, however, a trend was apparent 
(p=.09). Finally, MDMA-users performed significantly worse than controls on the 
Logical Memory recognition subtest, a measure of cued recall. This difference in 
recognition performance did not remain after controlling for the effects of intelligence 
and sex, however again a trend was observed (p=.08).
The recognition performance for the two groups on the Logical Memory subtest was 
broken down by story to determine if differences between the two groups were masked 
by the combined measure of cued recall for both single and repeated presentations of
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verbal material. Distinguishing between the recognition performance for Story A and B 
allows further examination of the nature of memory impairment. In the case of Story A, 
controls’ cued recall performance (M = 13.13, SD = 1.59) was comparable to MDMA- 
users (M = 12.48, SD = 1.69), t(59) = 1.54, p>.05. However, controls correctly 
recognised significantly more information from Story B (M = 14.67, SD = 0.55) than 
MDMA-users (M = 14.22, SD = 0.10), t(59) = 2.33, g<.05) and this difference was not 
influenced by any of the potential confounders and no covariates remained in the final 
regression model.
Group performance was then compared for the total Verbal Paired Associates (VPA) 
subtest, in addition to comparisons for each of the four recall trials (a -  d). Recall 
performance after the delay of 25 to 35 minutes (VPA II) was also compared for the two 
groups. The recognition subtest was not included in the analysis because it became 
apparent that the task was not sufficiently challenging when every subject obtained a 
perfect score.
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Table 2.12: WMS-III Verbal Paired Associates (VPA) Subtest Means and Comparisons 
for MDMA-Users (n = 31) and Controls (n = 30).
Subtest M ean U nadjusted A djusted U nadjusted  t A djusted t
M ean M ean
D ifference D ifference
V PA  I Total
Control 29.23 3.69 3.28 2.66* -2.56*
MDMA
V PA  I 
L ist a
25.55
Control 6.27 2.04 2.24 3.40** -4.01***
MDMA
V PA  I 
L ist b
4.23
Control 7.47 0.95 .652 2.12* -1.51
MDMA
V PA  I 
L ist c
6.52
Control 7.77 0.51 .320 1.81 -1.16
MDMA
V PA  I 
L ist d
7.26
Control 7.73 0.19 0.08 0.77 -0.42
MDMA 7.55
V PA  II
Control 7.60 0.25 0.07 0.71 -0.28
MDMA 7.36
*p<.05, **p<.01, ***p<001
It can be seen from the unadjusted and adjusted analyses in Table 2.12 that MDMA- 
users performed significantly worse than controls on the total VPA subtest, a measure of 
immediate verbal memory and learning (intelligence, age, sex, and anxiety were 
significant covariates). MDMA-users recalled significantly fewer word pairs than 
controls after the first presentation of the list (List ‘a’) (sex and anxiety were significant 
covariates). The unadjusted analysis for List ‘b’, presented in Table 2.12, reveals that 
MDMA-users recalled significantly fewer word pairs than controls after the second 
presentation of the list, however, this group difference was no longer apparent after 
controlling for the effects of intelligence, age, and sex. Finally, there was no difference 
between the two groups in the number of pairs recalled after subsequent presentations of
85
the list (list ‘c’ and ‘d’) or after the delay of 25 to 35 minutes. The pattern of results 
recorded over the four trials of this subtest is represented in Figure 2.1.
Controls
MDMA-Users
List 'a' List ’b' List 'c' List'd' Delay
VPA Trials
Figure 2.1: Verbal Paired Associates Learning Curve
The pattern of results for the VPA subtest evident in Figure 2.1, indicates that the 
difference between MDMA-users and controls’ performance is quite marked on the first 
trial, but recovers to be comparable to controls over successive trials. While MDMA- 
users’ performance improves after the second presentation of the word pairs to become 
equivalent to that of the controls, the controls’ performance improves from the first to 
the second trial and subsequently levels out.
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Visual Memory Subtests
In the following section both the unadjusted and adjusted comparisons between 
MDMA-users and controls’ performance in the visual memory subtests are presented. 
The performance of controls and MDMA-users on the immediate (I) and delayed (II) 
conditions of the Faces subtest, a measure of cued visual recall, and the Family Pictures 
subtest, a measure of memory for contextual visual material, were compared using the 
aforementioned analyses. The results of these analyses are presented in Table 2.13.
Table 2.13: WMS-III Faces and Family Pictures Subtest Means and Comparisons for 
MDMA-Users (n = 31) and Controls (n = 30).
Subtest M ean U nadjusted
M ean
D ifference
A djusted
M ean
D ifference
U nadjusted  t A djusted t
Faces I
Control
MDMA
Faces II
39.43
37.23
2.21 2.21 2.17* -2.17*
Control
MDMA
Fam ily  
Pictures I
39.13
36.68
2.46 2.46 1.95 -1.95
Control
MDMA
Fam ily  
Pictures II
49.40
45.19
4.21 3.31 2.26* -1.78
Control
MDMA
49.10
45.03
4.07 3.14 2.29* -1.75
*p<.05
It is evident from Table 2.13 that MDMA-users recognised fewer faces than controls in 
the immediate condition of the Faces subtest. There were no significant covariates, thus 
the unadjusted analysis was retained. There was no significant difference between the 
performance of MDMA-users and controls on the Faces subtest in the delayed 
condition, however a trend was evident (p=.06). Again the unadjusted regression model 
was retained since there were no significant covariates. An examination of the 
unadjusted and adjusted analyses for the Family pictures subtest, presented in Table
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2.13, indicates that MDMA-users recalled significantly less information than controls 
from the family pictures in both the immediate (I) and delayed (II) conditions, however, 
these group differences did not remain after controlling for the effects of age and 
intelligence. A trend was evident, however, for recall performance on both the 
immediate (p=.08) and delayed (p=.09) conditions.
Attention and Working Memory Subtests
In the following section, comparisons between MDMA-users and controls’ performance 
on the WMS-III attention and working memory subtests are presented. The results of 
these analyses are presented in Table 2.14. As demonstrated earlier, controls and 
MDMA-users were comparable in terms of potential confounding variables, apart from 
other drug use. As it is unlikely that the more extensive recreational drug use amongst 
MDMA-users would have a beneficial effect on attention or working memory 
functioning, it was perceived that group differences would not be masked and become 
evident after the adjusted analysis. Thus it was determined that the unadjusted analyses 
were sufficient to conclude that no significant differences between the two groups were 
evident.
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Table 2.14: WMS-III Letter-Number Sequencing, Spatial 
Span and Digit Span Subtest Means and Unadjusted t 
values for MDMA-Users (n = 31) and Controls (n= 30).
Subtest Mean Unadjusted
Mean
Unadjusted t
Difference
Letter Number 
Sequencing
Control 13.33 1.04 1.59
MDMA 12.29
Spatial Span 
Total
Control 18.16 0.65 0.87
MDMA 17.52
Spatial Span 
Forward
Control 9.10 0.33 0.68
MDMA 8.77
Spatial Span 
Backward
Control 8.93 0.19 0.52
MDMA 8.74
Digit Span 
Total
Control 20.37 1.40 1.28
MDMA 18.97
Digit Span 
Forward
Control 11.60 0.54 0.92
MDMA 11.07
Digit Span 
Backward
Control 8.77 0.86 1.37
MDMA 7.90
It can be seen in Table 2.14 that there were no significant differences between MDMA- 
users and controls’ performances on the attention and working memory subtests.
2.2.5 Examination of a Dose-Response Relationship Between MDMA Exposure 
and Verbal Memory Performance
The possibility of a dose-response relationship between MDMA use and memory 
dysfunction was examined in the cohort of MDMA-users. As outlined in a previous 
section, the estimated total lifetime dose of MDMA, the highest frequency of MDMA 
use in one month and the highest number of pills swallowed at the same time were
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combined to create a composite measure of MDMA exposure. This measure of MDMA 
exposure was then included in regression analyses to examine the relationship between 
exposure and memory performance on each of the WMS-III memory indexes and 
subtests, while controlling for the effects of age, sex, intelligence, anxiety, depression 
and other drug use. Significant regression analyses suggesting a dose-response 
relationship between the extent of MDMA exposure and memory dysfunction are 
presented in Tables 2.15 to 2.17. There was no dose-response relationship observed for 
the general, immediate and working memory indexes, the auditory immediate and 
delayed indexes, the visual immediate and delayed indexes, the auditory recognition 
index, the Logical Memory subtests, the faces and family pictures subtests, or the 
subtests assessing attention and concentration.
Table 2.15: Multiple Linear Regression Model Examining Dose-Response 
Relationship Between MDMA Use and VP A I Total Performance While Adjusting 
for Potential Confounders (n = 31).
V a r ia b le B S E T P a
MDMA Exposureb -.001 .000 -2.17 .040
IQ .334 .124 2.70 .012
Anxiety .277 .107 2.58 .016
Age -.471 .198 -2.38 .025
F=6.21, p=001 
Adjusted R Square=.418
Note: B = unstandardised regression coefficient 
aTwo-tailed
bMDMA Exposure = highest frequency of use per month x estimated total dose x highest dose
It can be seen in Table 2.15 that a dose-response relationship between MDMA-exposure 
and VP A Total performance was evident after controlling for the effects of potential 
confounders. This relationship suggests that the greater the exposure to MDMA, the 
poorer the total performance on the VPA subtest, a measure of immediate verbal 
memory and learning.
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Table 2.16: Multiple Linear Regression Model Examining Dose-Response 
Relationship Between MDMA Use and VP A I List ‘a’ Performance While 
Adjusting for Potential Confounders (n=31).
V ariable B SE T Pd
MDMA Exposure15 -.000 .000 -3.18 .050
IQ .139 .054 2.55 .017
Anxiety .122 .047 2.58 .016
F=5.66, p=.004 
Adjusted R Square=.325
Note: B = unstandardised regression coefficient 
aTwo-tailed
bMDMA Exposure = highest frequency of use per month x estimated total dose x highest dose
An examination of a dose-response relationship between MDMA-exposure and each of 
the VPA subtest trials revealed significant relationships between exposure and 
performance on the first and third trials, but not the second or final trials. It can be seen 
in Table 2.16 that a dose-response relationship between MDMA-exposure and recall 
after the first presentation of the VPA word pairs (List ‘a’) was evident after controlling 
for the effects of potential confounders. This relationship again suggests that the greater 
the exposure to MDMA, the poorer the immediate verbal memory performance.
Table 2.17: Multiple Linear Regression Model Examining Dose-Response 
Relationship Between MDMA Use and VPA I List ‘c’ Performance While 
Adjusting for Potential Confounders (n=31).
V ariable B SE T Pd
MDMA Exposure15 -.000 .000 -2.08 .048
IQ .066 .033 2.04 .052
Anxiety .049 .028 1.73 .097
Age -.074 .052 -1.41 .170
F=3.27, p=.028 
Adjusted R Square=.238
Note: B = unstandardised regression coefficient 
aTwo-tailed
bMDMA Exposure = highest frequency of use per month x estimated total dose x highest dose
A dose-response relationship between MDMA-exposure and memory performance after 
the third presentation of the VPA word pairs (List ‘c’) was evident after controlling for 
the effects of potential confounders (see table 2.17). As in the case of List ‘a’, this 
relationship suggests that the greater the exposure to MDMA, the poorer the recall 
performance of the word pairs on the third trial.
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2.3 DISCUSSION
This study set out to ascertain whether recreational MDMA-users manifest memory 
dysfunction, after controlling for the influence of potentially confounding variables on 
memory performance. More importantly, in light of the failure to date to present a 
meaningful clinical picture of memory dysfunction in MDMA-users, it was intended 
that the present study would explore the nature of memory impairment in MDMA-users. 
Several conclusions can be drawn from the comparative examination of memory 
functioning in recreational MDMA-users and controls presented in the previous section. 
First, MDMA-users manifested comparative deficits in immediate and delayed memory 
functioning, after controlling for the effects of intelligence, age, sex, depression, anxiety 
and other drug use. Dysfunction was evident in both the verbal and visual modalities 
for immediate memory and the visual modality for delayed memory. Working memory, 
attentional capacity, and delayed memory functioning in the verbal modality remained 
intact. Second, the clinical examination of verbal memory functioning in MDMA-users 
revealed a pattern of dysfunction that was consistent with encoding rather than retrieval 
deficits. Furthermore, the impact of encoding problems in MDMA-users was more 
apparent on tasks of greater complexity. Third, observations of comparable rates of 
forgetting for controls and MDMA-users indicated intact storage of information in the 
MDMA using cohort, ruling out a rapid rate of decay as a possible explanation for 
memory dysfunction. Finally, a dose-response relationship was evident between 
MDMA exposure and verbal memory performance.
A discussion of the comparative analyses for the WMS-III memory indexes is presented 
in the following section to address the question of whether MDMA-users manifest 
memory dysfunction. A clinical examination of the individual subtest performances is
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then carried out to determine the nature of memory dysfunction and evidence supporting 
the hypothesis that encoding dysfunction was responsible for the memory impairment 
evident in MDMA-users is presented. Finally, the observation of a dose-response 
relationship between MDMA exposure and verbal memory functioning is addressed.
2.3.1 Memory Dysfunction in MDMA-Users
An examination of immediate and delayed memory functioning, in both the verbal and 
visual modalities, was carried out through comparative analyses of the WMS-III 
composite memory indexes for MDMA-users and controls, while controlling for the 
effects of age, sex, intelligence, depression, anxiety and other drug use. It was apparent 
that MDMA-users manifested significantly poorer functioning for both immediate and 
delayed memory. Working memory functioning, however, was intact. The 
examination of immediate memory functioning by modality revealed MDMA-users 
demonstrated impairment in both verbal and visual memory when compared to controls. 
Comparative deficits in delayed memory functioning were also evident in the visual 
modality, however, delayed verbal memory remained intact. The auditory recognition 
index of the WMS-III revealed significant differences between the two groups’ cued 
memory functioning, however, this index was interpreted with caution because it is 
comprised of performances on the recognition tasks for both the word pairs and story 
subtests. The word pairs recognition task was overly simplistic and was not 
independently examined in the analysis because every subject obtained a perfect score 
on this measure. Consequently, the observed difference between the two groups on the 
recognition index could only be attributed to recognition performance on the story 
subtest. Recognition functioning was therefore examined through performances on this 
subtest alone, and is described in detail below.
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It can be concluded from the comparative analyses of the WMS-III memory indexes 
that MDMA-users manifest memory dysfunction which cannot be attributed to the 
effects of age, sex, intelligence, other drug use, depression or anxiety. Indeed the 
construction of the regression analyses revealed that many of these factors do 
significantly influence memory performance in MDMA-users. Therefore, failure to 
control for these factors in the existing literature and in future studies is problematic. 
The observation of memory dysfunction in the cohort of MDMA-users in the present 
study is consistent with the two other well controlled studies in the literature. 
Gouzoulis-Mayffank et al. (2000) found that MDMA-users, without a history of 
polydrug use, were impaired in immediate verbal and visual memory functioning when 
compared to cannabis users and non-drug using controls. Importantly, the non-polydrug 
using sample of MDMA-users in this study rules out the cumulative effects of polydrug 
use, in conjunction with MDMA, as an alternative explanation for memory impairment 
in this population. The unique association between memory impairment and MDMA 
use was further consolidated by Morgan (1999), who found that MDMA-users had 
poorer immediate and delayed verbal memory when compared to polydrug-using and 
non-drug using controls. The results of the present study confirm that MDMA-use is 
associated with memory impairment. In the following section, the pattern of memory 
impairment observed in the MDMA-using cohort is examined from a clinical 
perspective to ascertain a meaningful picture of the nature of memory impairment in 
MDMA-users.
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2.3.2 The Nature of Memory Dysfunction in MDMA-Users
Lezak (1995) postulates that memory dysfunction may result from a variety of sources, 
including compromised learning due to defective encoding, the rapid loss of newly 
required information (forgetting) due to storage deficits, and retrieval problems. 
Retrieval problems are evident when recognition or cueing techniques indicate that 
more learning has occurred than free recall performance indicates. A clinical 
examination of the comparative memory performances on each of the WMS-III subtests 
for controls and MDMA-users was carried out to ascertain whether the memory 
impairment identified by the WMS-III indexes resulted from defective encoding, 
retrieval or rapid forgetting. Total subtest performance scores were considered a crude 
indication of functioning and therefore were not interpreted. Instead individual subtests 
and subtest trials were examined to gain an in depth understanding of the pattern of 
memory impairment. This investigation revealed a pattern of impairment, across 
several subtests, that was consistent with encoding problems. Furthermore, rapid 
forgetting was ruled out as a possible explanation for the memory dysfunction observed 
in MDMA-users and the observed pattern of impairment was not consistent with 
retrieval problems.
MDMA-users consistently manifested comparative deficits in recall performance after a 
single presentation of verbal material. A plausible explanation for this dysfunction in 
single trial learning is that MDMA-users do not encode information as efficiently as 
controls and require repeat exposure to stimuli before effective recall is possible. As 
shown in Figure 2.1, MDMA-users’ recall of simple verbal information (VPA word 
pairs) recovered to levels comparable to controls after the second presentation of the 
stimuli (List ‘b’), and their recall performance was equivalent to controls on the 
remaining trials (Lists ‘c’ and ‘d’). After the delay, MDMA-users’ recall continued to
95
be comparable to controls, indicating that once encoded, the information was retained in 
the memory store and effectively retrieved. This pattern of dysfunction suggests 
inadequate or inefficient encoding processes, which initially impede effective learning, 
but which are overcome after repeat exposure. On the Logical Memory subtest, which 
required the recall of more complex contextual verbal information, single trial learning 
in MDMA-users was similarly impaired when compared to controls. MDMA-users 
recalled significantly less information than controls immediately after exposure to the 
two separate stories (Story A and B). Furthermore, they failed to recover to levels 
comparable to controls after being exposed to Story B a second time. An examination 
of the adjusted mean differences revealed that MDMA-users improved their recall 
performance at a rate similar to controls after the second exposure to Story B, however, 
they remained impaired in comparison to controls. It is likely that MDMA-users’ 
performance would have eventually equaled controls, if given the opportunity of 
repeated exposure to the story. However, unlike their performance on the word pairs 
task, they failed to benefit immediately from repeat exposure due to the complexity of 
the material. This pattern of dysfunction is consistent with the hypothesis that MDMA- 
users manifest problems with encoding processes, which prevent them from learning 
information as efficiently as non-users. Consequently, they require greater exposure to 
information before being able to recall comparable amounts as non-users. Furthermore, 
this effect becomes more apparent as the complexity of the information to be recalled is 
increased.
MDMA-users’ story recall remained impaired after the delay in the case of Story A. 
Despite the finding that MDMA-users recalled significantly less from Story B than 
controls in the immediate condition, the difference between the two groups’ delayed 
recall of Story B failed to reach statistical significance after controlling for potential
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confounders. However, a definite trend was observed. The failure to find a statistically 
significant difference for the delayed recall of Story B, may be interpreted as indicative 
of comparable memory performance for controls and MDMA-users after the delay, 
perhaps as a result of consolidation of information in memory in MDMA-users or 
greater decay in the controls’ performance. However, an examination of the adjusted 
mean differences revealed that MDMA-users recalled approximately two items less than 
controls from Story B, on both the immediate and delayed condition of this task. This 
similarity in the adjusted mean differences, in addition to the observed trend, indicates 
that the difference between the Story B recall for the two groups after the delay may not 
have reached statistical significance as a result of the small size of the sample. This 
conclusion is supported by findings of delayed verbal memory impairment in the 
existing literature (Morgan, 1999)
Indications of encoding problems were further supported through an examination of the 
recognition subtests for the two stories. In the assessment of memory functioning, 
unimpaired free recall performance is indicative of intact encoding and retrieval 
processes. Problematic free recall and intact recognition are indicative of retrieval 
processes dysfunction but intact encoding, whereas problematic recognition is indicative 
of encoding processes dysfunction (Lezak, 1995). Recognition performance from the 
Logical Memory subtest was therefore used, in the present study, to further examine 
whether memory dysfunction in MDMA-users occurred as a result of problematic 
encoding or retrieval processes. An explanation of retrieval dysfunction would be 
plausible, if recognition performances were equivalent for controls and MDMA-users, 
in light of the impaired free recall performance for MDMA-users on both Story A and 
B. This would suggest that although MDMA-users had effectively encoded similar 
amounts of information as controls, retrieval problems prevented them from freely
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recalling as much information. Alternatively, if MDMA-users failed to recognise 
comparable amounts of information as controls, problems in encoding would be 
apparent. It was evident that MDMA-users’ cued recognition performance for Story B 
was significantly poorer than controls, indicating that an encoding rather than a retrieval 
problem was responsible for the memory dysfunction observed in MDMA-users. The 
difference between the cued recognition performance for MDMA-users and controls on 
Story A, however, failed to reach statistical significance. In the context of the pattern of 
results already presented, this result was not deemed to be indicative of a retrieval 
problem, because suggestions of retrieval dysfunction were not justified by 
performances on other subtests, such as the VPA word pairs. It should be noted that 
Story B is more complex than Story A, because it contains specific information 
regarding times, temperature, and numerical values, as opposed to general contextual 
information. It is therefore plausible that encoding problems in MDMA-users were 
more readily apparent on Story B as a result of the complexity of this task. Recognition 
tasks are generally considered to be less cognitively demanding than free recall, and 
thus it is possible that the difficulty of the recognition task for the less complex Story A 
was not of a sufficient magnitude to differentiate between controls and MDMA-users. 
A similar ceiling effect was evident on the overly simplistic recognition task for the 
word pairs subtest, which was excluded from the analysis after every subject obtained a 
perfect score.
Finally, an examination of the adjusted mean differences for each of the immediate and 
delayed story trials revealed that a comparable rate of forgetting was evident from the 
immediate presentation to the delayed recall for both groups. Therefore it was apparent 
that storage in MDMA-users was intact and the rapid loss of newly required information 
was ruled out as a possible explanation for memory dysfunction in MDMA-users.
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It has been hypothesised that a plausible explanation for the observed deficit in single 
trial learning in MDMA-users, in conjunction with their recovery after repeated 
exposure to simple verbal information but failure to recover after repeated exposure to 
complex verbal information, is that MDMA-users do not encode information as 
effectively as controls. This hypothesis is supported by the recognition dysfunction 
evident in MDMA-users for more complex material, and the comparable rates of 
forgetting for the two groups, which do not support retrieval dysfunction or rapid 
forgetting as possible explanations for memory dysfunction in MDMA-users. Further 
support is to be found in the clinical interpretation of the existing literature on memory 
dysfunction in MDMA-users, developed in Chapter 1. This examination confirms that 
when presented with tasks of sufficient complexity, MDMA-users manifest problems 
with single trial learning and require greater exposure to material before it is committed 
to memory, when compared to non-users (Gouzoulis-Mayffank et al., 2000; McCann et 
al., 1999). This pattern of dysfunction observed in the existing studies of memory in 
MDMA-users is consistent with problems in encoding processes and lends further 
support to the argument that memory impairment in MDMA-users occurs as a result of 
encoding dysfunction.
However, several criticisms regarding the encoding dysfunction hypothesis need to be 
considered. First, indications of recognition impairment were only evident on one of 
the two stories. Comparable recognition performance on the single presentation story is 
inconsistent with encoding problems in light of MDMA-users’ impaired free recall on 
this task. However, when considered in the context of the pattern of findings, this result 
was not deemed sufficient to contradict the indications of encoding problems in 
MDMA-users. It is evident, however, that further studies need to be carried out to rule
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out concurrent retrieval problems. Second, the examination of the attention and 
working memory subtests revealed no indications of impairment in MDMA-users, a 
finding that is inconsistent with other studies in the literature (Wareing et al., 2000; 
Gouzoulis-Mayffank et al., 2000). It may be argued that encoding dysfunction would 
also be apparent on these tasks, and the present study’s failure to find evidence of 
impairment is inconsistent with the encoding hypothesis. However, upon consideration 
of the nature of the attention and working memory subtests, it can be argued that they 
were not of a sufficient complexity for MDMA-users to manifest encoding difficulties. 
It has consistently been observed, both in the present study and in the existing literature, 
that MDMA-users maintain comparable levels of memory and attentional functioning 
until challenged by more complex tasks, requiring manipulation and recall of greater 
amounts of information (Gouzoulis-Mayffank et al., 2000; Wareing et al., 2000). 
Alternatively, the high functioning status of the MDMA-using cohort in the present 
study may account for the failure to replicate comparative deficits in working memory 
functioning observed in other studies. Gouzoulis-Mayffank et al. (2000) found that 
MDMA-users performed significantly worse on the digits span backwards subtest of the 
Wechsler Adult Intelligence Scale-Revised, which is an identical task to the digits span 
backwards task of the WMS-III performed in the present study. However, only one 
subject in the Gouzoulis-Mayffank et al. study had completed a university degree, 
whereas, 17 MDMA-users in the present study had completed a university degree at 
either the undergraduate or postgraduate level. It is plausible that the MDMA-users in 
the present study were able to employ alternative cognitive strategies to compensate for 
compromised working memory functioning. Finally, it is also possible that the failure 
to control for depression and anxiety in the Gouzoulis-Mayffank et al. study may have 
contributed to the inconsistencies between the two studies, since both depression and 
anxiety are known to adversely affect attention and concentration (Lezak, 1995). In
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conclusion, encoding dysfunction in MDMA-users remains a plausible explanation for 
the comparative memory deficits evident in this cohort.
An examination of the comparative analyses of the visual memory subtests revealed a 
significant deficit in MDMA-users’ immediate memory for faces. The difference 
between the two groups’ performance on this subtest after the delay did not reach 
statistical significance, however, a definite trend was evident. Similar trends were 
observed for the immediate and delayed conditions of the family pictures subtest, 
involving memory of contextual visual information, which failed to reach statistical 
significance after controlling for covariates. The composite measures of immediate and 
delayed visual memory functioning, which are comprised of performances on both 
visual subtests, indicated visual memory dysfunction in MDMA-users, suggesting that 
power might have been a problem when considering the subtests in isolation. 
Alternatively, evidence for visual memory impairment in the Gouzoulis-Mayffank et al. 
(2000) study, which had a similar sample size to the present study, suggests that the 
failure to find a significant difference on measures of visual memory performance might 
also be attributed to the high functioning status of the present study’s cohort of MDMA- 
users.
The apparent inconsistencies between the findings of the present study and the two 
other highly controlled studies in the literature highlight several methodological 
limitations in the study of cognitive dysfunction in MDMA-users. As outlined earlier, 
sampling problems are evident because of the illicit nature of MDMA use, and the fact 
that MDMA-users are therefore a hidden population. As a result, it is impossible to 
randomly sample this population and differences between cohorts of MDMA-users 
prevent confident generalisations from being made to the MDMA-using population at
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large. However, despite differences between cohorts, memory dysfunction has 
consistently been demonstrated using a diverse range of assessment batteries across 
samples drawn in several different countries. Furthermore, alternative explanations for 
differences in memory and cognitive functioning between MDMA-users and non-users, 
such as intelligence, sex, age, and other drug use, have been statistically controlled for 
in two published studies, and the present study’s results are consistent with these after 
further controlling for the effects of anxiety and depression. Additionally, the present 
study’s findings of patterns of impairment that are indicative of encoding dysfunction 
are consistent with a clinical interpretation of the results of existing studies in the 
literature. Thus, although inconsistencies in the patterns of cognitive impairment are 
evident between different MDMA-using cohorts, the body of evidence as a whole 
suggests that memory dysfunction is a feature of MDMA use, and this dysfunction 
appears to result from encoding problems.
2.3.3 Dose-Response Relationship Between Memory Functioning and MDMA- 
Exposure
The observation of a dose-response relationship between MDMA exposure and verbal 
memory performance on the word pairs subtest suggests that greater exposure to 
MDMA is associated with greater impairment in verbal memory and learning. It is 
evident, however, that the pattern of results for the word pairs trials is inconsistent. 
Indications of encoding problems in the present study and the existing literature suggest 
that a dose-response relationship between the initial recall trial of the word pairs subtest 
(‘List a’) and MDMA-exposure is expected. Indeed, decrements in performance on this 
trial were apparent in the MDMA-using group. However, the significant dose-response 
relationship between MDMA-exposure and the third recall trial, in the absence of a 
significant relationship for the second trial, is not consistent with what is known of
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encoding problems in MDMA-users. The failure to find a significant dose-response 
relationship between MDMA exposure and memory performance on other verbal and 
visual subtests, in addition to the inconsistent results apparent in the current literature, 
raises the question of whether the concept of a dose-response relationship is appropriate 
in the case of MDMA use. Firstly, measurement problems regarding the assessment of 
exposure to MDMA are inherent as a result of the unknown dose and composition of 
MDMA pills, and the problematic nature of self-report of drug using behaviour. The 
present study’s use of a valid and reliable measurement technique attempted to 
minimise measurement error, however, it is likely that problems with reliability persist. 
Secondly, animal studies have demonstrated factors such as frequency of 
administration, absolute concentrations of MDMA in the bloodstream and total 
exposure, influence the neurotoxic process. The cumulative and multiplicative effects 
of variations in these dose regimens are unknown in humans and consequently, it is 
questionable as to whether a linear dose-response equation is appropriate. Moreover a 
threshold effect may also be apparent. Finally, the multiplicative effects of polydrug 
use on the neurotoxic process are also unknown, further challenging the capacity to 
detect any dose-response relationship that might exist. The examination of concurrent 
cocaine and amphetamine use in the present study failed to shed light on this question 
and no significant relationship between concurrent polydrug use and memory 
functioning was found. In conclusion, drawing meaningful conclusions from the 
relationship between MDMA-exposure and memory functioning is problematic as a 
result of measurement problems and the unknown nature of the neurotoxic process in 
recreational users, in addition to the numerous other factors and individual differences 
that influence memory and cognitive functioning. The inconsistent pattern evident in 
the results of the examination of a dose-response relationship in the present study is 
therefore not surprising.
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In conclusion, it has been established by the present study that MDMA-users manifest 
memory impairment. Furthermore, the clinical examination of the nature of memory 
impairment revealed that MDMA-users demonstrated a pattem of impairment that was 
consistent with encoding deficits. The present study highlights the need for future 
research to confirm the existence of inefficient encoding processes in other samples of 
MDMA-users, and to rule out the possibility of concurrent retrieval deficits. Finally the 
observation of memory impairment in the present study raises the question of whether 
impairment persists after abstinence from MDMA. This question is particularly 
pertinent in light of observations of neuronal regeneration in animal studies (Steele et 
al., 1994). The study presented in the following chapter will address this question and 
examine memory dysfunction in previous MDMA-users who have been abstinent from 
the drug for two years.
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CHAPTER 3
Memory Dysfunction in Two Year Abstinent MDMA-Users:
A clinical examination of the long-term cognitive effects of
recreational MDMA use.
As has been discussed in Chapter 1, the possible neurotoxic consequences of 
recreational MDMA use were first raised by animal studies, which demonstrated that 
MDMA is a selective neurotoxin to serotonergic pathways in the brains of experimental 
animals and non-human primates. The observation of serotonergic neurotoxicity in 
non-human primates after oral administration of MDMA in doses comparable to 
recreational use of the drug consolidated concerns that similar patterns of toxicity were 
occurring in humans. Investigations of serotonergic integrity in the brains of human 
recreational users have confirmed indications of neurotoxicity. Neuroimaging, 
neuroendocrine, and CSF studies suggest that recreational MDMA-users manifest 
indicators consistent with serotonergic degeneration and that these effects are dose- 
related. It is evident from the existing literature and the study reported in the previous 
chapter that one of the functional implications of MDMA-induced neurotoxicity is 
memory dysfunction. The evidence presented in Chapter 2 suggests that the nature of 
this memory dysfunction is consistent with impaired encoding processes. The review of 
the literature in the first chapter indicates that general cognitive impairment has also 
been associated with recreational MDMA-use. These findings are consistent with what 
is known of the dense serotonergic innervation of the hippocampus and cortex, the areas 
of the brain implicated in memory and general cognitive functioning respectively, 
suggesting that these brain regions are particularly vulnerable to the neurotoxic effects 
of MDMA. The observation of memory dysfunction in current recreational MDMA- 
users presented in the previous study poses the question of whether memory impairment
is a permanent consequence of MDMA use, or whether axonal regeneration and 
consequently, cognitive recovery occurs over time.
On the basis of the animal literature investigating the long-term effects of MDMA, it 
can be hypothesised that MDMA-induced neurotoxicity in humans may also be 
enduring. It has been observed that MDMA-induced neural damage in primates is 
prolonged and possibly permanent. However, indications of neuronal recovery are also 
evident. An examination of serotonergic functioning in MDMA-treated monkeys 18 
months after administration found evidence to suggest persistent serotonergic 
degeneration in some brain regions and reinnervation in other areas (Insel et al., 1989). 
Similar patterns of neuronal reinnervation were found in MDMA-treated primates seven 
years after administration of MDMA (Hatzidimitriou et al., 1999). In this study, ten 
squirrel monkeys were injected with MDMA twice daily (5mg/kg) on four consecutive 
days, while control monkeys received injections of saline at the same dose regimen. 
Post-mortem analyses of half of the sample, two weeks after administration, revealed 
pronounced reductions in serotonergic axon density in the cerebral cortex, 
hippocampus, striatum, amygdala and thalamus, and slight to moderate reductions in the 
hypothalamus of MDMA-treated monkeys when compared to controls. Post-mortem 
analyses of the remaining monkeys, seven years after administration of MDMA, 
revealed that serotonergic axon density remained decreased in the neocortex, although 
significant recovery relative to the two-week survivors was evident. Recovery in one 
field of the hippocampal region also occurred in the seven year survivors, however, 
significant decreases in serotonin axon density remained apparent in the remaining 
fields. Similar indications of partial recovery were apparent in the striatum of the seven 
year survivors, while complete recovery was evident in the thalamus and hypothalamus 
and some areas of the amygdala. The researchers concluded from their findings that
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monkeys treated with MDMA continue to show altered brain serotonin innervation 
patterns seven years after administration, suggesting that some MDMA-induced 
alterations in serotonergic innervation may be permanent (Hatzidimitriou et al., 1999). 
The study findings suggest that although some serotonergic recovery does take place 
over a seven year period, this recovery is not always complete and does not occur in a 
number of regions. Of particular significance to the study of memory and cognitive 
dysfunction in human recreational users is the observation that those areas of the brain 
that do not completely recover include the neocortex and hippocampus.
The pattern of partial recovery and prolonged MDMA-induced damage in primates 
leads to the question of whether similar patterns of deinnervation persist in humans, 
after discontinuation of use. The effects of MDMA-use on serotonergic functioning in 
humans has not been investigated after long periods of abstinence to date. However, a 
neuroendocrine study of MDMA-users 12 months after discontinuation of MDMA use 
has demonstrated that indications of long-lasting serotonergic system impairment are 
also evident in humans (Gerra et al., 2000). Fifteen male recreational MDMA-users 
with a history of at least 25 occasions of use were administered a d-fenfluramine 
challenge (a specific serotonergic agonist) after both three weeks and 12 months of 
abstinence from MDMA. Blunted prolactin and cortisol responses to d-flenfluramine in 
comparison to controls were observed after three weeks of abstinence, indicating an 
overall reduction of serotonergic transmission in MDMA users. Blunted prolactin 
responses remained unchanged after 12 months of abstinence, and were significantly 
reduced in comparison to controls, suggesting that the overall reduction in serotonergic 
transmission observed after three weeks of abstinence had endured. In contrast, cortisol 
responses were restored after 12 months discontinuation of MDMA. Comparisons 
revealed that cortisol responses for 12 month abstinent MDMA-users did not differ
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significantly from controls, and had improved significantly when compared to responses 
recorded three weeks after discontinuation. It was argued by the researchers that the 
restored responses of cortisol in the 12 month abstinent MDMA users may represent an 
expression of initial recovery in the serotonergic system. Furthermore, the recovery of 
the cortisol responses after 12 months, in comparison to the enduring reduction in 
prolactin responses, suggests that MDMA-induced neurotoxicity may differently affect 
distinct areas of the serotonergic system (Gerra et al., 2000).
Observations of prolonged and possibly permanent serotonergic degeneration in 
monkeys seven years after administration of MDMA, in addition to indications of 
enduring serotonergic system damage in humans 12 months after discontinuation of use, 
suggest that long-term cognitive consequences of recreational MDMA-use are also 
probable. It was the purpose of the study reported in this chapter to determine if 
functional implications of MDMA-induced serotonergic neurotoxicity were apparent 
after two years of abstinence and, specifically, if the memory and cognitive dysfunction 
observed in current MDMA-users was evident two years after discontinuation of 
MDMA use.
3.1 METHOD
3.1.1 Participants
A total of sixty individuals, thirty abstinent MDMA-users and thirty controls, 
participated in the study. The MDMA group was comprised of thirty abstinent 
recreational MDMA-users who had used MDMA at least 10 times in their lives and 
who had not used the drug within the previous two years. As mentioned in the previous 
study, MDMA-users are a hidden population of unknown size and composition and it is 
therefore impossible to systematically sample from this population. Thus subjects were
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recruited via peer networks using the snowball technique. Initial contacts were 
generated through abstinent MDMA-users already known to the experimenter and 
leaflets and posters distributed in music stores throughout Canberra city. The abstinent 
MDMA-users were compared to the 30 control subjects described in the previous study. 
Comparisons between abstinent MDMA-users and the 31 current MDMA-users 
recruited for the previous study were also conducted. Abstinent MDMA-users were 
paid $20 for their participation in the study. Controls completed the study to obtain 
credit points as a component of their undergraduate degree in psychology. There was 
no mean difference between the two groups in age, depression and anxiety. The two 
groups differed significantly in mean intelligence and sex distribution. Exclusion 
criteria for the study included: past or present psychotic illness, previous incidence of 
serious head injury, and English as a second language. Neither depression nor anxiety 
were grounds for exclusion because both conditions were measured and controlled for 
statistically.
Three cases in the abstinent MDMA-users cohort were current heroin users. There were 
too few cases to control for the possible confounding effects of heroin use through 
regression analyses, thus a sensitivity analysis was conducted, where the regression 
analyses were re-run with the exclusion of these cases. No differences in the outcome 
of the results were evident, thus these cases were retained in the analyses.
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3.1.2 Study Design
The retrospective cohort study design described in the previous chapter was employed 
to examine the long-term effects of MDMA use on memory functioning.
3.1.3 Procedure
The procedure outlined in the previous study was replicated to study the long-term 
effects of MDMA-use on memory functioning. The identical screening process, 
consent form, questionnaire and time line interview method were implemented and the 
assessment battery described in the previous chapter was administered. Completed 
profiles were stored under the same restricted conditions to protect the confidentiality 
and anonymity of participants and the study was granted approval by the Australian 
National University Human Research Ethics Committee.
3.1.4 Data Analysis
The data were analysed using the software package SPSS for Windows Version 9.0. 
The procedures recommended by Tabachnick and Fidell (1989) were used to screen the 
data prior to statistical analyses.
Two sets of comparative analyses in memory functioning were conducted: comparisons 
between controls and abstinent MDMA-users, and comparisons between current and 
abstinent MDMA-users. For discrete variables, comparisons between groups were 
performed using Pearson’s chi-square test and Fisher’s exact test, where expected cell 
frequencies in two by two tables were less than five. For continuous variables with 
approximate normal distributions, comparisons between groups were made using 
student’s t-test for independent samples. For variables not conforming to a normal 
distribution, comparisons between groups were made using the non-parametric Mann- 
Whitney U-test. All statistical tests employed a two-tailed alpha criterion of 0.05.
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As outlined in the previous study, comparisons between the groups’ memory 
performances were made while adjusting for possible confounding variables by 
developing multiple linear regression models. In order to maximise power and 
precision, each of these models was reduced using the backward elimination method 
(Kleinbaum, Küpper & Muller, 1988). As described previously, variables were 
removed from the model when they were not statistically significant, providing that they 
did not substantially alter the estimates of the variables remaining in the model. This 
method results in the most parsimonious model that is able to explain the data, while 
increasing the precision of the estimates of interest. The adjusted mean differences and 
t-values were derived from the final regression models. The assumptions of linearity 
and normality of the error distribution were assessed by graphical analysis of the 
residuals, while outliers were also assessed graphically. The results of these statistical 
analyses are presented in the following section.
3.2 RESULTS
The outcomes of the aforementioned comparative analyses are reported in the following 
sections. The results of the comparisons between abstinent MDMA-users and controls 
are presented first, followed by the results of the comparisons between the two MDMA- 
using cohorts. In each set of analyses, demographic information, estimations of current 
psychological and intellectual functioning, recreational drug use and memory 
functioning are compared. In the second set of analyses the pattern of MDMA use for 
the two cohorts is also compared, in addition to an examination of the dose-response 
relationship between past MDMA-exposure and memory performance.
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COMPARATIVE ANALYSES BETWEEN ABSTINENT MDMA-USERS AND 
CONTROLS
3.2.1 Demographic Information
The demographic characteristics of the sample are presented in Tables 3.1 to 3.3. As 
discussed in the previous chapter, age, sex, intellectual functioning, depression and 
anxiety influence memory functioning (Lezak, 1995). Thus differences between the 
abstinent MDMA-using cohort and controls on these variables were assessed to 
establish whether the two groups were well matched.
Table 3.1: Means, Standard Deviations for Age, Education and 
Estimated Intelligence (IQ). (N = 60)
Age Education IQ
(years) (years) (NART)
Controls 23.33 (6.59) 14.67(1.94) 106.97 (7.17)
Abstinent
MDMA
24.80 (6.84) 12.88 (2.47)** 100.53 (10.51)**
**p<.01
As can be seen from Table 3.1, the cohort of abstinent MDMA-users was well matched 
with controls for age, t(58) = -.846, p>.05, however significant differences between the 
two groups were apparent in years of education and estimated intelligence, as measured 
by the NART. Controls had completed significantly more years of education than 
abstinent MDMA-users, t(58) = 3.11, p<.01 and had higher estimated intelligence than 
abstinent MDMA-users, t(58) = 2.78, p<.01. In past studies of memory dysfunction in 
MDMA-users, years of education has been used as an indicator of intellectual 
functioning in place of more concise measures (e.g. Wareing et al, 2000). It was 
perceived that estimated IQ would be a more genuine estimation of intellectual 
functioning, thus education was not controlled for statistically.
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Table 3.2: Sex Distribution for Controls and Abstinent MDMA-Users
Sex
Female (%) Male (%) Total
Control 20 (66.7) 10(33.3) 30
Abstinent
MDMA
9 (30.0) 21 (70.0) 30
Total 29 (48.3) 31 (51.7)
As shown in Table 3.2, there was a significant difference between the two groups in 
terms of the distribution of males and females in each group, % (1, N = 60) = 8.08, 
p<.01. This group difference was controlled for statistically in subsequent comparative 
analyses for memory functioning.
Table 3.3: Means and Standard Deviations for 
Depression and Anxiety
Depression Anxiety
(BDI) (BAI)
Controls 8.07 (8.72) 8.03 (8.30)
Abstinent
MDMA
11.80 (11.17) 11.87 (12.21)
It is evident from Table 3.3 that there were no significant differences between controls 
and MDMA-users on measures of depression, t(58) = -1.44, p>.05 and anxiety, t(58) = - 
1.42, p>.05. As was the case in the previous study, an examination of the clinically 
relevant categories of severity for the BDI and BAI indicated that the means for both 
groups were within the ‘Minimal’ range for depression and the ‘Mild’ range for anxiety. 
The distribution of depression and anxiety scores in terms of these clinically relevant 
categories of severity were also analysed (see Tables 3.4 and 3.5). As described in the 
previous chapter, it was perceived that the mean scores of depression and anxiety could 
potentially underestimate group differences by masking variance in the distribution of 
severity on these measures.
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Table 3.4: Distribution of Depression Scores for Categories of Severity on BDI
Depression -  BDI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Control 27 (90.0) 3 (10.0) 30
Abstinent
MDMA
24 (80.0) 6 (20.0) 30
Total 51 (85.0) 9(15.0)
Table 3.5: Distribution of Anxiety Scores for Categories of Severity on BAI
Anxiety- BAI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Control 25 (83.3) 5 (16.7) 30
Abstinent
MDMA
21 (70.0) 9 (30.0) 30
Total 46 (76.7) 14(23.3)
However, the two groups were also well matched in terms of depression and anxiety, as 
measured by the BDI and BAI respectively (see Tables 3.4 and 3.5). There were no 
significant differences between the two groups in the distribution of either depression, 
Fisher’s exact test, p>.05, or anxiety scores, y2 (1, N = 60) = 1.49, £>.05.
3.2.2 Patterns of Recreational Drug Use
As mentioned in the previous chapter, alcohol consumption and illicit drug use have 
potential consequences for general cognitive functioning (Lezak, 1995), therefore an 
estimate of recreational drug use was obtained to control for group differences. 
Differences in the lifetime use and current use of recreational drugs other than MDMA 
were analysed and are presented in Table 3.6. As described earlier, for the purposes of
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this study, lifetime use was defined as reporting having ever taken the drug, and current 
use was operationalised as reporting use of the drug once a month or more frequently.
Table 3.6: Patterns of Other Recreational Drug Use
Lifetime Use 
(ie. ever used) 
(%)
Current Use
(ie. once a month or
more) (%)
A lcohol
Control 25 (83.3) 24 (80.0)
Abstinent MDMA 30 (100.0) 23 (76.7)
Cannabis
Control 17(56.7) 6 (20.0)
Abstinent MDMA 26 (86.7)* 19(63.3)**
B enzodiazapine
Control 1 (3.3) 0 (0)
Abstinent MDMA 14 (46.7)*** 2 (6.7)
A m phetam ine
Control 2 (6.7) 2 (6.7)
Abstinent MDMA 25 (83.3)*** 6 (20.0)
Heroin
Control 0 (0) 0 (0)
Abstinent MDMA 13 (43.3)*** 3 (10.0)
Cocaine
Control 1 (3.3) 0 (0)
Abstinent MDMA 20 (66.7)*** 4(13.3)
LSD
Control 2 (6.7) 2 (6.7)
Abstinent MDMA 28 (93.3)*** 2 (6.7)
Inhalants
Control 2 (6.7) 1 (3.3)
Abstinent MDMA 17(56.7)*** 0 (0)
*p< .05, **p<.01 ***p<.001
As might be expected, there were a number of differences between the abstinent 
MDMA-users and controls in the lifetime use of recreational drugs. As shown in Table 
3.6 MDMA-users had significantly greater lifetime use of cannabis, %2( \ , N = 60) = 
6.65, p<.05, benzodiazapines, x (1, N = 60) = 15.02, p<.001, amphetamine, % (1, N = 
60) = 35.62, p<.001, cocaine, x2(U N = 60) = 26.44, p<.001, heroin, x2(l> N = 60) = 
16.60, £<.001, LSD, x2(1,N = 60) = 45.07, p<.001 and inhalants, x2(l, N = 60) = 17.33, 
p<.001. These differences were statistically controlled for in later comparative analyses 
for memory functioning. Despite the marked differences in lifetime use of other drugs,
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the two groups were well matched in terms of current drug use, with the exception of 
cannabis consumption. A greater number of MDMA-users currently used cannabis 
once a month or more frequently, x2(l, N = 60) = 11.59, p<.01 and this difference was 
controlled for in later comparative analyses.
3.2.3 Memory Functioning in Abstinent MDMA-Users and Controls
The results of the analyses comparing the memory performance of abstinent MDMA- 
users and controls follow the same format as the previous study and are presented in the 
following sections. Firstly, comparisons between abstinent MDMA-users and controls 
on the WMS-III memory indexes are presented. Immediate, delayed and working 
memory functioning are examined, followed by the indexes representing immediate and 
delayed memory functioning for both the auditory (verbal) and visual modalities. 
Secondly, comparisons between abstinent MDMA-users and controls are made for 
performances on each of the verbal and visual memory subtests. Finally, results of the 
comparison between abstinent MDMA-users and controls for attention and working 
memory performance are presented. Final regression models can be found in Appendix 
IV for significant comparisons and comparisons which were no longer significant after 
controlling for potential confounders.
Memory Indexes
Both adjusted and unadjusted comparisons between abstinent MDMA-users and 
controls for memory functioning, as measured by the WMS-III memory indexes, are 
presented in this section. The results of these analyses are summarised in Tables 3.7 to 
3.9.
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Table 3.7: WMS-III Memory Index Means and Comparisons for Abstinent MDMA-Users 
(n = 30) and Controls (n = 30).
WMS-III 
Memory Index
Mean Unadjusted
Mean
Difference
Adjusted
Mean
Difference
Unadjusted t Adjusted t
Immediate
Memory
Control
Abstinent MDMA
112.83
94.63
18.20 17.44 6.01*** -5.38***
General Memory
(delayed)
Control
Abstinent MDMA
110.23
95.07
15.17 15.17 5.25*** -5.25***
Working Memory
Control
Abstinent MDMA
111.47
101.03
10.43 9.84 2.90** -2.43*
*p<.05, **p<.01, ***p<.001
It is evident from Table 3.7 that abstinent MDMA-users displayed significantly poorer 
immediate, general (delayed) and working memory functioning, as measured by the 
WMS-III composite memory indexes. The differences between the two groups’ 
memory functioning remained after adjusting for the effects of potential confounders. 
Intelligence was a significant covariate for the immediate memory index, while 
intelligence and sex were significant covariates for the working memory index. No 
covariates were significant in the final regression model for the general memory index, 
thus the unadjusted analysis was retained.
An examination of the differences between abstinent MDMA-users and controls in 
terms of immediate memory functioning in the verbal and visual modalities, revealed 
statistical significant differences between the two groups.
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Table: 3.8 WMS-III Immediate Memory Index Means and Comparisons for Abstinent 
MDMA-Users (n = 30) and Controls (n = 30).
W M S-III Memory 
Index
Mean Unadjusted
Mean
Difference
Adjusted
Mean
Difference
Unadjusted t Adjusted t
Auditory (verbal) 
Immediate 
Controls
Abstinent MDMA
118.87
101.77
17.10 12.68 5.61*** -4 09***
Visual Immediate
Controls
Abstinent MDMA 102.07
88.67
13.40 14.87 4 j4*** -4.73***
***p<.001
As can be seen from the unadjusted and adjusted comparisons presented in Table 3.8, 
MDMA-users displayed significantly poorer verbal and visual immediate memory 
functioning than controls. Intelligence and age were significant covariates for the 
verbal immediate memory index and anxiety was a significant covariate for the visual 
immediate memory index.
Table 3.9: WMS-III Delayed Memory Index Means and Comparisons for Abstinent 
MDMA-Users (n = 30) and Controls (n = 30).
W M S-III Memory 
Index
Mean Unadjusted
Mean
Adjusted
Mean
Unadjusted t Adjusted t
Difference Difference
Auditory (verbal) 
Delayed 
Controls 111.70 11.70 10.36 2 94*** -3.28**
Abstinent MDMA 100.00
Visual Delayed
Controls 101.63 14.30 14.30 4.22*** _4.22***
Abstinent MDMA 87.33
Auditory
Recognition
Controls 113.83 10.50 10.50 3.63** -3.63**
Abstinent MDMA 103.33
**p<.01, ***p<001
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It is apparent from Table 3.9 that both the unadjusted and adjusted comparisons were 
also statistically significant for the WMS-III delayed memory indexes. Abstinent 
MDMA-users’ delayed memory functioning was poorer than controls in the verbal 
modality, where intelligence was a significant covariate, and the visual modality, where 
there were no significant covariates. Finally, it is also apparent from Table 3.9 that 
abstinent MDMA-users’ cued recall performance, as measured by the WMS-III verbal 
recognition index, was significantly poorer than controls. The unadjusted analysis was 
retained as no covariates were significant in the model.
Verbal Memory Subiests
In this section, abstinent MDMA-users and controls’ performance on the verbal 
memory subtests are compared. Given significant differences were found between 
MDMA-users and controls on the WMS-III verbal memory indexes, individual subtest 
performances were examined to establish the nature of the verbal memory dysfunction 
in MDMA-users. Tables 3.10 and 3.11 represent the comparisons in performance on 
each of the verbal memory subtests, both before and after controlling for the potentially 
confounding effects of sex, age, intelligence, depression, anxiety and other drug use. 
As described in the previous study, the total logical memory subtest performance for the 
immediate (I) and delayed (II) conditions were compared for abstinent MDMA-users 
and controls, in addition to an examination of group performance on each of the 
individual stories (A and B), including the two trials of Story B in the immediate 
condition (Bi and Bii). Finally, performance on the recognition trial of logical memory, 
a measure of cued recall, was compared. The results of these analyses are presented in 
Table 3.10. Final regression models for significant comparisons, and comparisons that 
were no longer significant after controlling for the influence of potential confounders, 
can be found in Appendix IV.
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Table 3.10: WMS-III Logical Memory Subtest Means and Comparisons for Abstinent 
MDMA-Users (n = 30) and Controls (n = 30).
Subtest M ean U nadjusted A djusted U nadjusted  t A djusted t
M ean M ean
D ifference D ifference
L ogical
M em ory I Total
Control 49.80 11.20 7.89 5.49*** -3.89***
Abstinent MDMA
Logical 
M em ory I 
Story A
38.60
Control 16.97 3.93 -3.15 5.25*** -4.23***
Abstinent MDMA 
Logical 
M em ory I 
Story B i
13.03
Control 13.87 3.27 -3.15 3.93*** -3.28**
Abstinent MDMA
Logical 
M em ory I 
Story B ii
10.60
Control 18.97 4.00 -2.51 4.55*** -2.95**
Abstinent MDMA
L ogical 
M em ory II 
Total
14.97
Control 31.40 8.63 -7.26 5.11*** -3.99***
Abstinent MDMA
L ogical 
M em ory II 
Story A
22.77
Control 14.07 4.73 -4.15 4.57*** -3.76***
Abstinent MDMA
Logical 
M em ory II 
Story B
9.33
Control 17.27 3.83 -2.85 3.96*** -2.77**
Abstinent MDMA
L ogical
M em ory
R ecognition
13.43
Control 27.80 1.60 -1.37 3.13** -2.56*
Abstinent MDMA 26.20
*p<.05, **p<.01, ***p<.001
The unadjusted and adjusted comparisons presented in Table 3.10 indicate that abstinent 
MDMA-users recalled significantly less information than controls on the total logical 
memory I subtest, a measure of immediate contextual verbal memory (intelligence and
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age were significant covariates). A break down of the two logical memory stories, 
indicated that MDMA-users recalled significantly less information than controls from 
Story A and from both the first and second presentation of Story B. Intelligence was a 
significant covariate for Story A, while intelligence, age and sex were significant 
covariates for the first presentation of Story B. Intelligence and age were significant 
covariates for the second presentation of Story B.
The adjusted and unadjusted analyses presented in Table 3.10 reveal that after a delay of 
25 to 35 minutes, abstinent MDMA-users recalled significantly less information than 
controls on the total logical memory II subtest, (age and intelligence were significant 
covariates). The analysis of the story recall performance of the two groups after the 
delay revealed that abstinent MDMA-users recalled significantly less information from 
both Story A and B. Sex was a significant covariate, in the case of Story A, and 
intelligence and age were significant covariates in the case of Story B. Finally, 
MDMA-users performed significantly worse than controls on the logical memory 
recognition subtest, a measure of cued recall, (age was a significant covariate).
As outlined in the previous study, the recognition performance for the two groups was 
broken down by story to determine if differences were apparent for both Story A and 
Story B. Controls’ cued recall performance for Story A (M = 13.13, SD = 1.59) was 
comparable to abstinent MDMA-users (M = 12.40, SD = 1.73), t(58) = 1.71, p>.05. 
However, controls correctly recognised significantly more information from Story B (M 
= 14.67, SD = 0.55) than abstinent MDMA-users (M = 13.83, SD = 1.23), t(58) = 3.38, 
p<.01). This difference endured after controlling for the effects of potential 
confounders (age was a significant covariate).
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Verbal memory performance was then compared for the two groups for the total Verbal 
Paired Associates (VPA) subtest, in addition to comparisons for each of the four recall 
trials (a -  d). Recall performance after the delay of 25 to 35 minutes (VPA II) was also 
compared for controls and abstinent MDMA-users. As was the case in the previous 
study, the VPA recognition subtest was not included in the analysis because every 
participant obtained a perfect score on this measure.
Table 3.11: WMS-III Verbal Paired Associates (VPA) Subtest Means and Comparisons 
for Abstinent MDMA-Users (n = 30) and Controls (n = 30).
S u b test M ean U n a d ju sted A d ju sted U n a d ju sted  t A d ju sted  t
M ean M ean
D ifferen ce D ifferen ce
V P A  I T ota l
Control 29.23 5.73 2.87 3.52** -1.60
Abstinent MDMA
V P A  I 
L ist a
23.50
Control 6.27 2.13 1.32 3.47** -1.91
Abstinent MDMA
V P A  I 
L ist b
4.13
Control 7.47 1.73 0.84 3.48** -1.54
Abstinent MDMA
V P A  I 
L ist c
5.73
Control 7.77 1.30 0.44 3.28** -1.03
Abstinent MDMA
V P A  I 
L ist d
6.47
Control 7.73 0.57 0.08 1.74 -0.42
Abstinent MDMA
V P A  II
7.17
Control 7.60 0.25 0.07 0.71 -0.28
Abstinent MDMA 6.80
**p<.01
As can be seen in Table 3.11, abstinent MDMA users performed significantly worse 
than controls on the total VPA subtest, a measure of immediate verbal memory and 
learning. However, this difference was no longer apparent after controlling for the 
effects of sex and intelligence. Abstinent MDMA-users recalled significantly fewer 
word pairs than controls after the first presentation of the word pairs (List ‘a’). This
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difference failed to reach statistical significance after controlling for the effects of 
intelligence and sex, however a trend was evident (p=.06). The unadjusted analysis for 
List ‘b’, presented in Table 3.11, reveals that MDMA-users recalled significantly fewer 
word pairs than controls after the second presentation of the word pairs, however, this 
group difference was again no longer apparent after controlling for the effects of 
intelligence and sex. Similarly, the unadjusted analysis of the third presentation of the 
word pairs (List ‘c’) indicates that abstinent MDMA-users recalled significantly fewer 
word pairs, but, this group difference was again no longer evident after controlling for 
the effects of sex, intelligence and age. Finally, there was no difference between the 
two groups in the number of word pairs recalled after the final presentation (List ‘d’) or 
after the delay of 25 to 35 minutes (VPA II).
Visual Memory Subtests
In the following section both the unadjusted and adjusted comparisons between 
abstinent MDMA-users and controls’ performance in the visual memory subtests are 
presented (final regression models can be found in Appendix IV for significant 
comparisons and comparisons which were no longer significant after controlling for 
confounders). The performance of controls and abstinent MDMA-users on the 
immediate (I) and delayed (II) conditions of the Faces subtest, a measure of cued visual 
recall, and the Family Pictures subtest, a measure of memory for contextual visual 
material, were compared using the aforementioned analyses. The results of these 
analyses are presented in Table 3.12.
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Table 3.12: WMS-III Faces and Family Pictures Subtest Means and Comparisons for 
Abstinent MDMA-Users (n = 30) and Controls (n = 30).
Subtest M ean U nadjusted
M ean
A djusted
M ean
U nadjusted t A djusted t
D ifference D ifference
Faces I 
Control 39.43 2.77 3.11 2.78** -3.15**
Abstinent MDMA 36.67
Faces II 
Control 39.13 3.03 3.03 2.85** -2.85**
Abstinent MDMA 36.10
Fam ily Pictures I
Control 49.40 10.07 12.31 4.16*** -5.02***
Abstinent MDMA 39.33
Fam ily Pictures II
Control 49.10 10.43 10.59 4 24*** _4 04***
Abstinent MDMA 38.67
**p<.01, ***p<.001
The unadjusted and adjusted comparisons presented in Table 3.12 indicate that abstinent 
MDMA-users recognised fewer faces than controls in both the immediate (I) and 
delayed (II) condition of the Faces subtest. Anxiety was a significant covariate for the 
immediate condition of the Faces sub test. No covariates were significant within the 
final model for the delayed condition, thus the unadjusted analysis was retained. An 
examination of the unadjusted and adjusted analyses for the family pictures subtest, 
presented in Table 3.12, indicates that abstinent MDMA-users recalled significantly less 
information than controls in both the immediate (I) and delayed (II) conditions. 
Significant covariates were intelligence and anxiety in the case of the immediate 
condition, and age and intelligence in the case of the delayed condition.
Attention and Working Memory Subtests
In this section, comparisons between abstinent MDMA-users and controls’ performance 
on the WMS-III attention and working memory subtests are presented. The results of 
these analyses are summarised in Table 3.13.
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Table 3.13: WMS-III Letter-Number Sequencing, Spatial Span and Digit Span Subtest Means 
and Comparisons for Abstinent MDMA-Users (n = 30) and Controls (n= 30).
Subtest M ean U nadjusted A d ju sted U nadjusted  t A djusted  t
M ean M ean
D ifference D ifference
L etter N u m b er  
S equencing
C ontrol 13.33 2.23 1.78 3.24** -2.48*
A bstinen t M D M A 1 1 . 1 0
Spatia l Span T otal
C ontrol 18.16 1.17 0.90 1.51 -1.09
A bstinen t M D M A 17.00
Spatia l Span Forw ard
C ontrol
A bstinen t M D M A 9.10 0.47 0.39 0.93 -0.73
8.63
Spatia l Span  
B ackw ard
C ontrol 8.93 0.57 0.45 1.39 - 1 . 0 2
A bstinent M D M A 8.37
D igit Span  
T otal
C ontrol 20.37 3.50 2.61 3 7 4 *** -2.77**
A bstinent M D M A 16.87
D igit Span  
Forw ard
C ontrol 11.60 0.97 0.41 1.81 -0.77
A bstinen t M D M A
D igit Span B ackw ard
10.63
C ontrol
A bstinent M D M A 8.77 2.43 2 . 1 2 4  7 i* * * -3.92***
6.33
*p<.05, * * p < 0 1 , ***p< 001
As can be seen from Table 3.13, abstinent MDMA-users performed significantly worse 
than controls on the letter-number sequencing subtest, a measure of working memory 
intelligence was a significant covariate). There were no significant differences between 
abstinent MDMA-users and controls’ performances on the spatial span subtests and this 
remained the case after adjusting for potential covariates. Abstinent MDMA-users’ 
performance on the total digit span subtest, a measure of attention and working 
memory, was significantly poorer than controls, (intelligence was a significant 
covariate). There were no differences between the two groups’ performance on the digit 
span forwards subtest, a measure of basic attention, for either the unadjusted or adjusted 
comparisons. However, significant differences between the two groups were evident on
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the digit span backward subtest, a measure of working memory (intelligence was a 
significant covariate).
COMPARATIVE ANALYSES BETWEEN ABSTINENT MDMA-USERS AND 
CURRENT MDMA-USERS
Comparative analyses were conducted between the two MDMA-using cohorts to 
examine possible differences in memory functioning. In the following section, 
demographic information describing the two cohorts is reported, followed by an 
examination of the two groups’ patterns of past and current MDMA-use. Comparisons 
between the two groups’ memory functioning are then presented.
3.2.4 Demographic Information
The demographic characteristics of the two groups are presented in Tables 3.13 to 3.15. 
Potential differences in age, sex, estimated intelligence, depression and anxiety were 
examined for the two groups to determine whether the MDMA-using cohorts were well 
matched for potential confounding variables.
Table 3.13: Means, Standard Deviations for Age, Education and 
Estimated Intelligence (IQ) (N = 61).
Age Education IQ
(years) (years) (NART)
Current
MDMA
24.00 (4.66) 13.77 (2.22) 103.39 (7.64)
Abstinent
MDMA
24.80 (6.84) 12.88 (2.47) 100.53 (10.51)
As can be seen from Table 3.13, the cohort of abstinent MDMA-users was well 
matched with current MDMA-users in terms of age, t(59) = -0.54, p>.05, years of 
education t(59) = 1.48, p>.05 and estimated intelligence, as measured by the NART, 
t(59) = 1.55, p>.05.
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Table 3.14: Sex Distribution for Current and Abstinent MDMA-Users.
Sex
Female (%) Male (%) Total
Current
MDMA
19(61.3) 12 (38.7) 31
Abstinent
MDMA
9 (30.0) 21 (70.0) 30
Total 28 (45.9) 33 (54.1)
There was a significant difference between the two cohorts in terms of the distribution 
of males and females in each group, x2(ri N = 61) = 6.01, p<.05 (Table 3.14). As 
described earlier, sex is a potential confounder for memory performance, therefore, this 
group difference was controlled for statistically using regression analysis.
Table 3.15: Means and Standard Deviations for 
Depression and Anxiety
Depression
(BDI)
Anxiety
(BAI)
Current 10.53 (10.37) 10.10(8.88)
MDMA
Abstinent 11.80(11.17) 11.87(12.21)
MDMA
Finally, as can be seen from Table 3.15, there were no significant differences between 
current and abstinent MDMA-users for measures of depression, t(58) = -0.46, p>.05 and 
anxiety, t(58) = -0.64, p>.05. Furthermore, the distribution of depression and anxiety 
scores, in terms of the BAI and BDI clinically relevant categories of severity, were 
comparable for the two groups (see Tables 3.16 and 3.17).
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Table 3.16: Distribution of Depression Scores for Categories of Severity on BDI.
Depression -  BDI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Current
MDMA
25 (80.6) 6(19.4) 31
Abstinent
MDMA
24 (80.0) 6 (20.0) 30
Total 49 (80.3) 12(19.7)
Table 3.17: Distribution of Anxiety Scores for Categories of Severity on BAI
Anxiety- BAI Categories
Minimal to Mild (%) Moderate to Severe (%) Total
Current
MDMA
22 (71.0) 9 (29.0) 31
Abstinent
MDMA
21 (70.0) 9 (30.0) 30
Total 43 (70.5) 18(29.5)
3.2.5 Patterns of MDMA Use in Current and Abstinent MDMA-Users
A comprehensive analysis of past and current recreational MDMA use was conducted 
for the abstinent users and current users respectively. As outlined in the previous study, 
the estimated total lifetime dose of MDMA, the highest frequency of MDMA use in one 
month and the highest number of pills swallowed at the same time were examined on 
the basis of the animal literature, which suggests these characteristics of MDMA 
consumption mediate the neurotoxic process (Steele et al, 1994). The results of these 
analyses are presented in table 3.18.
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Table 3.18: Patterns of MDMA Use in Current (n = 31) and Abstinent MDMA-Users 
(n = 30).
Minimum Maximum Median Mean (SD)
Estimated Total 
Dose (no. of pills) 
Current 11 680 104 166 (171)
Abstinent 12 7426 104 523 (1363)
Highest frequency 
of Usea
Current 0.5 16 4 5 (4)*
Abstinent 0.5 300 8 20 (54)
Highest Doseb 
Current 0.5 5 1 2 (1)
Abstinent 0.5 12 2 2 (2)
Time Since Last 
Use (days) 
Current 7 168 28 37 (33)***
Abstinent 730 2920 730 977 (468)
Duration of Use 
(months)
Current 5 156 36 50 (36)
Abstinent 2 120 42 43 (32)
Age of first Use 
(years)
Current 14 30 19 20 (4)
Abstinent 13 35 18 19 (5)
Polydrug Usec 
Current 0 184 15 44 (60)
Abstinent 0 3713 6 251 (736)
*p<.05, ***p<.001
aHighest number of occasions of MDMA use in one month.
bHighest number o f MDMA pills swallowed at one time.
dum ber of occasions cocaine and/or amphetamine were taken concurrently.
It can be seen from Table 3.18 that the two cohorts of MDMA-users had comparable
patterns of MDMA use in terms of estimated total exposure to MDMA, t(59) = -2.20,
p>.05 and highest dose, t(59) = -1.58, p>.05. However, the abstinent cohort had
previously used MDMA with a greater degree of regularity than current users, Mann-
Whitney U-test, z = -2.05, p<.05. As was expected, there was a significant difference
between the two groups for the length of time since last use of MDMA, t(59) = -10.97,
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£<.001, however, the duration of use for the two groups was comparable, t(59) = -0.70, 
p>.05. Finally, the number of occasions of concurrent use of amphetamine and / or 
cocaine with MDMA was not significantly different for the two groups, t(59) = -1.54, 
p>.05.
It is also apparent from Table 3.18 that the cohort of abstinent MDMA-users manifested 
a diverse range of past MDMA use. The estimated extent of total exposure for the 
cohort was highly variable and ranged from 12 to 7426 pills consumed in a lifetime, (M 
= 523). The frequency of use ranged from less than one occasion of use per month, to 
300 occasions in one month, which represented a high level of consumption on a daily 
basis. The mean for the highest frequency of use was 20 occasions per month, which is 
five occasions of use per week. The number of pills swallowed at the one time ranged 
from a half to 12 pills (M = 2). It is also evident from Table 3.18 that the period of 
abstinence within the cohort ranged from 2 to 8 years, (M = 3), and the duration of 
MDMA use ranged from 2 months to 10 years, with a mean duration of approximately 4 
years of use. Finally, the mean age of first use of 19 in the abstinent cohort (range 13 to 
35), was similar to the current users (M = 20), t(59) = 0.85, p>.05.
The possibility of a dose-response relationship between memory functioning and past 
MDMA exposure was examined for abstinent MDMA-users by constructing an 
exposure variable from the estimated total lifetime dose of MDMA, the highest 
frequency of use in one month and the highest number of pills swallowed at the same 
time. Correlational analyses between this measure of exposure and memory 
performance for each of the WMS-III indexes and subtests revealed no significant 
relationships. Correlational analyses also failed to reveal a significant relationship
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between memory performance on any of the WMS-III indexes or subtests and polydrug
exposure.
3.2.6 Lifetime and Current Patterns of Recreational Drug Use for Abstinent and 
Current MDMA-Users
Differences between current and abstinent MDMA-users in terms of lifetime use and 
current use of recreational drugs other than MDMA were examined using chi-squared 
analyses and are presented in Table 3.19.
Table 3.19: Patterns of Other Recreational Drug Use.
Lifetime Use 
(ie. ever used) 
(%)
Current Use
(ie. once a month or
more) (%)
Alcohol
Current MDMA 31 (100.0) 27 (87.1)
Abstinent MDMA 30(100.0) 23 (76.7)
Cannabis
Current MDMA 21 (67.7) 19(61.3)
Abstinent MDMA 26 (86.7) 19(63.3)
Benzodiazapine
Current MDMA 9 (29.0) 2 (6.5)
Abstinent MDMA 14(46.7) 2 (6.7)
Amphetamine
Current MDMA 26 (83.9) 14 (45.2)
Abstinent MDMA 25 (83.3) 6 (20.0)*
Heroin
Current MDMA 2 (6.5) 1 (3.2)
Abstinent MDMA 13 (43.3)** 3 (10.0)
Cocaine
Current MDMA 18(58.1) 6 (19.4)
Abstinent MDMA 20 (66.7) 4(13.3)
LSD
Current MDMA 19(61.3) 6 (19.4)
Abstinent MDMA 28 (93.3)** 2 (6.7)
Inhalants
Current MDMA 8 (25.8) 0(0)
Abstinent MDMA 17 (56.7)* 0(0)
*p< .05, **p<.01
It is evident from Table 3.19 that there were a number of differences between the 
abstinent and current MDMA-users in the lifetime use of recreational drugs. A greater
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proportion of abstinent MDMA-users had a lifetime use of heroin, )[ (1, N = 61) = 
11.18, n<-01, LSD, x2(l, N = 61) = 8.85, e<.01, and inhalants, i 2{\, N = 61) = 6.00, 
p<.05. Despite these differences in lifetime use of other drugs, the two groups were 
well matched in terms of current drug use, with the exception of amphetamine 
consumption. A greater number of current MDMA-users used amphetamine once a 
month or more frequently, x2(l, N = 61) = 4.38, p<.05.
3.2.7 Memory Functioning in Abstinent and Current MDMA-Users
The comparative analyses examining potential differences between current and 
abstinent MDMA-users’ memory performance on the WMS-III indexes and subtests are 
reported in the following section. The final reduced regression models can be found in 
Appendix V in cases where significant differences between the two groups were 
apparent or differences were no longer apparent after controlling for the effects of 
potential confounders.
Memory Indexes
The adjusted and unadjusted comparisons between abstinent and current MDMA-users 
for memory functioning, as measured by the WMS-III memory indexes, are presented 
in Tables 3.20 to 3.22.
• 2
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Table 3.20: WMS-III Memory Index Means and Comparisons for Abstinent (n = 30) 
and Current MDMA-Users (n = 31).
WMS-III 
Memory Index
Mean Unadjusted
Mean
Difference
Adjusted
Mean
Difference
Unadjusted t Adjusted t
Immediate
Memory
Current MDMA 
Abstinent MDMA
100.97
94.63
6.33 3.85 2.08* -1.19
General Memory
(delayed)
Current MDMA 
Abstinent MDMA
101.61
95.07
6.55 4.66 2.63* -1.78
Working Memory
Current MDMA 
Abstinent MDMA
105.81
101.03
4.77 3.87 1.51 -1.23
*p<.05
It is evident from Table 3.20 that abstinent MDMA-users displayed significantly poorer 
immediate and general (delayed) memory than current users, as measured by the WMS- 
III composite indexes, however, these differences were no longer apparent after 
controlling for the effects of intelligence and sex. There was no difference between the 
two MDMA-using cohorts in terms of working memory functioning.
Table 3.21: WMS-III Immediate Memory Index Means and Comparisons for Abstinent 
(n = 30) and Current MDMA-Users (n = 31).
WMS-III 
Memory Index
Mean Unadjusted
Mean
Difference
Adjusted
Mean
Difference
Unadjusted t Adjusted t
Auditory (verbal)
Immediate
Current MDMA 106.97 5.20 1.22 1.62 -0.41
Abstinent MDMA 101.77
Visual Immediate
Current MDMA 94.19 5.53 5.31 1.66 -1.46
Abstinent MDMA 88.67
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The unadjusted and adjusted comparisons presented in Table 3.21 reveal that there were 
no significant differences between current and abstinent MDMA-users’ verbal and 
visual memory functioning, as measured by the respective WMS-III indexes.
Table 3.22: WMS-III Delayed Memory Index Means and Comparisons for Abstinent 
(n= 30) and Current MDMA-Users (n = 31).
W M S-III  
M em ory  Index
M ean U nadjusted
M ean
D ifference
A d justed
M ean
D ifferen ce
U n adju sted  t A djusted t
A u d itory  (verbal) 
D elayed
Current MDMA 
Abstinent MDMA
106.61
100.00
6.61 4.12 2.45* -1.45
V isu a l D elayed  
Current MDMA 
Abstinent MDMA
93.23
87.33
5.89 6.50 1.88 -1.96
A u d itory
R ecogn ition
Current MDMA 
Abstinent MDMA
105.81
100.00
5.81 1.05 1.29 -0.36
*p<.05
Finally, it is evident from Table 3.22 that abstinent MDMA-users displayed
significantly poorer delayed memory functioning than current users in the verbal 
modality. However, after controlling for the effects of intelligence and sex, these group 
differences were no longer apparent. There were no differences between the two 
MDMA-using cohorts in delayed memory functioning in the visual modality, or cued 
recall performance, as measured by the WMS-III verbal recognition index.
Verbal Memory Subtests
The adjusted and unadjusted analyses comparing performances of abstinent and current 
MDMA-users on the verbal memory subtests of the WMS-III are presented in this 
section. Comparisons between abstinent and current MDMA-users for the total logical 
memory subtest performances and individual story performances, in the immediate (I) 
and delayed (II) conditions, are presented in Table 3.23. Abstinent and current MDMA-
134
users’ performances were then compared for the total Verbal Paired Associates (VPA) 
subtest and four recall trials (a -  d), in addition to recall performance after the delay of 
25 to 35 minutes (VPA II). The results of these analyses are presented in Table 3.24. 
As was the case in previous comparative analyses, the VPA recognition subtest was not 
reported because all participants obtained a perfect score.
Table 3.23: WMS-III Logical Memory Subtest Means and Comparisons for Current 
(n = 31) and Abstinent MDMA-Users (n = 30).
Subtest M ean Unadjusted
Mean
Adjusted
Mean
Unadjusted t Adjusted t
Difference Difference
Logical
M em ory I Total
Current MDMA 41.61 3.01 1.63 1.39 -0.78
Abstinent MDMA 38.60
Logical 
M em ory I 
Story A  
Current MDMA 13.48 0.45 0.29 0.51 0.33
Abstinent MDMA 13.03
Logical 
M em ory I 
Story B i
Current MDMA 11.32 0.72 0.76 0.93 -0.91
Abstinent MDMA 10.60
Logical 
M em ory I 
Story B ii
Current MDMA 16.81 1.84 1.58 1.94 -1.68
Abstinent MDMA 14.97
Logical
M em ory II Total
Current MDMA 26.26 3.49 2.50 2.13* -1.48
Abstinent MDMA 22.77
Logical 
M em ory II 
Story A 
Current MDMA 11.07 0.12 0.82 1.64 -0.74
Abstinent MDMA 9.33
Logical 
M em ory II 
Story B
Current MDMA 15.19 1.76 1.29 2.08* -1.56
Abstinent MDMA 13.43
Logical
M em ory Recognition
Current MDMA 26.71
Abstinent MDMA 26.20 0.51 0.25 0.95 -0.49
*p<.05
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The analyses presented in Table 3.23 reveal that abstinent MDMA-users recalled 
significantly less information than controls on the total logical memory II subtest, a 
measure of delayed contextual verbal memory. However this group difference did not 
remain after controlling for the effects of sex. A similar pattern was evident in the case 
of delayed recall for Story B. The unadjusted analyses indicate that the abstinent 
MDMA-users recalled significantly less information from Story B than current users 
after the delay, however, the two groups’ performance on this subtest was comparable 
after controlling for the effects of age and intelligence. The unadjusted and adjusted 
analyses presented in Table 3.23 indicate that there were no differences between the two 
MDMA-using cohorts for performance on the remaining logical memory subtests. 
Further analysis of the recognition task for Story A and B revealed no significant 
differences in cued recall from Story A for current users (M = 12.48, SD = 1.69) and 
abstinent users (M = 12.40, SD = 1.73), t(59) = 0.19, p>.05. Similarly, current users’ 
cued recall performance on Story B (M = 14.23, SD = 0.88) was comparable to 
abstinent users (M = 13.83, SD = 1.23), t(59) = 1.43, p>.05). Regression analyses 
revealed that the two groups’ recognition performances remained comparable after 
controlling for the effects of potential confounders.
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Table 3.24: WMS-III Verbal Paired Associates (VPA) Subtest Means and Comparisons 
for Abstinent (n = 30) and Current (n = 31) MDMA-Users.
S u b te s t M e a n U n a d ju s te d A d ju s te d U n a d ju s te d  t A d ju s te d  t
M e a n M e a n
D iffe r e n c e D if fe r e n c e
V P A I  T o ta l
Current MDMA 2 5 .5 5 2 .05 0 .3 3 1.13 0 .2 0
Abstinent MDMA
V P A  I 
L is t  a
2 3 .5 0
Current MDMA 4 .2 3 0 .0 9 0 .73 0 .1 4 1.18
Abstinent MDMA
V P A  I 
L is t  b
4 .1 3
Current MDMA 6 .5 2 0 .78 0 .0 5 1.35 -0 .0 9
Abstinent MDMA
V P A  I 
L is t  c
5 .73
Current MDMA 7 .2 6 0 .7 9 0 .2 8 1.35 -0 .6 4
Abstinent MDMA
V P A  I 
L is t  d
6 .4 7
Current MDMA 7 .55 0 .38 0 .0 7 1 .17 -0 .2 2
Abstinent MDMA
V P A  II
7 .1 7
Current MDMA 7 .3 6 0 .55 0 .1 6 1.33 -0 .3 7
Abstinent MDMA 6 .8 0
It evident from Table 3.24 that there were no significant differences between the two 
MDMA-using cohorts’ performances on the VP A subtest, a measure of immediate 
verbal memory and learning. The pattern of results recorded over the four trials of this 
subtest for current and abstinent MDMA-users in comparison to controls is represented 
in Figure 3.1.
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# — Current MDMA-TJsers
Abstinent MDMA-Lsers
List 'ä' List V  lis t 'c' l is t  ’cf Delay
VPA Trial
Figure 3.1: Verbal Paired Associates Learning Curve
It is apparent from Figure 3.1 that a similar pattern o f learning was evident for the two 
MDMA cohorts. Performance on the first recall o f the word pairs for the two groups is 
almost identical and is similarly impaired when compared to controls. Thus problems 
in single trial learning were apparent in both cohorts, when compared to controls. This 
difference did not reach statistical significance for abstinent users, however, a trend was 
evident (p=.06). Recall performance on the second presentation o f  the word pairs then 
recovered for MDMA-users and remained comparable to controls over subsequent 
trials.
Visual Memory Subtests
The performance o f controls and abstinent M DMA-users on the immediate (I) and 
delayed (II) conditions o f  the Faces subtest, a measure o f  cued visual recall, and the 
Family Pictures subtest, a measure o f memory for contextual visual material, are 
compared in this section. Both the unadjusted and adjusted comparisons between
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current and abstinent MDMA-users’ performances on these visual memory subtests are 
presented in Table 3.25.
Table 3.25: WMS-III Faces and Family Pictures Subtest Means and Comparisons for 
Abstinent MDMA-Users (n = 30) and Controls (n = 30).
S u b te s t M e a n U n a d ju s te d
M ea n
D iffe r e n c e
A d ju s te d
M e a n
D if fe r e n c e
U n a d ju s te d  t A d ju s te d  t
F a c e s  I
Current MDMA 
Abstinent MDMA
37.23
36.67
0.56 0.53
F a c e s  II
Current MDMA 
Abstinent MDMA
36.68
36.10
0.58 0.53
F a m ily  P ic tu r e s  I
Current MDMA 
Abstinent MDMA
45.19
39.33
5.86 5.50 2.47* -2.39*
F a m ily  P ic tu r e s  11
Current MDMA 
Abstinent MDMA
45.03
38.67
6.37 5.55 2.62* -2.27*
*p<.05
Note: Adjusted mean difference and t-value not reported for Faces I and II because 
regression model not significant.
It can be seen in Table 3.25 that abstinent MDMA-users recalled significantly less 
information than current users from the family pictures in both the immediate and 
delayed conditions. These group differences remained after controlling for the effects 
of potential confounders. Significant covariates included age, in the case of the 
immediate condition, and intelligence, sex and age, in the case of the delayed condition. 
There were no significant differences between the two MDMA-using cohorts in the 
number of faces recalled in the immediate (I) and delayed (II) condition.
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Attention and Working Memory Subtests
Comparisons between abstinent and current MDMA-users performance on the WMS-III 
attention and working memory subtests are presented in Table 3.26.
Table 3.26: WMS-III Letter-Number Sequencing, Spatial Span and Digit Span Subtest Means 
and Unadjusted t values for Current (n = 31) and Abstinent MDMA-Users (n = 30).
Subtest M ean U nadjusted
M ean
A djusted
M ean
U nadjusted  t A djusted t
D ifference D ifference
L etter N um ber  
Sequencing
Current MDMA 12.29 1.19 0.74 2.19* -1.45
Abstinent MDMA 11.10
Spatial Span Total
Current MDMA 17.52 0.52 0.23 0.61 -0.29
Abstinent MDMA 17.00
Spatial Span  
Forw ard
Current MDMA 8.77 0.14 0.25
Abstinent MDMA 8.63
Spatial Span  
B ackw ard
Current MDMA 8.74 0.38 0.95
Abstinent MDMA 8.37
D igit Span  
Total
Current MDMA 18.97 2.10 1.76 2.01* -1.67
Abstinent MDMA 16.87
D igit Span  
Forw ard
Current MDMA 11.07 0.43 0.46 0.75 -0.80
Abstinent MDMA 10.63
D igit Span  
B ackw ard
Current MDMA 7.90 1.57 1.23 2.56* -1.76
Abstinent MDMA 6.33
*p<.05
Note: adjusted analyses for Spatial Span forwards and backwards not reported because 
regression models not significant
It can be seen in Table 3.26 that abstinent MDMA-users performed significantly worse 
than controls on the letter-number sequencing subtest, a measure of working memory. 
However, this group difference did not endure after controlling for the effects of age 
and intelligence. There were no significant differences between abstinent MDMA-users
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and controls’ performances on the spatial span subtests. Abstinent MDMA-users’ 
performance on the total digit span subtest, a measure of attention and working 
memory, was significantly poorer than controls, however this difference was no longer 
apparent after adjusting for the effects of intelligence. No significant differences in 
performance on the digit span forwards task were apparent and the differences between 
current and abstinent users on the digits backward task was no longer significant after 
controlling for the effects of intelligence and lifetime use of heroin.
3.3 DISCUSSION
The study presented in this chapter set out to determine whether memory impairment in 
recreational MDMA-users endured after two years of abstinence from the drug. Several 
conclusions can be drawn from the comparative analyses between controls and abstinent 
MDMA-users presented in the previous section. First, it is evident that after two years 
of abstinence from MDMA, dysfunction in memory and cognitive functioning endures. 
Abstinent MDMA-users manifested dysfunction in immediate, delayed and working 
memory. Furthermore, comparative deficits were evident in both the verbal and visual 
modalities. Second, when compared to the previous study, it was evident that the cohort 
of abstinent MDMA-users demonstrated impairment in a wider range of memory and 
cognitive functioning, when compared to controls, than current users. Third, the cohort 
of abstinent MDMA-users manifested significantly poorer performances than the cohort 
of current MDMA-users, on a measure of visual memory for meaningful contextual 
material. The inconsistencies between the pattern of impairment evident in abstinent 
and current MDMA-users when compared to controls may be due to differences 
between the two cohorts’ frequency of MDMA-use, a factor believed to mediate the 
neurotoxic process. Finally, similar patterns of dysfunction consistent with encoding
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problems were evident in abstinent MDMA-users, however, indications of concurrent 
retrieval problems in this cohort cannot be ruled out.
A discussion of the comparative analyses between abstinent MDMA-users and controls 
and the two cohorts of MDMA-users is presented below. Firstly, comparative analyses 
between abstinent MDMA-users and controls on the WMS-III memory indexes will be 
discussed to address the question of whether past MDMA-users continue to manifest 
memory impairment after two years of abstinence from MDMA. The findings of the 
present study will then be discussed in comparison to the study presented in the 
previous chapter. Secondly, the comparative analyses between the two cohorts of 
MDMA-users will be discussed. Finally, the pattern of impairment evident in the 
abstinent cohort will be examined through the clinical examination of performance on 
the WMS-III subtests.
3.3.1 Enduring Memory Dysfunction in MDMA-Users After Two Years of 
Abstinence
Immediate, delayed and working memory functioning in abstinent MDMA-users was 
examined through comparative analyses of the WMS-III composite memory indexes for 
abstinent MDMA-users and controls, while controlling for the potentially confounding 
effects of sex, age, intelligence, depression, anxiety and other drug use. It was apparent 
that abstinent MDMA-users manifested dysfunction in immediate and delayed memory 
when compared to controls and these comparative deficits in memory functioning were 
evident in both the verbal and visual modality. Furthermore, abstinent MDMA-users 
demonstrated comparative deficits in working memory functioning. As outlined in the 
previous chapter, cued memory functioning was examined through the independent 
analysis of the story recognition subtest, rather than the auditory recognition index, and
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is discussed in a later section. The recognition index is comprised of recognition 
performance on both the story subtest and the word pairs subtest, which was deemed 
invalid because every subject obtained a perfect score on this measure.
It can be concluded from the comparative analyses of the WMS-III memory indexes 
that recreational MDMA-users, who had been abstinent from the drug for two years, 
manifested dysfunction in immediate, delayed and working memory functioning. The 
differences in memory functioning between controls and abstinent MDMA users 
persisted after adjusting for the effects of intelligence, sex, age, anxiety, depression, and 
other drug use, suggesting that enduring cognitive dysfunction is a consequence of 
recreational MDMA-use. The results of the present study suggest that MDMA-induced 
cognitive dysfunction continues to be manifested two years after discontinuation of use. 
The cognitive dysfunction observed in the cohort of two-year abstinent users is largely 
consistent with the dysfunction observed in the current users participating in the study 
reported in the previous chapter and other studies of current users, providing support for 
the validity of the findings of the present study (Gouzoulis-Mayffank et al., 2000; 
Morgan, 1999). Further studies of cognitive functioning in other cohorts of abstinent 
MDMA-users are needed to confirm these results and the question of whether some 
recovery in cognitive functioning occurs, as suggested by the observation of axonal 
regeneration in animal studies, needs to be addressed by long term studies of abstinent 
cohorts.
It is evident from the pattern of impairment observed in the present study that the cohort 
of abstinent MDMA-users manifested impairment in a more diverse range of cognitive 
functioning when compared to controls than was evident in the cohort of current users 
in the previous study. Abstinent MDMA-users demonstrated impairment in working
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memory and delayed verbal memory when compared to controls, whereas the current 
users examined in the previous study displayed intact functioning on these measures. 
Furthermore, the differing patterns of cognitive dysfunction were apparent after 
controlling for factors that may potentially explain the difference between the two 
MDMA-using cohorts’ cognitive performance, such as intelligence, sex, age, 
depression, anxiety and other drug use. The two MDMA-using cohorts were 
comparable in terms of total exposure to MDMA and highest dose of MDMA. 
However, a significant difference between the two cohorts’ frequency of MDMA use 
was apparent. On average, abstinent MDMA-users’ frequency of use was four times 
greater than current users. Moreover, the cohort of abstinent users’ average frequency 
of MDMA use was five times per week, which constituted heavy consumption in 
comparison to studies of other Australian cohorts in the literature, which indicate the 
average frequency of use in MDMA-users is approximately once every 10 days (Topp 
et al., 1999). It is therefore hypothesised that the more diverse dysfunction evident in 
the abstinent MDMA-users may be due to their higher frequency of MDMA use, which 
could potentially have resulted in greater neurotoxicity. The absence of a dose-response 
relationship in the present study may be considered contradictory to this hypothesis, 
however, the possibility of a threshold effect for MDMA-induced neurotoxicity 
suggests that a dose-response relationship may not be observed in such a high use 
group.
Despite the differences in the pattem of impairment evident for the two groups when 
compared to controls, comparative analyses of the two MDMA-using cohorts revealed 
that the two groups’ cognitive functioning was comparable on all memory indexes and 
subtests apart from the family pictures subtest, a measure of visual memory for 
contextual information. Impaired performance on this isolated test is not sufficient to
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imply dysfunction, particularly in the absence of impairment in the remaining subtests 
and indexes.
In summary, the comparative analyses of memory functioning in abstinent MDMA- 
users and controls suggest that cognitive dysfunction is an enduring consequence of 
MDMA use. Additionally, the high frequency of use observed in the present study’s 
cohort of abstinent MDMA-users may explain the more diverse manifestation of 
cognitive impairment observed in this cohort, when compared to the pattem of 
impairment observed in current users in the previous chapter. Finally, despite 
differences in the diversity of impairment in the two cohorts when compared to 
controls, memory performance was largely comparable for abstinent and current 
MDMA-users. The following section will examine the nature of the memory 
dysfunction evident in abstinent MDMA-users through a clinical examination of the 
WMS-III subtest performances.
3.3.2 The Nature of Memory Impairment in Two Year Abstinent MDMA-Users
As outlined in the previous chapter, memory dysfunction may potentially arise from 
defective encoding, storage deficits and retrieval problems (Lezak, 1995). A clinical 
examination of the comparative performances on the individual WMS-III subtests was 
conducted to determine whether the memory dysfunction evident in abstinent MDMA- 
users occurred as a result of defective encoding, retrieval or storage. Total subtest 
performances were not interpreted because they were considered to provide a 
nonspecific indication of dysfunction. The investigation of the nature of memory 
dysfunction revealed that abstinent MDMA-users manifested a pattern of impairment, 
across several subtests, that was consistent with encoding problems. In support of this 
hypothesis, comparable rates of decay in controls and abstinent users rule out rapid
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forgetting as a possible explanation for memory dysfunction in the abstinent cohort. 
The pattern of impairment was inconsistent with retrieval problems, however, further 
studies need to be conducted before concurrent retrieval problems are definitively ruled 
out. Thus it was observed that indications of inefficient encoding processes, evident in 
the current users in the previous study, were also apparent in two-year abstinent users.
As was the case for the current users in the previous study, abstinent MDMA-users 
manifested comparative deficits in single trial learning. A definite trend was evident on 
the first trial of the Verbal Paired Associates (VPA) subtest, but recall performances 
over the remaining trials were comparable. Abstinent MDMA-users recalled fewer 
word pairs than controls from List £a’, however, this difference did not reach statistical 
significance after controlling for the effects of potential confounders. The trend 
observed suggests that the failure to reach statistical significance may be due to the 
small sample size. A plausible explanation for the dysfunction in single trial learning, 
suggested by abstinent MDMA-users’ performance on the VPA subtest, is that abstinent 
MDMA-users do not encode information as efficiently as non-users and therefore 
require greater exposure to the stimuli before effective retrieval is possible. Recall 
performance was comparable after the delay, indicating that after repeat exposure, the 
information was encoded, retained in the memory store and effectively retrieved. On 
the more complex Logical Memory subtest, abstinent MDMA-users were similarly 
impaired after a single exposure to both Story A and B, and they failed to recover to 
recall performances comparable to controls after the second presentation of Story B. An 
examination of the mean differences revealed that abstinent MDMA-users improved 
their recall performance at a similar rate to controls after the second presentation of 
Story B, but remained comparatively impaired. Thus, unlike their performance on the 
less complex word pairs subtest, abstinent MDMA-users failed to recover to levels
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comparable to controls after repeat exposure. This pattern of impairment is consistent 
with problematic encoding processes.
The encoding dysfunction hypothesis is consistent with the observation that abstinent 
MDMA-user’s recall performance remained impaired after the delay for both Story A 
and B. Comparable rates of memory decay for both abstinent users and controls, from 
the immediate to the delayed condition, ruled out rapid forgetting as an alternative 
explanation for the observed memory dysfunction. Indications of encoding dysfunction 
were further verified through the examination of the recognition subtest for Story B. 
Abstinent MDMA-users recognised significantly less information from Story B than 
controls, suggesting that encoding, rather than retrieval problems were responsible for 
the comparative deficits observed in recall performance on this subtest. No significant 
difference between abstinent MDMA-users and controls’ recognition performance for 
Story A was observed, which is consistent with the pattern of recognition performance 
reported in the previous study. As was outlined in the previous study, the significant 
difference observed between the two groups’ recognition for Story B, but not Story A, 
can be attributed to the complexity of Story B when compared to Story A. It is 
suggested that the simplicity of the recognition task for Story A prevented 
differentiation between the two groups’ performance. However, further studies need to 
be carried out to definitively rule out retrieval problems.
An examination of the visual memory subtests indicated that abstinent MDMA-users 
demonstrated impairment in their memory for faces and contextual meaningful visual 
material, when compared to controls. These observations of visual memory dysfunction 
are consistent with the evidence for visual memory problems in current MDMA-users 
(Gouzoulis-Mayffank et al., 2000).
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Examination of the WMS-III indexes for the two groups indicated that abstinent 
MDMA-users manifested dysfunction in working memory when compared to controls. 
The nature of working memory dysfunction was assessed through the clinical 
examination of the WMS-III subtests. The concept of working memory refers to the 
cognitive task of holding, manipulating and transforming cognitive material before 
generating a response. The WMS-III digits span backwards, letter-number sequencing 
and spatial span backwards subtests require the manipulation and transformation of 
letters and numbers in the memory and were therefore used in the present study to 
determine the nature of working memory functioning. Digits span forwards and spatial 
span forwards do not involve the same degree of manipulation of cognitive material in 
memory and thus were considered measures of simple attentional functioning. It was 
revealed that working memory dysfunction was only apparent in the auditory-verbal 
modality (digits span backwards and letter-number sequencing). Visual working 
memory, as assessed by the spatial span backwards subtest was intact. Furthermore, 
abstinent MDMA-users performances on measures of simple attention were comparable 
to controls (digits span forwards and spatial span forwards). The pattern of impairment 
evident in abstinent MDMA-users on the working memory and attention subtests is 
consistent with other studies of current users. Gouzoulis-Mayfrank et al. (2000) 
demonstrated that current MDMA-users manifested dysfunction on complex tasks 
requiring higher order attention and concentration skills, however, they displayed intact 
functioning on attentional tasks requiring a lesser degree of mental manipulation. The 
present study of abstinent users replicates the Gouzoulis-Mayfrank et al. study findings 
for current users on the digits span subtest. While performance on the digits span 
forwards was comparable for current users and controls subtest in the Gouzoulis- 
Mayfrank et al. study, performance on the more complex digit span backwards was
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impaired. The similarity between this study of current users and the present study’s 
findings in abstinent users suggests that the impairment evident in MDMA-users for 
working memory may endure after two years of abstinence from the drug. Further 
studies of long-term working memory dysfunction need to be conducted in abstinent 
MDMA-users to replicate these findings.
In summary, it is apparent that MDMA-induced immediate, delayed and working 
memory dysfunction is evident after two years of abstinence from the drug. The pattern 
of impairment is largely consistent with studies of current users and appears to result 
from problematic encoding processes, which are more readily apparent on tasks of 
greater complexity. Further long-term research of abstinent MDMA-users needs to be 
conducted to determine if axonal regeneration observed in animal studies, also occurs in 
humans, and if cognitive recovery is therefore possible. The sampling problems 
highlighted in the previous chapter were again evident in the present study’s 
comparison between the two cohorts of current and abstinent users, which demonstrated 
that abstinent users had used MDMA with a greater degree of regularity. The effects of 
differing patterns of use on cognitive functioning in MDMA-users needs to be 
examined to determine if particular patterns of use place recreational users at a greater 
risk for cognitive dysfunction. The present investigation of abstinent users suggests that 
a higher frequency of administration may be a risk factor in the manifestation of long­
term cognitive dysfunction.
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CHAPTER 4
The review of the literature in Chapter 1 presents several lines of evidence which 
converge to support a causal relationship between recreational MDMA-use and 
memory and cognitive dysfunction. Animal studies have demonstrated that MDMA 
is a selective neurotoxin to serotonergic pathways in the brains of non-human 
primates, and this damage occurs when administered orally and in dose regimens 
comparable to human recreational use of the drug. The hippocampus and neocortex 
have been identified as particularly sensitive to MDMA’s neurotoxic effects, as a 
result of their dense innervation by serotonergic neurons, and these brain regions are 
thought to be involved in memory and cognitive functioning. Neuroimaging, 
neuroendocrine and CSF serotonin metabolite studies have suggested similar patterns 
of neurotoxicity occur in recreational users (Steele et al., 2000; Boot et al., 2000). 
The study of long-term effects of MDMA in non-human primates has demonstrated 
that neurotoxicity is enduring in some brain regions, including the hippocampus and 
neocortex (Hatzidimitriou et al., 1999). Consistent with these findings is the study of 
neuroendocrine functioning in human recreational users, which has yielded 
indications of impairment in the serotonin system of users 12 months after 
discontinuation of use (Gerra et al., 2000). These collective findings indicate that 
MDMA-users risk inflicting enduring damage on brain serotonin pathways through 
their recreational use of the drug.
The study of the implications of MDMA-induced neurotoxicity has revealed that 
memory dysfunction and cognitive impairment are associated with recreational 
MDMA-use. As reviewed in Chapter 1, dysfunction in immediate, delayed and
working memory and attentional capacity have been identified as characteristics of 
recreational MDMA-users when compared to non-users (Gouzoulis-Mayfrank et al., 
2000; Morgan, 1999). These findings are consistent with what is known of the 
function of the hippocampus and neocortex in memory and cognition and the probable 
impact of damage to these brain regions (Lezak, 1995). The study reported in Chapter 
2 confirmed that MDMA-users continued to manifest memory dysfunction when 
compared to non-users, after controlling for the effects of potential confounders. 
Thus the memory impairment evident in the MDMA-users could not be attributed to 
differences in age, sex, intelligence, depression, anxiety and other recreational drug 
use. When taken with the current literature, this finding suggests that MDMA-users 
are at risk of incurring cognitive deficits through their recreational use of the drug.
The study of cognitive and memory dysfunction in MDMA-users to date has failed to 
present a revealing clinical picture of the nature of memory impairment. Therefore, 
the study reported in Chapter 2 set out to determine whether memory impairment in 
MDMA-users occurred as a result of encoding, storage or retrieval problems, while 
adequately controlling for confounding factors which may potentially influence 
memory functioning. This study revealed a pattern of memory impairment in 
MDMA-users that was consistent with encoding difficulties. The enduring nature of 
this memory dysfunction was revealed by the study presented in Chapter 3. The 
observation of enduring neurotoxicity in non-human primates in some brain regions, 
in addition to indications of reinnervation in other areas (Hatzidimitriou et al., 1999), 
raised the question of whether the cognitive impairment evident in current MDMA- 
users persisted after discontinuation of use. The study of the long-term consequences
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of MDMA-use revealed that dysfunction in immediate, delayed and working memory 
endured after two years of abstinence from the drug.
In summary, the examination of memory functioning in MDMA-users in the studies 
presented in Chapters 2 and 3 has revealed that, when compared to non-users, 
MDMA-users manifest memory dysfunction, which cannot be attributed to other 
factors which influence memory functioning, such as age, sex, intelligence, anxiety, 
depression and other drug use, and the nature of this memory dysfunction is consistent 
with encoding difficulties. Moreover, memory dysfunction endures after two years of 
abstinence from MDMA.
These findings posit the question of whether the memory dysfunction evident in 
MDMA-users represents a clinically significant impairment with implications for 
everyday functioning. The examination of the WMS-III index scores, in comparison 
to normative data, revealed that on average, MDMA-users continued to function 
within the “average range” for memory performance when compared to their peers in 
the normal population, suggesting that their memory dysfunction has limited clinical 
significance. However, examination of index scores for individual cases suggested 
that a proportion of MDMA-users are functioning within the WMS-III “borderline 
range” and below, for memory performance. These clinical categories represent 
scores which lie two standard deviations below the mean for the normal population. 
In these cases, memory dysfunction may represent a significant clinical impairment, 
with potential implications for everyday functioning. This investigation was beyond 
the scope of the present studies, however, the pattern of results suggests that future 
studies are needed to determine what differentiates those individuals manifesting
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more severe cognitive impairment from other recreational users. It is likely that larger 
sample sizes than those employed in the studies to date, will be needed to identify 
enough individuals to answer this question (Hall et al., 2000).
The comparison between the pattern of impairment evident in the two cohorts of 
MDMA-users studied in Chapters 2 and 3 revealed that frequent dose regimens may 
place recreational users at risk for more pervasive cognitive impairment. The 
abstinent cohort manifested a more pervasive pattern of memory impairment than the 
current using cohort, which could not be attributed to differences between the two 
cohorts in sex, age, intelligence, anxiety, depression or other drug use. The abstinent 
cohort did, however, use MDMA with greater frequency than current users, and in 
comparison to other Australian cohorts represented a very high frequency of use 
sample. It was cautiously concluded that the high frequency of MDMA use amongst 
this cohort may have contributed to their more pervasive pattern of cognitive 
impairment. This hypothesis is consistent with what is known of the neurotoxic 
process from animal studies, which suggest that higher frequency of administration 
results in greater neurotoxicity. These findings suggest that an important area for 
future research is the investigation of characteristics of recreational use, in 
conjunction with individual vulnerabilities, that place users at greater risk for 
cognitive impairment. It is proposed that recreational users who inject MDMA are 
also at a particularly high risk for neurotoxicity and cognitive impairment, as a result 
of being exposed to higher blood concentrations of the drug. In their survey of 
recreational patterns of use amongst MDMA-users in Sydney, Topp et al. (1999) 
reported that 16% of their sample had injected ‘Ecstasy’. Future research of injecting
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MDMA-users is needed to determine whether injecting MDMA-users represent a 
high-risk sample for cognitive impairment.
Criticisms regarding the conceptualisation of a linear dose-response relationship 
between MDMA-use and memory dysfunction have been raised in Chapter 2, 
suggesting the impact of differing dose regimens needs to be examined in greater 
detail to determine high risk patterns of use. The animal literature has indicated that 
total exposure, highest blood concentrations and frequency of administration each 
mediate the neurotoxic process (Steele et al., 1994). The present studies’ attempts to 
establish a dose-response relationship while acknowledging these three factors 
yielded inconsistent results. These inconsistencies may be due to measurement 
limitations, the possibility of a threshold effect for MDMA-exposure and/or the 
numerous individual differences that influence cognitive functioning. Nevertheless, 
more sensitive measurement of these dose-response factors is needed to provide 
recreational users with information regarding harm minimisation practices. At 
present, harm minimisation for MDMA use appears to concentrate on the acute 
physiological and toxic effects of the drug (White et al., 1996). The results of the 
present studies indicate that recreational users also need to be informed of the short 
and long-term cognitive consequences of MDMA.
Several areas have been highlighted as appropriate starting points for future research. 
First, replication of encoding difficulties in MDMA-users are needed to confirm the 
hypothesis that memory dysfunction in MDMA-users occurs as a result of problems 
with encoding processes. Further studies examining the nature of memory 
impairment are required before concurrent retrieval dysfunction is ruled out as
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contributing to the pattern of memory impairment in MDMA-users. Second, 
replication of memory dysfunction in other two year abstinent cohorts is needed to 
confirm that memory dysfunction in MDMA-users is enduring. Furthermore, the 
examination of memory functioning in users after longer periods of abstinence will 
determine whether memory disturbance continues. Third, long-term studies of 
MDMA-using cohorts are needed to examine whether recovery in cognitive 
functioning occurs over time, as suggested by the observation of reinnervation of the 
serotonergic system in non-human primates. The two-year abstinent cohort studied in 
the present study may potentially have recovered cognitive functioning relative to 
their memory performance while they were actively using MDMA. Alternatively, 
cognitive functioning may decline in MDMA-users over time. Damage to the 
serotonergic system may have implications for cognitive functioning in later life and 
the prospective study of recreational users as they age would determine whether these 
individuals were more adversely affected by the aging process than non-users. The 
study of neurodegenerative disorders which involve dysfunction in the serotonergic 
system, such as dementia, suggest that memory deficits are a feature of these 
conditions. Recreational MDMA-users may potentially be more adversely affected 
by memory dysfunction in old age.
In summary, the results of the studies reported in Chapters 2 and 3 indicate that 
recreational MDMA-users are at risk of incurring memory dysfunction, which may 
result from defective encoding processes, and that this pattern of memory impairment 
is enduring. Future studies of cognitive functioning in MDMA-users are needed to 
clarify high-risk patterns of use and the long-term consequences of recreational 
MDMA-use, to ensure that harm minimisation strategies regarding the use of MDMA
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can be developed and recreational users are made aware of the long-term cognitive 
risks involved in the use of the drug.
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APPENDIX I: CONSENT FORM GIVEN TO PARTICIPANTS
THE AUSTRALIAN NATIONAL UNIVERSITY 
SURVEY OF “ECSTASY” USE
CONSENT FORM
You are invited to participate in the Australian National University Survey 
of “Ecstasy” Use. This study examines different characteristics of people 
who use “Ecstasy” . The purpose of the survey is to find out what kind of 
people use “Ecstasy” and to look at different aspects of their functioning 
such as their mood and memory.
If you decide to participate, I will ask you a series of questions about your 
background, your drug use over the last few years, and how you have been 
feeling lately. I’ll also ask you to complete several memory tasks which 
look at your short term memory for numbers, words or shapes.
Any information that is obtained in connection with this study will remain 
confidential. The information disclosed by you will be stored under a 
number, without names, to maintain your anonymity and confidentiality. 
The results of the study will be published in a way thatwill not identify you 
as having taken part. You are able to withdraw from the study at any time 
and you will be given a copy of this form to keep.
The interview will take about one hour.
Signed Date / /
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APPENDIX II:
DEMOGRAPHIC INFORMATION AND MDMA USE QUESTIONNAIRE
THE AUSTRALIAN NATIONAL UNIVERSITY 
SURVEY OF ECSTASY USE
Subject No.
Demographics
Age years Sex M / F
Education_________ yrs
Primary / Year 10 / Year 12 / Tertiary / Postgraduate
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Ecstasy Use
How old were you when you first started using “ecstasy”? years
How long has it been since you last used “ecstasy”? days
DURATION OF USE months
During this period, how often have you used “ecstasy”? times per month.
Can you estimate the total number of times you have used “ecstasy”?
How many “ecstasy” tablets do you usually take on the one occasion?
What is the most ‘ecstasy’ you have taken at the one time?
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Other Drug Use
Do you usually take other drugs with ‘ecstasy’?
Alcohol
Cannabis
Benzodiazapines
Amphetamine (speed)
Opiates (heroin)
Cocaine
Hallucinogens (LSD)
Inhalents
Others
Do you regularly use any other recreational drugs?
Alcohol
Cannabis
Benzodiazapines
Amphetamine (speed)
Opiates (heroin)
Cocaine
Hallucinogens (LSD)
Inhalents
Others
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APPENDIX III:
SIGNIFICANT FINAL MULTIPLE REGRESSION MODELS FROM 
COMPARATIVE ANALYSES BETWEEN MDMA-USERS AND CONTROLS
Each of the final regression models presented in this appendix has been reduced using 
the backward elimination method where variables are removed from the model if they 
are not statistically significant (Kleinbaum et al., 1988). The process began with a full 
model, which included intelligence, sex, age, anxiety, depression, and other drug use. 
This method was employed to maximise the power and precision of the models. If none 
of the potential confounding variables were significant, the unadjusted model is 
presented.
1. Immediate Memory Index
Table 1: Multiple Linear Regression Model Predicting Immediate Memory Index 
While Adjusting For Potential Confounders (N=61).
Variable B SE t ~ Y ~
Group -10.30 2.89 -3.57 .001
IQ 0.44 0.19 2.27 .027
F=11.54, p=.000 
Adjusted R Square=.260
Note: B = unstandardised regression coefficient 
aTwo-tailed
2. General Memory Index
Table 2: Multiple Linear Regression Model Predicting General Memory Index While 
Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -6.60 2.70 -2.45 .018
IQ 0.48 0.18 2.63 .011
Sex -5.47 2.78 -1.97 .054
F=6.66, p=.001 
Adjusted R Square=.221
Note: B = unstandardised regression coefficient 
aTwo-tailed
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3. Auditory Immediate Index
Table 3: Multiple Linear Regression Model Predicting Auditory Immediate Index 
While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -9.73 2.71 -3.60 .001
IQ 0.53 0.18 2.88 .006
Sex -5.30 2.78 -1.90 .062
F=10.28, p=.000 
Adjusted R Square=.317
Note: B = unstandardised regression coefficient 
aTwo-tailed
4. Visual Immediate Index
Table 4: Multiple Linear Regression Model Predicting Visual Immediate Index While 
Adjusting For Potential Confounders (N=61).
Variable B SE t Pa
Group -7.87 3.14 -2.51 .015
F=6.30, p=.015 
Adjusted R Square-.081
Note: B = unstandardised regression coefficient 
aTwo-tailed
5. Visual Delayed Index
Table 5: Multiple Linear Regression Model Predicting Visual Delayed Index While 
Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -6.94 3.30 -2.11 .040
IQ 0.41 0.22 1.87 .067
F=5.20, p=.008 
Adjusted R Square=. 123
Note: B = unstandardised regression coefficient 
aTwo-tailed
6. Auditory Recognition Index
Table 6: Multiple Linear Regression Model Predicting Auditory Recognition Index 
While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -7.67 2.81 -2.73 .008
Sex -6.63 2.93 -2.27 .027
F=6.65, p= 003 
Adjusted R Square=. 159
Note: B = unstandardised regression coefficient 
aTwo-tailed
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7. Logical Memory I Total
Table 7: Multiple Linear Regression Model Predicting Logical Memory I Total 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t PJ
Group -6.98 1.97 -3.55 .001
IQ 0.40 0.13 3.08 .003
Depression 0.27 0.14 1.94 .058
Anxiety -0.28 0.15 -1.79 .079
F=7.96, p=.000 
Adjusted R Square=.321
Note: B = unstandardised regression coefficient 
aTwo-tailed
8. Logical Memory I Story A
Table 8: Multiple Linear Regression Model Predicting Logical Memory I Story A 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group 3.88 6.20 0.63 .000
IQ 0.15 0.06 2.67 .010
Depression 8.39 0.04 1.97 .054
F=T0.11, p=.000 
Adjusted R Square=.317
Note: B = unstandardised regression coefficient 
aTwo-tailed
9. Logical Memory I Story Bi (first presentation)
Table 9: Multiple Linear Regression Model Predicting Logical Memory I Story Bi 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t Pa
Group -2.14 0.81 -2.65 .010
IQ 0.11 0.05 2.09 .041
F=7.45, p=.001 
Adjusted R Square=.177
Note: B = unstandardised regression coefficient 
aTwo-tailed
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10. Logical Memory I Story Bii (second presentation)
Table 10: Multiple Linear Regression Model Predicting Logical Memory I Story Bii 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t Pa
Group -1.71 0.83 -2.08 .042
IQ 0.13 0.06 2.27 .027
F=6.21,p=.004 
Adjusted R Square=. 148
Note: B = unstandardised regression coefficient 
aTwo-tailed
11. Logical Memory II Total
Table 11: Multiple Linear Regression Model Predicting Logical Memory II Total 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t Pa
Group -3.93 1.60 -2.45 .017
IQ 0.31 0.11 2.82 .007
Sex -3.04 1.70 -1.78 .080
Depression 0.28 0.11 2.51 .015
Anxiety -0.32 0.13 -2.55 .014
F=5.19, p=.001 
Adjusted R Square=.262
Note: B = unstandardised regression coefficient 
aTwo-tailed
12. Logical Memory II Story A
Table 12: Multiple Linear Regression Model Predicting Logical Memory II Story A 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -2.48 0.97 -2.57 .013
IQ 0.15 0.07 2.26 .028
Sex -2.25 1.03 -2.19 .033
Depression 0.20 0.07 2.92 .005
Anxiety -0.19 0.08 -2.50 .015
F=5.19, p=.001 
Adjusted R Squares 262
Note: B = unstandardised regression coefficient 
aTwo-tailed
169
13. Logical Memory II Story B
Table 13: Multiple Linear Regression Model Predicting Logical Memory II Story B 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t Pd
Group -1.58 0.92 -1.72 .093
IQ 0.14 0.06 2.23 .029
F=5.17,p=009 
Adjusted R Square=.122
Note: B = unstandardised regression coefficient 
aTwo-tailed
14. Logical Memory Recognition
Table 14: Multiple Linear Regression Model Predicting Logical Memory Recognition 
Performance While Adjusting For Potential Confounders (N=61).
Variable B SE t Pa
Group -0.87 0.49 -1.78 .080
IQb 0.04 0.03 2.25 .215
Sex -1.45 0.50 -2.90 .005
F=4.75, p= 005 
Adjusted R Square=. 158
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
15. Logical Memory Recognition Story B
Table 15: Multiple linear regression model predicting Logical Memory Recognition 
performance for Story B while adjusting for potential confounders (N=61).
Variable B SE t Pa
Group -0.44 0.19 -0.29 .023
F=5.45, p=.023 
Adjusted R Square =.069
Note: B = unstandardised regression coefficient 
aTwo-tailed
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16. Verbal Paired Associates Total (over four trials)
Table 16: Multiple Linear Regression Model Predicting VP A Total Performance While 
Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -3.28 1.28 -2.56 .013
IQ 0.16 0.09 1.84 .071
Age -0.26 0.11 -2.30 .026
Sex -3.44 1.36 -2.53 .014
Anxiety 0.15 0.08 2.01 .050
F=6.50, p=.000 
Adjusted R Square=.318
Note: B = unstandardised regression coefficient 
aTwo-tailed
17. Verbal Paired Associates I List ‘a’ (first presentation)
Table 17: Multiple Linear Regression Model Predicting VP A I List ‘a’ Performance 
While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -2.24 0.56 -4.01 .000
Sex -1.24 0.59 -2.09 .041
Anxiety 8.56 0.03 2.56 .013
F=9.47, p - 000 
Adjusted R Square =.301
Note: B = unstandardised regression coefficient 
aTwo-tailed
18. Verbal Paired Associates I List ‘b’ (second presentation)
Table 18: Multiple Linear Regression Model Predicting VP A I List ‘b’ Performance 
While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -0.65 0.43 -1.51 .137
IQ 0.05 0.03 1.70 .094
Sex -1.07 0.44 -2.41 .019
Age -0.09 0.04 -2.37 .021
F=9.47, p=.000 
Adjusted R Square =.301
Note: B = unstandardised regression coefficient 
aTwo-tailed
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19. Faces I
Table 19: Multiple Linear Regression Model Predicting Faces I Performance While 
Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -2.21 1.02 -2.17 .034
F = 4.72 , p = .034  
A djusted R  Square= 058
Note: B = unstandardised regression coefficient 
aTwo-tailed
20. Family Pictures I
Table 20: Multiple Linear Regression Model Predicting Family Pictures I Performance 
While Adjusting For Potential Confounders (N=61).
Variable B SE t
Group -3.31 1.86 -1.78 .081
IQb 0.18 0.13 1.42 .161
Age -0.37 0.17 -2.27 .027
F = 3.83 , p= .014  
A djusted R Square=.124
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
21. Family Pictures II
Table 21: Multiple Linear Regression Model Predicting Family Pictures II Performance 
While Adjusting For Potential Confounders (N=61).
Variable B SE t p^
Group -3.14 1.80 -1.75 .086
IQ 0.21 0.12 1.69 .096
Age -0.29 0.16 -1.83 .072
F = 3.54 , p=  020  
A djusted R  Square=. 113
Note: B = unstandardised regression coefficient 
aTwo-tailed
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APPENDIX IV:
SIGNIFICANT FINAL MULTIPLE REGRESSION MODELS FOR 
COMPARATIVE ANALYSES BETWEEN CONTROLS AND ABSTINENT
MDMA-USERS
Each of the final regression models presented in this appendix has been reduced using 
the backward elimination method where variables are removed from the model if they 
are not statistically significant (Kleinbaum et ah, 1988). The process began with a full 
model, which included intelligence, sex, age, anxiety, depression, and other drug use. 
This method was employed to maximise the power and precision of the models. If none 
of the potential confounding variables were significant, the unadjusted model is 
presented. The final regression models are also presented for cases where differences 
between the two groups were no longer apparent after controlling for potential 
confounders.
1. Immediate Memory Index
Table 1: Multiple Linear Regression Model Predicting Immediate Memory Index 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -17.44 3.24 -5.38 .000
IQb 0.12 0.17 0.69 .495
F = 18.10, p = .000  
Adjusted R Square=.3 67
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
2. General Memory Index
Table 2: Multiple Linear Regression Model Predicting General Memory Index While 
Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -15.17 2.89 -5.25 .000
F=6.66, p=.001  
Adjusted R Square^.221
Note: B = unstandardised regression coefficient 
aTwo-tailed
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3. Working Memory Index
Table 3: Multiple Linear Regression Model Predicting General Memory Index While 
Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -9.34 4.05 -2.43 .018
IQ 0.40 0.20 1.97 .054
Sexb 5.32 3.84 1.39 .171
F=5.70, p=.002 
Adjusted R Square=.193
Note: B = unstandardised regression coefficient 
aTwo-tailed
bSex retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al, 
1988).
4. Auditor) Immediate Index
Table 4: Multiple Linear Regression Model Predicting Auditory Immediate Index 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -12.68 3.10 -4.09 .000
IQ 0.53 0.18 3.02 .004
Age -0.69 0.24 -2.91 .005
F=16.47, p=.000 
Adjusted R Square=.440
Note: B = unstandardised regression coefficient 
aTwo-tailed
5. Visual Immediate Index
Table 5: Multiple Linear Regression Model Predicting Visual Immediate Index While 
Adjusting For Potential Confounders (N=60).
Variable B SE t p
Group -14.87 3.14 -4.73 .000
Anxiety 0.39 0.15 2.55 .013
F=6.30, p=.015 
Adjusted R Square-.081
Note: B = unstandardised regression coefficient 
aTwo-tailed
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6. Auditory Delayed Index
Table 6: Multiple Linear Regression Model Predicting Auditory Delayed Index While 
Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -10.33 3.15 -3.28 .0 0 2
IQ 0 .2 1 0.17 1.28 .207
F = 8.64 , p= 001 
A djusted R Square=.206
Note: B = unstandardised regression coefficient 
aTwo-tailed
7. Visual Delayed Index
Table 7: Multiple Linear Regression Model Predicting Visual Delayed Index While 
Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -14.30 3.39 -4.22 .000
F = 17.77 , p = .000  
A djusted R Square=.221
Note: B = unstandardised regression coefficient 
aTwo-tailed
8. Auditory Recognition Index
Table 8: Multiple Linear Regression Model Predicting Auditory Recognition Index 
While Adjusting For Potential Confounders (N=60).
Variable B SE t p^
Group -10.50 2.90 -3.63 .001
F = 13.14 , p=.001  
A djusted R Square=.171
Note: B = unstandardised regression coefficient 
aTwo-tailed
9. Logical Memory I Total
Table 9: Multiple Linear Regression Model Predicting Logical Memory I Total 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -7.89 2.03 -3.89 .000
IQ 0.41 0.12 3.52 .001
Age -0.48 0.15 -3.13 .003
F = 17.60 , p = .000  
Adjusted R Square=.458
Note: B = unstandardised regression coefficient 
aTwo-tailed
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10. Logical Memory I Story A
Table 10: Multiple Linear Regression Model Predicting Logical Memory I Story A 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -3.15 0.74 -4.23 .000
IQ 0.12 0.04 3.08 .003
F=20.54, p= .000 
A djusted R  Square=.398
Note: B = unstandardised regression coefficient 
aTwo-tailed
11. Logical Memory I Story Bi (first presentation)
Table 11: Multiple Linear Regression Model Predicting Logical Memory I Story Bi 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t Pd
Group -3.15 0.96 -3.28 .002
IQb 0.06 0.05 1.28 .208
Age -0.16 0.07 -2.33 .023
Sexb 1.46 0.91 1.61 .112
F=6.07, p=.000 
A djusted R  Square=.256
Note: B = unstandardised regression coefficient 
aTwo-tailed
bSex and IQ retained in final model despite probability greater than 0.1 because 
estimates of variables remaining in the model altered substantially when removed 
(Kleinbaum et al., 1988).
12. Logical Memory I Story Bii (second presentation)
Table 12: Multiple Linear Regression Model Predicting Logical Memory I Story Bii 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE T
Group -2.51 0.85 -2.95 .005
Age -0.25 0.07 -3.87 .000
IQ 0.17 0.05 3.60 .001
F=15.51, p=.000 
A djusted R  Square=.425
Note: B = unstandardised regression coefficient 
aTwo-tailed
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13. Logical Memory II Total
Table 13: Multiple Linear Regression Model Predicting Logical Memory II Total 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -7.26 1.82 -3.99 .000
Age -0.30 0.14 -2.18 .034
IQb 0.15 0.10 1.40 .166
F= 10.82, p=.000 
A djusted R  Square=.333
Note: B = unstandardised regression coefficient 
aTwo-tailed
bSex and IQ retained in final model despite probability greater than 0.1 because 
estimates of variables remaining in the model altered substantially when removed 
(Kleinbaum et al., 1988).
14. Logical Memory II Story A
Table 14: Multiple Linear Regression Model Predicting Logical Memory II Story A 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -4.15 1.10 -3.76 .000
Sexb -1.59 1.10 -1.44 .154
F = 1 1.67, p= .000 
A djusted R  Square=.266
Note: B = unstandardised regression coefficient 
aTwo-tailed
bSex retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
15. Logical Memory II Story B
Table 15: Multiple Linear Regression Model Predicting Logical Memory II Story B 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t p^
Group -2.85 1.03 -2.77 .008
Age -0.19 0.08 -2.44 .018
IQ 0.11 0.06 1.87 .067
F=7.90, p=.000 
A djusted R  Square=.260
Note: B = unstandardised regression coefficient 
aTwo-tailed
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16. Logical Memory Recognition
Table 16: Multiple Linear Regression Model Predicting Logical Memory Recognition 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -1.37 0.53 -2.56 .013
Age -0.12 0.04 -2.83 .007
IQb 0.01 0.03 0.33 .746
F = 4 .7 5 , p = .0 05  
A d ju sted  R  S q u are= .158
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et ab, 
1988).
17. Logical Memory Recognition Story B
Table 17: Multiple Linear Regression Model Predicting Logical Memory Recognition 
Story B Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -0.39 0 . 1 2 -3.23 . 0 0 2
Age -0.04 0 . 0 2 -1.92 .060
F = 7 .8 3 , p = .0 0 1  
A d ju sted  R  Square=. 188
Note: B = unstandardised regression coefficient 
aTwo-tailed
18. Verbal Paired Associates Total (over four trials)
Table 18: Multiple Linear Regression Model Predicting VP A Total Performance While 
Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -2.87 1.79 -1.60 .114
Sex -5.46 1.70 -3.22 .002
IQ 0.13 0.09 1.50 .140
F = 8 .3 6 , p = .0 0 0  
A d ju sted  R  S q u are= .272
Note: B = unstandardised regression coefficient 
aTwo-tailed
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19. Verbal Paired Associates I List ‘a’ (first presentation)
Table 19: Multiple Linear Regression Model Predicting VP A I List ‘a’ Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -1.32 0.69 -1.91 .061
Sex -1.84 0.66 -2.81 .007
IQb 0.02 0.03 0.62 .539
F = 7.06 , p = .000  
Adjusted R Square = .236
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
20. Verbal Paired Associates I List ‘b’ (second presentation)
Table 20: Multiple Linear Regression Model Predicting VP A I List ‘b’ Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -0.84 0.55 -1.54 .129
Sex -1.69 0.52 -3.27 .002
IQb 0.04 0.03 1.56 .124
F = 8.42 , p = .000  
Adjusted R Square = .274
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et ah, 
1988).
21. Verbal Paired Associates I List 4c’ (third presentation)
Table 21: Multiple Linear Regression Model Predicting VPA I List ‘c’ Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -0.44 0.43 -1.03 .309
Sex -0.99 0.41 -2.42 .019
IQ 0.06 0.02 2.60 .012
Age -0.08 0.03 -2.52 .015
F = 7.18 , p = .000  
Adjusted R Square = .295
Note: B = unstandardised regression coefficient 
aTwo-tailed
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22. Faces I
Table 22: Multiple Linear Regression Model Predicting Faces I Performance While 
Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -3.11 0.99 -3.15 .003
Anxiety 0.09 0.05 1.91 .061
F=5.88, p= 005 
Adjusted R Square=. 142
Note: B = unstandardised regression coefficient 
aTwo-tailed
23. Faces II
Table 23: Multiple Linear Regression Model Predicting Faces II Performance While 
Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -3.03 1.06 -2.85 .006
F=8.13, p=.006 
Adjusted R Squares 108
Note: B = unstandardised regression coefficient 
aTwo-tailed
24. Family Pictures I
Table 24: Multiple Linear Regression Model Predicting Family Pictures I Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -12.31 2.45 -5.02 .000
IQb -0.20 0.13 -1.53 .131
Anxiety 0.24 0.11 2.14 .037
F=9.33, p=.000 
Adjusted R Square=.298
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
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25. Family Pictures II
Table 25: Multiple Linear Regression Model Predicting Family Pictures II Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t p
Group -10.59 2.62 -4.04 .000
Age -0.37 0.20 -1.85 .069
IQb -0.11 0.15 -0.73 .467
F =8.54, p = .000  
A djusted R Square=.277
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et ah, 
1988).
26. Letter Number Sequencing
Table 26: Multiple Linear Regression Model Predicting Letter Number Sequencing 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -1.78 0.72 -2.48 .016
IQ 0.07 0.04 1.83 .073
F =7.13, p=.002  
A djusted R S q u a res  172
Note: B = unstandardised regression coefficient 
aTwo-tailed
27. Digit Span Total
Table 27: Multiple Linear Regression Model Predicting Digit Span Total Performance 
While Adjusting For Potential Confounders (N=60).
Variable B SE t Pa
Group -2.61 0.94 -2.77 .008
IQ 0.14 0.05 2.75 .008
F = 1 1.56, p = .000  
A djusted R Square=.264
Note: B = unstandardised regression coefficient 
aTwo-tailed
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28. Digit Span Backwards
Table 28: Multiple Linear Regression Model Predicting Digit Span Backwards 
Performance While Adjusting For Potential Confounders (N=60).
Variable B SE t
Group -2.12 0.54 -3.92 .000
IQ 0.05 0.03 1.69 .096
F=12.89, p=  000 
A djusted R  Square=.287
Note: B = unstandardised regression coefficient 
aTwo-tailed
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APPENDIX V:
SIGNIFICANT FINAL MULTIPLE REGRESSION MODELS FOR 
COMPARATIVE ANALYSES BETWEEN CURRENT AND ABSTINENT
MDMA-USERS
The final regression models presented in this appendix were reduced using the 
backward elimination method where variables are removed from the model if they are 
not statistically significant (Kleinbaum et al., 1988). This method was employed to 
maximise the power and precision of the models. The process began with a full model, 
which included intelligence, sex, age, anxiety, depression, and other drug use. If none 
of the potential confounding variables were significant, the unadjusted model is 
presented. The final regression models are also presented for cases where differences 
between the two groups were no longer apparent after controlling for potential 
confounders.
1. Immediate Memory Index
Table 1: Multiple Linear Regression Model Predicting Immediate Memory Index 
While Adjusting For Potential Confounders (N=61)
Variable B SE t
Group -3.85 3.23 -1.19 .239
IQb 0.16 0.12 1.38 .173
Sexb -5.27 3.18 -1.66 .103
F = 2.89 , p= .043  
A djusted R Square=.086
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ and sex retained in final model despite probability greater than 0.1 because 
estimates of variables remaining in the model altered substantially when removed 
(Kleinbaum et al., 1988).
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2. General Memory Index
Table 2: Multiple Linear Regression Model Predicting General Memory Index While 
Adjusting For Potential Confounders (N=61)
Variable B SE t Pd
Group -4.66 2.62 -1.78 .081
IQ 0.20 0.09 2.09 .041
Sexb -2.75 2.58 -1.06 .292
F = 4 .11, p=.010 
A djusted R  Square=. 135
Note: B = unstandardised regression coefficient 
aTwo-tailed
bSex retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
3. Auditory Delayed Index
Table 3: Multiple Linear Regression Model Predicting Auditory Delayed Index While 
Adjusting For Potential Confounders (N=61)
Variable B SE t Pa
Group -4.12 2.84 -1.45 .153
IQb 0.17 0.10 1.63 .108
Sex -5.18 2.80 -1.85 069
F=3.93, p=.013 
A djusted R  Square=.128
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
4. Logical Memory II Total
Table 4: Multiple Linear Regression Model Predicting Logical Memory II Total 
Performance While Adjusting For Potential Confounders (N=61)
Variable B SE t Pa
Group -2.50 1.70 -1.48 .145
Sex -3.16 1.70 -1.86 .068
F=4.08, p=.022 
A djusted R  Square=.093
Note: B = unstandardised regression coefficient 
aTwo-tailed
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5. Logical Memory II Story B
Table 5: Multiple Linear Regression Model Predicting Logical Memory II Story B 
Performance While Adjusting For Potential Confounders (N=61)
Variable B SE t Pa
Group -1.29 0.83 -1.56 .124
Age -0.19 0.08 -2.48 .016
IQ 0.11 0.05 2.23 .030
F=4.19, p= .009 
A djusted R  Square=. 138
Note: B = unstandardised regression coefficient 
aTwo-tailed
6. Family Pictures I
Table 6: Multiple Linear Regression Model Predicting Family Pictures I Performance 
While Adjusting For Potential Confounders (N=61)
Variable B SE t Pa
Group -5.50 2.30 -2.39 .0 2 0
Age -0.46 0 .2 0 -2.28 .027
F=5.86, p=. 005 
A djusted R  Square=. 139
Note: B = unstandardised regression coefficient 
aTwo-tailed
7. Family Pictures II
Table 7: Multiple Linear Regression Model Predicting Family Pictures II Performance 
While Adjusting For Potential Confounders (N=61)
Variable B SE t Pa
Group -5.55 2.44 -2.27 .027
IQb 0.08 0.10 0.82 .416
Age -0.49 0.22 -2.25 .028
F=4.10, p=.011 
A djusted R  Square=.134
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
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8. Letter Number Sequencing
Table 8: Multiple Linear Regression Model Predicting Letter Number Sequencing 
Performance While Adjusting For Potential Confounders (N=61)
Variable B SE t Pd
Group -0.74 0.51 -1.45 .152
Ageb -0.06 0.05 -1.34 .186
IQ 0.08 0.02 3.82 .000
F=6.80, p= 001  
Adjusted R  Square=.225
Note: B = unstandardised regression coefficient 
aTwo-tailed
bAge retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et ah, 
1988).
9. Digit Span Total
Table 9: Multiple Linear Regression Model Predicting Digit Span Total Performance 
While Adjusting For Potential Confounders (N=61)
Variable B SE t p
Group -1.76 1.05 -1.67 .100
IQb 0.07 0.04 1.65 .105
F=3.44, p=.039 
A djusted R  Square=.075
Note: B = unstandardised regression coefficient 
aTwo-tailed
blQ retained in final model despite probability greater than 0.1 because estimates of 
variables remaining in the model altered substantially when removed (Kleinbaum et al., 
1988).
10. Digit Span Backwards
Table 10: Multiple Linear Regression Model Predicting Digit Span Backwards 
Performance While Adjusting For Potential Confounders (N=61)
Variable B SE t
Group -1.23 0.70 -1.76 .084
Lifetime Heroinb -0.37 0.80 -0.46 .647
IQb 0.04 0.02 1.59 .118
F=3.05, p=.036 
A djusted R  Square=.093
Note: B = unstandardised regression coefficient 
aTwo-tailed
bIQ and lifetime heroin use retained in final model despite probability greater than 0.1 
because estimates of variables remaining in the model altered substantially when 
removed (Kleinbaum et al., 1988).
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